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SUMMARY 
Burkitt’s lymphoma (BL) is the most common cancer in children of equatorial Africa, 
and is endemic to areas where people are chronically co-infected with Epstein-Barr virus 
(EBV) and the malaria pathogen Plasmodium falciparum. Although the contribution of both 
pathogens in the oncogenic process remains poorly understood, we showed earlier that the 
activation of Toll-like receptor (TLR) 9 by hemozoin, a disposal product formed from the 
digestion of blood by P. falciparum, suppresses the lytic reactivation of EBV in BL cells. As 
latency is a prerequisite for transformation, a clear understanding of the factors that regulate 
lytic infection is critical. The ability of latent EBV to evade the immune system, and its 
unique oncogenic potential, might thus be reinforced by co-infection with P. falciparum. 
In the work presented here, we explore, in EBV-positive BL cell lines as a model 
system, the TLR9-induced pathway involved in the repression of the viral transcription factor 
BZLF1, the master gene controlling EBV lytic reactivation. Based on previous results, we 
hypothesized that triggering TLR9-triggering inhibits EBV lytic gene expression through an 
alternative pathway not yet described. 
Moreover, using a luciferase gene reporter system combined with chromatin immune-
precipitation assays, we evaluated the effect of TLR9-induction on the histone modifications 
of Zp, the promoter of BZLF1, upon lytic reactivation. We observed that, in contrast to the 
native EBV viral genome, TLR9 triggering did not affect the activation of Zp reporter 
constructs of different length; therefore we hypothesized a distinct chromatin structure of the 
transfected Zp reporter construct compared to EBV’s viral genome.  
The data presented here provide new insights concerning the signaling pathway 
linking TLR9 to the Zp promoter. Most importantly, our data confirm that histones 
modifications are the key step in the TLR9-induced suppression of EBV lytic gene expression 
and that reporter system based assays do not necessarily reflect the physiologic situation.  
These findings are of great importance for the development of new therapeutic 
strategies using the viral lytic reactivation to clear EBV latently infected cancers cells.  
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ZUSAMMENFASSUNG 
Burkitt-Lymphom (BL) ist die häufigste Krebserkrankung bei Kindern in äquatorialen 
Afrika und ist endemisch in Gebiete, in denen Menschen chronisch mit Epstein-Barr-Virus 
(EBV) und mit dem Malaria-Erreger Plasmodium falciparum infiziert sind. Unseres Labor 
zeigte, obwohl der Beitrag der beiden Pathogene im onkogenen Prozess nach wie vor schlecht 
verstanden ist, dass die Aktivierung von Toll-like Rezeptor (TLR) 9 durch Hämozoin, ein 
Entsorgungsprodukt das aus der Verdauung von Blut durch P. falciparum gebildet wird, die 
lytische Reaktivierung von EBV in BL-Zellen unterdrückt. Da die Latenz eine Voraussetzung 
für die Transformation von Wirtszellen durch EBV ist, ist ein klares Verständnis der 
Faktoren, die lytische Infektion regulieren, kritisch. Die Fähigkeit des latenten EBV, dem 
Immunsystem auszuweichen, und sein einzigartiges onkogenes Potential, könnte somit durch 
eine Co-Infektion mit P. falciparum verstärkt werden. 
In der vorliegenden Arbeit untersuchen wir in EBV-positiven BL-Zelllinien als 
Modellsystem den TLR9-induzierten Weg, der an der Repression des viralen 
Transkriptionsfaktors BZLF1, der Master-Gene der die EBV-lytische Reaktivierung 
kontrolliert, beteiligt ist. Basierend auf früheren Ergebnissen haben wir die Hypothese 
aufgestellt, dass die auslösende TLR9-Aktivierung die EBV-lytische Genexpression durch 
einen alternativen, noch nicht beschriebenen Weg beeinflusst. 
Darüber hinaus untersuchten wir die Wirkung der TLR9-Induktion auf die 
Histonmodifikationen von Zp, dem Promotor von BZLF1, nach lytischer Reaktivierung mit 
einem Luciferase-Gen-Reportersystem, kombiniert mit Chromatin-Immunpräzipitationstests. 
Wir beobachteten, dass im Gegensatz zum nativen EBV-Virusgenom die TLR9-Triggerung 
die Aktivierung von Zp-Reporterkonstrukten unterschiedlicher Länge nicht beeinflusste. 
Daher haben wir eine unterschiedliche Chromatinstruktur des transfizierten Zp-
Reporterkonstruktes gegenüber dem viralen Genom von EBV vermutet. 
Die hier präsentierten Daten liefern neue Erkenntnisse über den Signalweg, der TLR9 
mit dem Zp-Promotor verbindet. Unsere Daten bestätigen, dass Histonmodifikationen der 
Schlüsselschritt bei der TLR9-induzierten Suppression der EBV-lytischen Genexpression sind 
und, insbesonders, dass Reportersystem-basierte Assays nicht notwendigerweise die 
physiologische Situation wiedergeben. 
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Diese Ergebnisse sind von großer Bedeutung für die Entwicklung neuer 
therapeutischer Strategien unter Verwendung der viralen lytischen Reaktivierung, um EBV 
latent infizierte Krebszellen zu klären. 
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INTRODUCTION 
The Epstein-Barr virus 
The Epstein-Barr virus (EBV or human herpes virus (HHV)4) is an enveloped double 
stranded DNA virus belonging to the γL or lymphocryptovirus (LCV) herpesvirus genus 
(Table 1) (1). EBV is widespread in the human population with more than 90% of the adults 
positive for serum IgG antibodies against the viral capsid antigen (VCA) complex of EBV 
(2). The virus is usually transmitted via saliva and in vivo mainly targets B lymphocytes and 
epithelial cells (3). Primary infection usually occurs during childhood and is often 
asymptomatic in toddlers. However, with the improvement of the hygienic conditions the 
primary infection may be delayed until adolescence or adulthood, resulting, in up to 75% of 
the cases, in the most frequent clinical manifestation of EBV infection called infectious 
mononucleosis (IM) or ‘kissing disease’ (4, 5). The IM symptoms, similar to the symptoms 
caused by flue or HIV infection, include fever, fatigue, enlarged spleen, tonsils and lymph 
nodes, sore throat, muscle weakness and abdominal pain and are due to a vigorous immune 
hyperactivation (5). Upon primary infection, the host remains a lifelong carrier of EBV. 
The 184 kb double stranded DNA genome of EBV is packaged in a capsid as a linear 
molecule surrounded by a lipid bilayer in the viral particles. Upon infection of a host cell the 
viral genome undergoes a circularization in the terminal repeat regions coupled to a 
chromatinization step. Once the viral latency is established in the host cell, the virus can 
replicate as an episome during the cellular mitosis using the host cell’s replication machinery. 
However, periodically, upon certain stimuli, the viral productive lytic state is re-activated 
leading to the horizontal transmission of the virus from cell to cell and from host to host. 
During lytic replication, the expression of two immediate early proteins called Zta (also 
known as ZEBRA, EB1, or Z) and Rta (also known as R) initiates the lytic transcription 
cascade of different classes of viral lytic genes (early and late) resulting in the production of 
infectious EBV particles and the death of the cell (6). 
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Table 1: Human herpesvirus taxonomy, nomenclature and main cellular tropism (adapted from (1)) 
Designation Trivial name (and acronym) 
Herpesvirus 
subfamily; genus Primary target cells 
HHV-1 Herpes simplex virus-1 (HSV-1) Alpha; Simplexvirus Mucoepithelia 
HHV-2 Herpes simplex virus-2 (HSV-2) Alpha; Simplexvirus Mucoepithelia 
HHV-3                 Varizella-zoster virus (VZV) Alpha; Varicellovirus Mucoepithelia 
HHV-4 Epstein-Barr virus (EBV) Gamma; Lymphocryptovirus B lymphocytes and epithelial cells 
HHV-5 Human cytomegalovirus (HCMV) 
Beta; 
Cytomegalovirus 
Epithelia, monocytes and 
lymphocytes 
HHV-6A/-6B Roseola virus (HHV-6A/-6B) Beta; Roseolovirus T lymphocytes 
HHV-7 Roseola virus (HHV-7) Beta; Roseolovirus T lymphocytes 
HHV-8 Kaposi’s sarcoma-associated herpesvirus (KSHV) 
Gamma; 
Rhadinovirus Probably lymphocytes and ephitelia 
 
EBV associated malignancies 
In 1958, Denis Burkitt, a British surgeon, reported an aggressive cancer caused by the 
uncontrolled multiplication of white blood cells. This cancer, common in young children 
across central Africa, was later named after him as Burkitt’s Lymphoma (7). Burkitt noticed a 
strong link to environmental conditions; the children living in rainy areas with a high 
temperature year-round were more affected by the cancer than others. This geographical 
pattern, very similar to the pattern of malaria, led him to believe that an insect-borne virus 
transmitted the lymphoma. This theory greatly excited a young cancer research doctor called 
Anthony Epstein. He had been working on the Rous sarcoma virus causing tumors in 
chickens and was determined to be the first to find a cancer-causing virus in humans. In 1964, 
Anthony Epstein with the help of Yvonne Barr and Burt Achong could, for the first time, 
show viral particles in lymphoblasts from Burkitt’s Lymphoma (8). This virus, later called 
EBV, was the first human virus to show the capacity to induce lymphoproliferation and 
cancers (9).  
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As already mentioned, EBV is a ubiquitous infectious agent infecting more than 90% 
of the world’s population. A vast majority of the infected individuals do not show any 
significant symptoms during their life. However, since EBV’s discovery it has been shown 
that EBV is clearly an important factor in the development of multiple human cancers. 
Moreover, association with neoplasia is a feature shared with other γ-herpesviruses like 
Kaposi’s sarcoma-associated-herpesvirus (KSHV), for example (10). Indeed, next to B cells 
lymphoproliferative diseases and lymphomas, including Burkitt’s lymphoma, Hodgkin’s 
lymphoma and post-transplant lymphoproliferative diseases (PTLD), EBV also causes tumors 
from other cell types such as T-cell lymphomas (angio-immunoblastic T-cell lymphoma, 
extranodal nasal-type natural killer /T-cell lymphoma), nasopharyngeal cancer (NPC) and a 
subset of gastric cancers (11). Therefore, one can raise the question of what are the unique 
aspects of infection in the people who develop cancers. The study of EBV and its associated 
tumors points out that many of the malignancies develop: 1) in immunosuppressive patients 
who are deficient in T-cell mediated immunity, following bone marrow or solid organ 
transplantation, or upon HIV infection, or 2) have an endemic pattern of incidence (12). 
Given the growth transforming properties of EBV in vitro (13), the association of the virus 
with post-transplant lymphoma or AIDS-associated lymphomas, in situations were the 
immune control of EBV-infected host cells is lowered, is not surprising. Next to that, 
Burkitt’s lymphoma is endemic to subequatorial Africa, but also Brazil, Egypt and Papua 
New Guinea; NPC occurs with high incidence in southern China and with elevated incidence 
in Inuit populations and in Mediterranean Africa; EBV-associated T-cell lymphomas develop 
with increased frequency in Taiwan and Japan and EBV-associated parotid gland tumors 
occur most frequently among Inuits. These observations suggest specific interactions between 
environmental, genetic, and viral factors (14). All these tumors are characterized by the 
presence of multiple extrachromosomal copies of the circular EBV genome in the tumor cells 
and expression of EBV-encoded latent genes, which appear to contribute to the malignant 
phenotype (15). Different types of tumors are characterized by different patterns of EBV gene 
expression, the more immune competent the host, the less genes EBV expresses to evade 
immune recognition (Table 2) (16).  
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Table 2: EBV associated malignancies and characteristic latent gene expression patterns (adapted from 
(16)).  
Malignancy EBV-
association 
(%) 
Latent EBV gene 
expressed 
Type of 
latency 
Burkitt’s lymphoma 
Endemic 
Sporadic  
AIDS-associated 
 
100 
15-85 
30-40 
 
EBERs, EBNA1 
 
 
I 
Hodgkin’s lymphoma 
Mixed cell; lymphocyte depleted 
Nodular sclerosing 
 
60-80 
20-40 
 
EBERs, EBNA1, LMP1, 
LMP2a-b 
 
II 
Post-transplant lymphoproliferative disease 
Immunodefficient 
Post-transplant 
AIDS-associated 
 
100 
>90 
>80 
 
EBERs, EBNA1-6, LMP1, 
LMP2a-b 
 
III 
Nasopharyngeal carcinoma 
Undifferentiated, non-keratinizing 
Undifferentiated, keratinizing 
 
100 
30-100 
 
EBERs, EBNA1, (LMP1 
a), LMP2a-ba 
 
I/IIa 
Gastric carcinoma 
UCNT 
Adenocarcinoma 
 
100 
5-15 
 
EBERs, EBNA1, (LMP2)b 
 
Ib;(II) 
 
NT/T-cell lymphoma 
VAHS-associated 
Nasal 
 
100 
100 
 
EBERs, EBNA1, (LMP1)c, 
LMP2 
 
IIc;(I) 
Leiomyosarcoma 
Immunodefficient 
Post-transplant 
AIDS-associated 
 
100 
100 
100 
 
(EBERs, EBNA1, 
EBNA2, LMP1, LMP2a-b) 
(17) 
 
(Type III 
suggested) 
(17) 
AIDS = acquired immunodeficiency syndrome; UCNT = undifferentiated carcinomas of the nasopharyngeal 
type; VAHS = virus-associated hemophagocytic syndrome; EBERs = EBV-encoded RNAs; EBNA = Epstein-
Barr nuclear antigen; LMP = latent membrane protein; a = intermediate latency type with variable levels of LMP 
expression (18); b = latency type I and 40% of the cases show LMP2 expression (19); c = latency pattern follows 
type II with LMP1 expression restricted to few cells (20). 
 
Burkitt’s Lymphoma 
Our research group focused on one of these EBV associated malignancies: the 
Burkitt’s lymphoma.  
Burkitt’s lymphoma (BL) can be classified into three forms: endemic (eBL), sporadic 
(sBL) and HIV-associated BL (21). The eBL harbors EBV in over 95% of tumors. 
Distribution of eBL in sub-Saharan and equatorial Africa coincides with the distribution of 
endemic Plasmodium falciparum malaria suggesting P. falciparum to be responsible for the 
tumor (7, 22). There, BL has an incidence of 5–10/100 000 children and accounts for up to 
74% of childhood malignancies. BL often manifests as tumors of the jaw or kidneys, it may 
also occur in the abdomen, ovaries, facial bones and other extranodal sites. In contrast to eBL, 
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sBL is rarely associated with EBV, has a low incidence rate worldwide (1-2% of adult 
lymphoma in Western Europe and America) and most frequently involves tumors of the 
abdomen. A third BL tumor form, where only about 30% of the tumors are EBV positive, 
develops in HIV carriers subject to severe immunosuppression coincident with the onset of 
AIDs. Finally BLs that display intermediate associations with EBV have also been 
documented in Egypt and Brazil, where up to 87% of the tumors are EBV positive (21, 23).  
All BL tumors, including the minority that are not EBV-associated, are characterized 
by a chromosomal translocation involving the immunoglobulin gene loci on chromosomes 14, 
22 or 2 and the c-myc oncogene on chromosome 8 resulting in its constitutive activation (24–
26) that induces a rapid proliferation and tumor formation. Moreover, there is also evidence 
for genetic alterations of the tumor suppressor p53 gene in 60% of BL cases (27), and of the 
putative tumor suppressor gene retinoblastoma-like 2 (RB2) in most cases of eBL and sBL 
(28, 29). These mutations indicate a certain genetic instability caused or favored by the 
presence of P. falciparum and EBV although in the case of sBL other factors are likely to play 
a role. 
The eBL tumor derives from cells that have undergone a somatic hypermutation, a 
feature of the germinal center (GC) reaction during B-cell activation and differentiation. The 
breakpoint in the Ig gene, to which c-myc is translocated in eBL, occurs at the V(D)J region, 
suggesting that translocation occurs during V(D)J recombination. The J segments flanking c-
myc translocated breakpoints typically exhibit deletions and/or additions of base pairs 
characteristic of normal Ig V(D)J segment rearrangement. This is a process catalyzed by B-
cell specific V(D)J recombinase activating enzymes RAG-1/2 which are expressed in both 
pre-B cells and GC B cells (30). Next to RAG-1/2, the c-myc translocation might also be 
mediated through the activation-induced cytidine deaminase (AID), which is highly expressed 
in the GC as it is responsible for the somatic hypermutation and class switch recombination of 
immunoglobulin genes as they undergo affinity maturation (31–33). In contrast to eBL, the 
chromosomal breakpoint in sBL and HIV-associated BL occurs most commonly in the class 
switch region. Somatic hypermutation and class switching are events that are normally 
confined to GC B cells. GC centroblast markers are expressed on BL cells and BL-associated 
factors such as holoendemic malaria, chronic HIV infection and EBV infection, stimulate the 
proliferation of the B-cells in germinal center. All these observations indicate that BL 
progenitor cells arise from B cells subjected to chromosomal rearrangements in the GC (15, 
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34). Thus, the GC events are responsible for the generation of B-cells carrying genetic 
alterations.  
Although the exact underlying mechanism linking EBV infection of B cells to the 
emergence of malignancy remains poorly understood, there are several potential explanations: 
- EBV could promote the genomic instability, deregulate telomere functions, and induce DNA 
damage in infected cells. That could increase the risk of genetic accidents as for example the 
c-myc translocation (35), - EBV could, through either the EBNA1 protein, through EBER 
transcripts, through the suppression of pro-apoptotic Bim function or through epigenetic 
modifications, provide a resistance to the apoptosis induced by the c-myc translocation, (36–
39). Thus, EBV would favor tumor cell survival. Finally, - EBV could drive the 
tumorigenesis, through its encoded microRNAs that have been identified in BL. Indeed, 
BHRF1-3 is suspected to regulate the immune-surveillance of the host transformed cells (40), 
BART-6-3p acts, in synergy with the cellular miR143, as a pro-oncogene by inhibiting the 
expression of the phosphatase and tensin homolog (PTEN) tumor suppressor (41) and 
different BARTs  decrease CASP3 apoptotic activity (42). 
The contribution of P. falciparum to the development of eBL is not well understood, 
but several studies suggest multiple immunomodulatory effects and B-cell activation (43–45). 
Malaria parasite DNA conjugated to hemozoin, an insoluble crystalline form of heme formed 
from the digestion of hemoglobin, is a ligand that activates the Toll-like receptor 9 (TLR9) 
signaling. The activation of TLR9 in turn increases the transformation of B-cell by EBV in 
vitro (46, 47). Therefore, chronic stimulation of TLR9 by P. falciparum DNA might increase 
EBV-induced B-cell transformation in vivo. Likewise, TLR9 activation by its synthetic ligand 
oligodeoxynucleotide (ODN) CpG, or hemozoin, inhibits EBV lytic reactivation in vitro in 
eBL cells (48). These concepts will be presented more in details later in the chapter dedicated 
to TLR9.  Furthermore, a malaria membrane protein increases the EBV genome copies in eBL 
and peripheral blood mononuclear cells (PBMCs) by an unknown mechanism (49). In the 
end, more than 50 years after first description of the virus, despite the huge progresses that 
have been made, we still do not exactly know by which mechanisms the different factors 
influence the development of BL. 
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EBV Life Cycle 
EBV is transmitted via saliva and infects new hosts in the oropharynx. Once passed 
the epithelial barrier, it gains access to B-cells within the lymphoid organs. In vivo, depending 
on the location and differentiation state of the infected B cell, EBV expresses three different 
gene expression programs associated with latent infection, which are: - the growth program, 
also called latency III, in which all nine known latent proteins are expressed; - the default 
program also called latency II, in which a restricted set of three latent proteins are expressed; - 
and the latency program, also called latency I, in which only few if any latent genes are 
expressed (Table 3).  
The very limited number of viral genes expressed during the latency I program enables 
the virus to avoid immune recognition and to persist in vivo in a quiescent state within the 
memory B cells that circulate in the peripheral blood (50–56). During a persistent infection 
between 0.5 and 50 per 106 memory B cells in the blood are latently infected with EBV (57).   
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Table 3: Latency transcription programs (adapted from (58))  
 
Latency gene expression 
program 
Genes 
expressed 
Proposed function 
Latency program / latency I 
EBNA1 
(LMP2A*) 
EBER1-2 
BARTs 
Allows persistence of the virus in resting recirculating 
memory cells in a way that is non-pathogenic and not 
detectable by the immune system 
Default program / latency II 
EBNA1 
LMP1 
LMP2A 
EBER1-2 
BARTs 
Provides necessary survival signals for: (i) infected 
lymphoblasts to differentiate into memory, and (ii) 
maintenance of persistently infected memory cells 
Growth program / latency III  
EBNA1-6 
LMP1 
LMP2A-B 
EBER1-2 
BARTs 
Activates a resting B cell to become a proliferating 
lymphoblast 
BARTs = BamHI A rightward transcript; EBERs = EBV-encoded RNAs; EBNA = Epstein-Barr nuclear antigen; 
LMP = latent membrane protein; * = The transcript for LMP2A is often detected in these cells. 
The in vitro transformation of B cells depends on the viral growth program and on the 
expression of the nine viral latent proteins that are under the control of the transcription factor 
EBV nuclear antigen 2 (EBNA2) (59).  
In vivo, in healthy individuals, the virus is continuously controlled by the immune 
system. Stable levels of cytotoxic T lymphocytes (CTL) and serum antibodies to lytic and 
latent proteins control and drive the three latent gene expression programs (60, 61). However, 
due to the ability of EBV to transform resting B-lymphocytes into activated proliferating 
lymphoblast in vitro, it is not surprising to observe that in combination with 
immunosuppressive conditions or in combination with environmental and genetic cofactors, 
EBV is associated with a number of neoplastic diseases, including lymphomas and 
carcinomas (16, 62).   
Finally, latent EBV can reactivate and switch to its lytic form. Upon lytic reactivation 
the immediate-early proteins Zta (also known as ZEBRA, EB1, or Z) coded by the BZLF1 
gene and Rta (also known as R) coded by the BRLF1 gene are the first viral products 
expressed. Zta and Rta are viral transcription factors that play multiple roles in the lytic 
replication of EBV; they activate in particular the lytic gene expression cascade. The 
expression of immediate-early genes BZLF1 and BRLF1 is followed by expression of early 
and late gene that leads to the formation of new viral particles and to the lysis of the host cell 
(6, 63). In vivo, the lytic reactivation of EBV occurs when a memory B cell is stimulated by 
its specific antigen and differentiates into a plasma cell (6, 64). On the other hand, in vitro, 
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several chemical and biological agents induce EBV lytic reactivation. These include the 
treatment of the latently infected cells with anti-immunoglobulin (anti-Ig), with transforming 
growth factor beta 1 (TGFβ1), with protein kinase C (PKC) agonists 12-O- 
tetradecanoylphorbol-13-acetate (TPA), with DNA methyltransferase inhibitors (e.g., 
azacytidine), with histone deacetylase (HDAC) inhibitors like sodium butyrate (SB) or 
trichostatin A (TSA), with addition of Ca2+ ionophores, and with infection with human 
herpesvirus 6 (65, 66). The differences in the stimulation time and in the response time 
required to observe BZLF1 and BRLF1 expressions, indicates that these agents operate 
through different mechanisms and different signaling pathways. Of these stimulations, the 
most relevant physiologically is the cross-linking of the B-cell receptor (BCR) with anti-Ig 
that mimics the mechanism of the antigen stimulation of a latently infected memory B cell, 
the germinal center reactions and/or the differentiation into a plasma cell (67, 68).  
During the lytic phase, all the viral genes are expressed in a sequential manner that 
leads to the production of new infectious viral particles, to the death of the host cell, to the 
infection of new susceptible cells and to the spread to new individuals (6, 58, 69). This event 
closes the viral life cycle and underscores how well EBV evolved and adapted to make use of 
the biology of normal B cells. 
The B-cell receptor pathway 
Cross-linking anti-immunoglobuling (anti-IgG) antibodies induce the lytic expression 
and reactivation of many EBV positive BL cell lines (63) and therefore, the BCR is a key 
element in analyzing the switch between latent and lytic EBV infection.  
The surface immunoglobulins (Ig) that form the BCR are coupled by a non-covalent 
bond between the Igα and the Igβ proteins. Each of the subunits contains a single 
immunoreceptor tyrosine-base activation motif (ITAM). Upon the cross-linking of an antigen, 
the BCR aggregates and undergoes conformational changes (70) that lead to LYN-mediated 
phosphorylation of the ITAMs. The phosphorylation of ITAMs creates a docking site for 
SYK and the recruitment of more LYN kinases (71). Four major signaling pathways are 
activated, which include the phospholipase C (PLC), the Rho family of GTPases, the rat 
sarcoma protein RAS and the phosphatidylinositol-3-kinase (PI3K) (72, 73). They recruit 
MAP-kinases like the extracellular signal-regulated kinase (ERK), the c-jun NH2-terminus 
kinase (JNK/SAPK) or p38 MAPK that phosphorylate different transcription factors including 
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Elk1 and c-Myc for ERK, c-Jun and ATF2 (activating transcription factor 2) for JNK and 
ATF2 and MAX for p38 MAPK, which lead to the transcription of a variety of genes.  
The BCR signal transduction is a complex network of regulatory signaling cascades 
operating with other stimuli to control the functions of B cells, the above-described process is 
a very simplified general model which does not take into account the modularity of this 
process based on the context of lymphatic tissue or peripheral blood and on maturation stage 
of the B cell (74).  
Interestingly, EBV encodes a latent membrane protein, LMP2A, which mimics BCR 
and disrupts its association with downstream kinases (75). Latently infected cells that express 
high levels of LMP2A are resistant to lytic reactivation via BCR engagement. 
EBV’s immediate-early lytic promoter Zp regulatory elements 
Zta is a sequence-specific DNA-binding protein, member of the bZIP family of 
leucine-zipper transactivators. It binds to methylated Zta-responsive-elements (ZRE) 
dependent on the presence of methylated CpGs (76). During primary infection Zta is 
transiently expressed but no lytic reactivation occurs, in contrast, lytic reactivation occurs 
from latent viral genome, which is heavily methylated. Therefore, methylation of viral DNA 
seems to be a key determinant of lytic activation (77, 78). By binding to the viral DNA origin 
of lytic replication, ori-lyt, and down regulating the latency-associated promoters Cp and Wp, 
Zta directly contributes to the EBV replication. Moreover Zta serves as a transcriptional 
transactivator of its own methylated promoter Zp and of other EBV lytic promoters including 
Rp, the promoter of Rta, and cellular promoters (6, 63). Its expression alone is sufficient to 
trigger the entire lytic cascade (79, 80), which indicates Zta to be the major immediate-early 
protein in EBV. 
As already mentioned, upon BCR engagement one or more of the phosphotyrosine 
kinases, BTK, SYK and LYN are activated, followed by the phosphatidylinositol-3-kinase 
(PI3K), PKC and mitogen-activated protein kinases (MAPK), which transduce the induction 
signal to Zp (81–84).  
The regulation of Zp has been investigated extensively. Several cis-DNA regulatory 
elements have been described: they are numbered ZI to ZV, in addition to SMAD-binding 
elements (SBEs) and the HIF response elements (Table 4). Most of the positive regulatory 
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elements promoting Zp expression seem to be located within the nucleotide (nt) region -221 to 
+12 relative to the promoter’s transcription initiation site. Indeed the -221 Zp region coupled 
to a luciferase gene was sufficient to activate the luminescent signal upon BCR cross-linking 
in gene reporter assays (85). 
In latently infected cells, in the absence of lytic inducing stimuli, suppressor factors 
such as MEF-2D, ZEB1 or ZEB2 play a role in compacting the local chromatin structure to 
prevent binding of constitutively expressed Zta and inhibit the activation function of Zta (86–
88). Three cis elements that negatively regulate Zp have been described within the nt -221 to 
+12 region relative to the promoter’s transcription initiation site, they are called ZV, ZIIR and 
HIε, and 5 cis elements have been described within the nt -551 to -222 region, they are called 
ZIV and HIα-HIδ (89) (Table 4). The protein ZEB1 and ZEB2 which are zinc finger E-box-
binding proteins bind to the ZV region (90, 91). MEF-2D binds to the ZI region and can 
associate with HDACs or with histone acetyltransferases (HATs) depending on its the 
phosphorylation state.   
 
Table 4: Zp promoter regions, their locations and their functions (adapted from (92)) 
Name Motif Location Function 
ZI (A-D) AT-rich Within -221 to +12 region Can bind the transcription factors Sp1, Sp3 
and MEF2D 
ZII CRE-like motif Within -221 to +12 region Can bind CREB, ATF family members, 
C7EBPs, and the AP-1 family of 
transcription factors 
ZIII  Within -221 to +12 region Contains multiple binding sites for Zta itself 
ZIV  Within -551 to -222 region Transcriptional silencing element 
ZV  Within -221 to +12 region Transcriptional silencing element, binds 
ZEB1 
ZIIIR  Within -221 to +12 region Transcriptional silencing element 
HIε  Within -221 to +12 region Transcriptional silencing element 
HIα-HIδ  Within -551 to -222 region Transcriptional silencing element 
 
As we have seen many Zp regulatory elements have already been described but still 
not all have been identified, especially the lytic suppressor elements. The role of the 
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epigenetic mechanisms to regulate EBV’s latency and lytic reactivation will be discussed in 
another part of this introduction  
Toll-like receptor 9 and its signaling in B cells  
TLRs and their role in the innate immunity  
The innate immune system acts as a first line of defense by sensing invading 
pathogens. It mediates direct antimicrobial effects and delivers important immunoregulatory 
signals to activate the defense mechanisms mediated through preexisting immune cells. The 
toll-like receptors (TLRs) are an essential element of the innate immune system. TLRs are 
members of the pattern-recognition receptors (PRRs) that also comprise the membrane-bound 
C-type lectin receptors (CLR) detecting fungi (93), the cytoplasmic nucleotide-binding 
oligomerization domain receptors (NRL) detecting bacterial products (94) and RIG-like 
receptors (RLR) detecting viral nucleic acid (95). The role of TLRs, as for the other PRRs, is 
to recognize structurally conserved molecules; the so-called pathogen associated molecular 
patterns (PAMPs) that include lipids, lipoproteins or nucleic acids, expressed by viral, 
bacterial, parasitic or fungal pathogens (96) and the so-called danger-associated molecular 
patterns (DAMPs), that are endogenous molecules released by necrotic or dying cells (97–99).  
Upon recognition of their specific ligands (Table 5) a signaling cascade is activated, leading 
to the expression of interferons (IFNs), pro-inflammatory cytokines and effector cytokines, 
which have anti-microbial effects. Moreover, by activating somatic hypermutation or by 
modulating the class-switch recombination in B cells, TLRs activation plays an important role 
to direct and shape the slower adaptive immune response upon pathogen invasion (100, 101). 
TLRs are type I transmembrane proteins characterized by an N-terminal leucin-rich 
repeats (LRRs) extracellular domain responsible for the ligand recognition, a single 
transmembrane domain and a C-terminal toll-interleukin 1 receptor (TIR) cytoplasmic domain 
that binds distinct adaptor molecules important for the signal transduction (102).  
In humans, 10 different TLRs have been identified and ligands for all TLRs except 
TLR10 have been established (Table 5). Moreover, the repertoire of TLRs activating ligands 
is extended by the ability of TLRs to heterodimerize with one another; for example TLR2 and 
TLR6 heterodimers are required to recognize diacylated lipoproteins, or TLR2 and TLR1 
dimers are required to recognize triacylated lipoproteins (103).  
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Table 5: Toll-like receptor location, ligands, signal adaptors and production (adapted from (96, 104)) 
Mo: monocytes, Mϕ: marcophages, DC: dendritic cells, MC: Mast cells, B: B cells, T: T cells, IE: Intestinal 
epithelium, HSP: heat shock protein, HMGB: high mobility group protein, IC: Inflammatory cytokines 
Receptor Immune Cell 
Expression 
PAMPs DAMPs Signal 
Adaptor 
Production 
TLR1- 
TLR2 
Cell surface 
Mo, Mϕ, DC, B 
Triacylated 
lipoproteins, 
Peptidoglycans, 
Lipopolysaccharides 
HSP 60, 70, 
Gp96, 
HMGB1, 
Proteoglycans 
TIRAP, 
MyD88/Mal 
IC 
TLR2- 
TLR6 
Cell surface 
Mo, Mϕ, MC, B 
Diacylated 
lipoproteins 
HSP 60, 70, 
Gp96, 
HMGB1, 
Proteoglycans 
TIRAP, 
MyD88/Mal 
IC 
TLR3 Endosomes 
B, T, NK, DC 
dsRNA, tRNA, 
siRNA 
mRNA, tRNA TRIF IC, type 1 
IFN 
TLR4 Cell surface/endosomes 
Mo, Mϕ, DC, MC, IE 
Lipopolysaccharides HSP22, 60, 
70, 72, Gp96, 
HMGB1, 
Proteoglycans, 
Fibronectin, 
Tenascin-C 
TRAM, 
TRIF, 
TIRAP, 
MyD88/Mal 
IC, type 1 
IFN 
TLR5 Cell surface 
Mo, Mϕ, DC, IE 
Flagellin  MyD88 IC 
TLR7 Endosomes 
Mo, Mϕ, DC, B 
ssRNA ssRNA MyD88 IC, type 1 
IFN 
TLR8 Endomes 
Mo, Mϕ, DC, MC 
ssRNA ssRNA MyD88 IC, type 1 
IFN 
TLR9 Endosomes 
Mo, Mϕ, DC, B, T 
CpG DNA Chromatin 
IgG complex 
MyD88 IC, type 1 
IFN 
TLR10 Cell surface 
Mo, Mϕ, DC 
Profiling-like 
proteins 
 MyD88 IC 
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TLRs can be divided into two groups based on their cellular location. TLR1, 2, 4, 5, 6, 
and 10 are located on the surface of the plasma membrane. Thus they are perfectly designed 
to recognize hydrophobic structures of the invading pathogens, such as lipoproteins, 
lipopeptides and lipopolysaccharides. TLR3, 7, 8 and 9, on the other hand, are located in 
endosomes and liposomes within the cells (Table 5). They are well suited to recognize the less 
easily accessible ligands like for example RNA and DNA, which are the most potent immune 
stimulatory components of viruses (104).  
TLR9 recognizes unmethylated CpG motifs that are relatively rare in vertebrate DNA 
but abundantly present in herpesviral genomes and senses members from all herpesvirus 
subgroups (105, 106) including EBV (107). The ligand of TLR3 is double-stranded RNA, a 
molecular pattern that is not inherently present in herpesvirus genomes but can be generated 
as intermediate structures during replication and act as TLR3 agonist (108). In the case of 
EBV, latency-associated EBV-encoded small RNAs (EBERs) are an additional ligand for 
TLR3 (109). Finally, TLR7 is responsive to single-stranded RNA and has been reported to 
complement TLR9 signaling to generate an efficient immune response against murine 
Cytomegalovirus even though the exact nature of the viral agonist is not known (110). 
TLR9 expression and signaling in B-cells 
The human B-cells, the cells we focused on in this study, commonly express TLR1, 6, 
7, 9 and 10.  However, the expression pattern might vary, depending if they are isolated from 
lymphatic tissue or peripheral blood and on the B-cell subset. TLR9 expression and 
responsiveness is increased in B-cells isolated from tonsils when compared to those isolated 
from peripheral blood (111). Moreover, naïve B-cells only express low levels of TLRs and, 
thus, poorly respond to TLR stimulation, whereas memory B-cells proliferate and 
differentiate into plasma cells upon TLR stimulations (112–115).   
Upon ligand binding, the activated TLRs recruit Toll/interleukin-1 receptor (TIR) 
homology domain containing adaptor proteins to start a phosphorylation cascade (116). 
Interestingly, different TLRs are able to trigger different signaling pathways depending on 
which adaptor protein is recruited (100, 117). Although the TLR engagement is multifaceted 
and implies additional factors besides the type of adapter protein, the signaling pathways can 
be separated in two groups: 1 - the Myeloid differentiation primary response gene 88 
(MyD88)-dependent pathway that leads to the production of pro-inflammatory cytokines with 
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activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
mitogen-activated protein kinase (MAPK); 2 - the MyD88-independent pathway associated 
with the TIR-domain-containing adapter-inducing interferon-β (TRIF) and translocation 
associated membrane protein (TRAM) adaptors, which activate TRAF family member-
associated NF-kappa-B activator (TANK)-binding kinase 1 (TBK1) and IκB kinase-ε (IKKε) 
that leads to the induction of type I IFN and IFN-inducible genes (118). Furthermore, TLR 
ligands induce cell-type-specific responses, but the involved mechanisms to explain how this 
is achieved are only partly revealed (119).  
Preformed inactive TLR9 homodimers, which we focused on in the present project, 
are initially present in the endoplasmatic reticulum (ER) of B-cells and dendritic cells. The 
TIR domains stay separated in order to avoid the spontaneous recruitment of MyD88 (120). 
Upon CpG oligonucleotide (ODN) uptake, TLR9 translocates to the same endo-lysosomal 
compartments, which results in ligand binding and signal activation (121, 122).  The binding 
of CpG ligand leads to a conformational change that brings the cytoplasmic TIR domains 
together (123). Subsequently, the TIR domains associate with the TIR domain-containing 
adaptor MyD88 (123). The latter recruits the interleukin-1 receptor-associated kinase (IRAK) 
4 to TLR9 through interaction of the death domains of both molecules. IRAK-1 is activated 
by phosphorylation and associates with the TNF receptor associated factor (TRAF) 6, thereby 
activating the IκB kinase (IKK) complex, leading to activation of mitogen-activated protein 
(MAP) kinases (JNK, p38, MAPK) and of nuclear factor kappa B (NF-κB). NF-κB promotes 
the transcription of genes involved in the cellular activation, proliferation and in the 
production of pro-inflammatory cytokines (124) (Fig. 1). Although human B-cells are 
generally considered poor cytokine producers, stimulation with TLR9 ligands results in the 
secretion of pro-inflammatory cytokines like IL-1β, IL-2, IL-6, IL-8, and to the release of 
immune regulatory cytokines that might limit the intensity of the inflammatory response, such 
as IL10 (115). TLR9 stimulation induces differentiation in the absence of significant 
proliferation in naïve and transitional human B-cells, whereas a proliferative response is 
observed in memory B-cells (125). Moreover, TLR triggering of terminally differentiated 
plasma cells augments Ig production. 
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Figure 1: The signaling pathways of endosomal Toll-like receptor 9. The binding of CpG ligand leads to a 
conformational change that brings the cytoplasmic Toll/interleukin-1 receptor (TIR) domains together. 
Subsequently, the TIR domains associate with the TIR domain-containing adaptor myeloid differentiation 
primary response protein 88 (MyD88) followed by the recruitment of IL1-receptor- associated kinase (IRAK) 1 
and 4 and tumor-necrosis-receptor-associated-factor 6 (TRAF6). Subsequent activation of Inhibitor of nuclear 
factor κB-kinase complex (IKK-complex) frees NF-κB from its inhibitor IκB and allows nuclear translocation 
where expression of pro-inflammatory cytokines is induced. Adapted from Akira & Takeda, Nat Rev Immunol. 
2004 (126) 
 
Interestingly, TLR ligands are known to induce cell-type-specific responses, but we 
only begin to understand how this is achieved. It is still partly unknown weather cell-type 
specific factors are involved nor if it is the subcellular positioning of certain adaptor 
molecules that plays a role (119). In the case of TLR9, the secondary and the tertiary DNA 
structures, and thereby the DNA sequence of potential ligands, have a great influence on the 
quantity and quality of the conformational changes of TLR9 and on the subsequent receptor 
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response, as exemplified by the various CpG DNA classes (123). The differential activity of 
the different CpG classes on immune cells and how the signals are transduced cannot be 
explained fully to date. Although it is known that different IRFs are activated depending on 
the type of CpG used, we do not know how the different effects and activated proteins are 
produced from the same TLR. Moreover, their effects on certain cell types can distinguish the 
CpG classes. A-class CpGs containing 5’ and 3’ G-rich stretches induce high levels of type I 
IFN but show low activation of B cell proliferation (127). B-class CpGs activate B-cells and 
TLR9-dependent NFκB signaling in recombinant cell lines but show low induction of IFN-α 
(128).  C-class CpGs induce high amounts of IFN-α and activate B cells. The recently 
discovered new P-Class ODNs show similar but superior properties to C-class ODNs. Even 
DNA without CpG motifs can act as TLR9 ligands, suggesting that TLR9 recognizes not only 
the CpG motifs but also other DNA structures (129). In our study we used mainly CpG ODN 
2006 a B-class CpG.  
 
Regulation of TLR9 activation by EBV 
TLRs activation is linked to antiviral effects through the expression of cytokines and 
interferons. However, recent data suggest, that several members of the herpesvirus family, 
such as EBV, hijack the TLR signaling pathways to evade recognition by other immune cells 
and maintain their latent infection.  
Several EBV encoded proteins manipulate the host TLR signaling pathways during 
latent or lytic phases, and thus, contribute to malignant cell proliferation, survival and viral 
expansion. EBV’s latent membrane protein (LMP) 1 mimics the CD40 receptor signaling, 
through 3 c-terminal cytoplasmic activation regions (CTAR1, 2 and 3). Each CTAR regions 
recruits a cellular adaptor protein to initiate a signaling pathway. CTAR1 binds TRAF2 
weather CTAR2 binds the TRADD complex both leading to the activation of NF-κB (130, 
131). Furthermore, LMP1 induces the expression of IRF4, which competes with IRF5 for the 
interaction with MyD88 upon TLR-activation.  Subsequently, TLR7 and MyD88 expression 
increases, leading to cellular proliferation (132). EBV’s LMP2A has an N-terminal 
cytoplasmic region containing eight tyrosine residues, which function as the immunoreceptor 
tyrosine-based activation domain (ITAM) motif (133). The phosphorylated ITAM region 
recruits Src-type tyrosine kinases, and this ITAM signalosome-mediated ERK-activation also 
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stimulates the c- Jun/AP-1 pathway (134). In addition, non-protein products from EBV, 
EBER1 and 2 are shown to affect host cell signaling. EBER1 and 2 are non-translated viral 
small RNA abundantly expressed in EBV latently infected cells. EBER activate the NF-κB 
and IRF3 pathways through association with RIG-I (135, 136). Besides latent EBV gene 
products, also lytic EBV genes impact the signaling induced downstream of TLRs. ZEBRA, 
the protein encoded by the immediate-early gene BZLF1 of EBV is on the one hand inducing 
NF-κB translocation into the nucleus (137), but is also able to inhibit binding of NF-κB to 
responsive promoters (138). All of these cellular signaling molecules and transcription factors 
are also activated downstream of TLR activation. This shows that EBV by itself modulates 
the innate immune system thereby preventing immune recognition of EBV-infected cells.  
Furthermore, TLR9 signaling contributes to shape the EBV viral gene expression and, 
thus, the balance between lytic and latent cycles. Earlier studies in our lab found that 
stimulation of BL cells with synthetic CpG ODN 2006 ligands of TLR9 suppresses EBV lytic 
reactivation in Vitro (48, 139). Transfection of p65, a subunit of NF-κB, was shown to inhibit 
the lytic replication of gamma-herpesviruses (140). However in the case of EBV, our group 
showed NF-κB not to be fully responsible for the TLR9-induced inhibition of lytic 
reactivation in BL cells suggesting an alternative mechanism to play a role (48).  
Finally, TLR9 activation turns out to be a double-edged sword: on one hand it induces 
and shapes the adaptive immune response and on the other hand it facilitates the long-term 
infection of EBV and the lymphomagenesis through induction of the infected host B-cell’s 
proliferation and survival. Thus, in the situation of EBV and P. falciparum co-infections, TLR 
stimulation might influence and disturb the balance between the infection and the immune 
control in asymptomatic long-term latency and might offer an explanation to the ontology of 
EBV-associated Burkitt’s lymphoma in immunocompetent patients. 
 Epigenetics 
Overview of the different epigenetic mechanisms 
The term epigenetic, according to Ptashne’s definition, describes “a change in the state 
of expression of a gene that does not involve a mutation, but that is nevertheless inherited in 
the absence of the signal or event that initiated the change” (141, 142). 
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The most important epigenetic mechanisms include DNA methylation, histone post-
translational modification and non-coding RNAs. These factors, influenced by many 
environmental agents, including: - heavy metals, - pesticides, - diesel exhaust, - tobacco 
smoke, - poly- cyclic aromatic hydrocarbons, - hormones, - radioactivity, - viruses, - bacteria, 
and - basic nutrients, alter how genes are expressed (143). Epigenetic changes, although 
reversible, might persist through cell divisions for the duration of the cell's life, and may last 
for multiple generations without altering the underlying DNA sequence (144).  
DNA methylation occurs mostly in CpG dinucleotides, at the 5th carbon of the 
cytosine residue and is associated with transcriptional silencing. Methylation plays also an 
important role in processes like imprinting, X-chromosome inactivation, silencing of 
repetitive and centromeric sequences (145).  
The genetic material of eukaryotic cells is packaged in the nucleus in the form of 
chromatin. Chromatin is made by octamers of four histone proteins – H2A, H2B, H3 and H4 
– around which the DNA is wound almost twice, in a unit called nucleosome (146). Histone 
post-translational modifications (PTM) alter the chromatin structure by the covalent addition 
or removal of functional groups like: -acetyl, -methyl, -phosphoryl, or -sumoyl, on the 
histones tails that protrude from the nucleosome and that are freely accessible to enzymes - 
the so called writers that create these covalent modifications (eg, DNA and histone 
methyltranferases, histone acetyl- transferases, etc.). These modifications influence directly 
the histone-histone and the histone-DNA interactions, thereby altering the DNA stability and 
accessibility to transcription factors and to the transcription machinery (145). In general, 
tightly folded chromatin (heterochromatin) tends to be inactive, while more open chromatin 
(euchromatin) is functional. Furthermore, protein effectors, also called readers, can recognize 
specifically and bind to the histone PTMs through specific protein domains (eg, 
bromodomain-containing proteins). The readers are the major players that govern dynamic 
changes in chromatin structure. On the basis of developmental or environmental stimuli, they 
recruit various components of the nuclear signaling network to the chromatin, mediating via 
chromatin remodeling fundamental processes such as gene transcription, DNA replication and 
recombination, DNA damage response. The readers bind specifically to certain histone PTMs, 
and the misreading of the histone PTM code has been shown to cause various diseases (147, 
148). The histone PTMs are reversible and can be removed by enzymes called erasers. The 
gene expression patterns can also be affected by non-covalent histone modifications, 
including ATP-dependent chromatin remodeling and introduction of histone variants (145). 
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Finally, non-coding RNAs, genomic imprinting and gene silencing are other 
prominent examples of epigenetic mechanisms that are essential for cell fate decisions (149). 
Epigenetic regulation of BZLF1 promoter and viral genome 
One of the hallmarks of EBV, the capacity to establish latent infection in the host, is 
regulated by diverse epigenetic mechanisms.  
The EBV viral capsid contains a linear double stranded DNA in an epigenetically 
naïve state. One of the first steps, upon infection of a host cell, is the circularization of the 
viral DNA in order to protect the DNA ends from degradation and avoid the induction of a 
DNA damage response (150). The circular DNA associates with histones and other cellular 
DNA-associated proteins to form nucleosomes (151) and the CpG dinucleotide become 
methylated (152). Thus, the viral DNA acquires all the features of cellular chromatin.  
The four types of global epigenetic modification known to repress EBV’s lytic viral 
genes during latency are: - histone modifications, - nucleosomal density and compaction of 
DNA, - DNA methylation, and - chromatin architecture. These modifications repress the 
expression of the viral lytic genes and tightly regulate the viral latent gene expression 
program. 
Although silencing of gene expression is essential for EBV to escape immune 
recognition during the latent phase, the advantage of epigenetic silencing is its efficient and 
fast reversion. Upon EBV lytic induction, a signaling cascade induces the expression of the 
immediate early viral transcription factor BZLF1, which in turn activates the lytic 
transcription cascade that, within few hours, leads to viral particle synthesis. BZLF1 
preferentially binds to a subset of CpG-methylated Zebra responsive element (ZRE) motifs. 
Due that the latent EBV genome, and especially the ZRE-containing lytic promoters, heavily 
features CpG DNA methylation, BZLF1 can disrupt the latency efficiently (76, 77, 153). 
The expression of BZLF1 is restricted by repressive factors including Jun dimerization 
protein 2 (JDP2) (154), zinc finger E-box binding factor (ZEB) (89), Yin Yang 1 (YY1) 
(155), and an unidentified repressor that binds to the ZIIR motif (156). In addition to this, like 
the other viral genes, BZLF1 expression is regulated by epigenetic modifications. While other 
EBV promoters are heavily methylated, there are very few CpG motifs, methylated or not, in 
the Zp promoter region of BZLF1 (157, 158). One possible explanation is that the silencing of 
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BLZF1 by CpG methylation would be too strong for a quick response. BZLF1 would not be 
expressed easily enough upon stimulation. Therefore, Zp is primarily silenced and regulated 
by histone modifications. Indeed, treatment of latently infected B-cells with histone 
deacetylase (HDAC) inhibitors, like sodium butyrate or trichostatin A (TSA) can reactivate 
the viral lytic phase in certain cells lines like, for example, the Akata BL cells (86, 159). 
We and others used chromatin immunoprecipitation assays to demonstrated that 
suppressive histone markers, including tri-methylation of histone H3 on lysine 27 
(H3K27me3), H3K9me2/3 and H4K20me3, are present in the Zp region of latent cells and 
that strong histone acetylation, phosphorylation, and H3K4me3 markers correlate with 
reactivation of the virus (86, 88, 160, 161).  
H3K27me3 is a characteristic marker of facultative heterochromatin, a reversible form 
of heterochromatin where the expression of a wide variety of genes is silenced by histone 
modifications (162). This type of heterochromatin can be reversed by specific signals, to 
become transcriptionally active, unlike constitutive heterochromatin. 
Thus, through chromatinization of its DNA genome, EBV mimics the host’s gene 
silencing, using epigenetic mechanisms to shut down its genome and hide from the immune 
recognition. Moreover, EBV exploits this reversible gene silencing to quickly and efficiently 
overcome the repression of its lytic genes within few hours after the induction of its lytic 
cycle, leading to de novo virus synthesis. 
TLR9 regulation of histone modification and gene expression 
As we have seen, TLRs recognize PAMPS or DAMPs and activate specific signaling 
cascades that lead to the expression of proinflammatory cytokines, chemokines and antiviral 
interferons. The TLR induced response, at the heart of every innate immune response, is 
dynamically controlled and cell type-specific. Of course, transcription factors like NF-κB, 
AP1, IRFs and others are crucial to transduce the signal from the TLRs to the promoters and 
the molecular signaling events, leading from the TLRs to the promoter regions of 
inflammatory response genes have been described in great detail. Far less is known about the 
role epigenetics plays in shaping the transcriptional responses downstream of the TLRs, as 
well as other innate immune receptor systems. However, epigenetic factors/chromatin-based 
mechanisms have proved to be critical for context-specific gene expression in diverse innate 
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immune cell types (163, 164). Recent publications have shown that TLR-induced epigenetic 
changes constitute a critical new mechanism in both the positive and negative regulation of 
TLR-induced genes. TLR-induced chromatin remodeling on the IL12p40 promoter has been 
described, indicating that chromatin remodeling is an additional level of TLR signaling 
specificity (165, 166). Foster et al found that individual host gene promoters can be targeted 
and modulated in its histone architecture after TLR engagement (164). Repeated triggering of 
TLRs was shown to repress activation of selected TLR-responsive promoters (TLR 
tolerance), while other TLR-responsive promoters were not affected (164). Moreover, TLRs 
also directly interfere with histone structure of pathogen gene promoters. Our group showed 
that TLR9 induction is changing the acetylation and phosphorylation states of histones on the 
BZLF1 lytic gene promoter of EBV leading to suppression in lytic gene expression (48). 
Thus, TLRs can interfere with lytic activation of a chronic pathogen like EBV residing in its 
latent form via alteration of histones on the viral gene promoter. 
Thus, one significant question to be answered is the molecular means by which 
general chromatin writers are targeted to the promoters of individual host and viral genes 
upon TLR9 triggering. No study has identified the exact mechanism by which TLR9 
stimulation induces changes in the histone architecture. TLR engagement strongly induces 
distinct sets of MAP kinase kinases (MKKs/MEKs) as well as MAPK phosphatases, e.g. 
DUSP1 (MAPK phosphatase 1) (167). In turn, these enzymes are able to differentially 
regulate the activity of the AGC kinase family members, e.g., MSK1/2 and RSK2, which are 
known to affect histone phosphorylation (167, 168). In the context of histone acetylation, 
TLR9 might affect the recruitment of co-activators, which have histone deacetylase (HDAC) 
or histone acetyl-transferase (HAT) activities (like p300/CBP), leading to chromatin 
remodeling on host and viral promoters and subsequent changes in gene expression. 
Importantly, MSKs, HDACs and HATs are known to modify a range of other non-histone 
proteins including transcription factors such as CREB, ATF-1, and NF-κB. 
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SUBJECT OF INVESTIGATION 
The main topic of my thesis work was the mechanisms by which innate immune 
stimulation influences EBV lytic reactivation in BL cells. The following topics were subject 
of investigation: 
1) From TLR9 stimulation to EBV lytic inhibition. A detailed analysis of the TLR9 
signaling pathway in BL cells and how it impacts BZLF1 expression. (Manuscript 
1) 
In this manuscript I investigated the signaling pathway linking TLR9 to the Zp 
promoter. Previous published results showed that neither NF-kB nor other known downstream 
components of the canonical TLR9 signaling pathway are keys for the TLR9-mediated 
suppression of lytic EBV, suggesting an alternative pathway to play a role. First, in order to 
direct the research, we tested if the TLR9-induced lytic inhibition requires a first round of de 
novo protein synthesis. Then, using siRNA and CRISPR Cas9 silencing technologies we 
targeted MyD88, IRAK4 and IRAK1 downstream of TLR9. For this project I performed all 
the CRISPR/Cas9 plasmids cloning, controls, WB and activity assays and I designed the 
experiments and supervised Jeannine Marty, a master student, for the protein synthesis and 
siRNA experiments. For the supplementary WB asked by the Journal of Virology reviewers, I 
stimulated and lysed the cells and Vanessa Mordasini performed the WB.  
2) From TLR9 stimulation to EBV lytic inhibition. A detailed analysis of the Zp 
lytic promoter upon TLR9 and/or BCR stimulation in reporter cells lines. 
(Manuscript 2) 
To characterize the effect of TLR9 on the Zp promoter sequence in detail, we 
evaluated the TLR9-induced suppression for different Zp regions coupled to a luciferase gene 
in a reporter system. Unexpectedly, TLR9 triggering did not affect the activation of Zp 
reporter constructs, independently of the length or region of the Zp promoter used on the 
reporter. Thus, we hypothesized that TLR9-induced histone modifications observed in 
genomic EBV upon lytic reactivation were not found in episomal reporter constructs. I 
completed all the figures with experiments using the pHEBo-2.3 kb Zp luciferase reporter 
plasmid and contributed to the second part of this manuscript, investigating the reason for the 
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different regulation of the reporter constructs, performing all the chromatin 
immunoprecipitation assays for the genomic EBV and the different reporter construct.  
3) How does the TLR9 polymorphism influence the effect of CpG agonists on BL 
cells? (Manuscript 3) 
Here, we used BL-cell lines to model direct effects of TLR9 stimulation on malignant 
cells, investigate the influence of EBV, and assess the impact of TLR9 SNPs, which we found 
in primary BL samples or in healthy primary cells. My contribution to this paper was the 
investigation of the cell death mechanism by measuring caspase activity and PARP cleavage 
and performing the assays with caspase inhibitors.  
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RESULTS 
Manuscript I: IRAK4 is essential for TLR9-induced suppression of Epstein-
Barr virus BZLF1 transcription in Akata Burkitt’s lymphoma cells  
Marc Jordi1, 2, Jeannine Marty1, 2, Vanessa Mordasini1, 2, Anna Lünemann1, 2, Scott McComb1, 
2, Michele Bernasconi1, 2, David Nadal1, 2, 3 
Manuscript submitted for publication 
Abstract 
Latent Epstein-Barr virus (EBV) infection is associated with endemic Burkitt’s 
lymphoma (eBL) that is epidemiologically linked to chronic infection with the malaria agent 
Plasmodium falciparum. Lytic reactivation of EBV eventually leads to the death of the host 
cell. Previously, we showed that activation of the innate immunity signaling via Toll-like 
receptor (TLR) 9 by hemozoin, a pigment of P. falciparum, is critical in inhibiting EBV lytic 
reactivation and thereby causing reinforcement of its latency in eBL cells. Here, we show that 
EBV lytic repression is reinforced by TLR9 engagement via a mechanism that is largely 
protein synthesis independent and that two TLR9 downstream signaling molecules, MyD88 
and IRAK4, exhibit central roles. Counteracting signaling of these molecules could allow 
lytic reactivation and thus provide novel treatment targets to combat eBL.  
 
For detailed information see attached manuscript 1. This manuscript is the main part 
of my work and thus will be the essential part in the discussion and outlook section.  
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Complementary Data and Results to Manuscript I 
A residual IRAK4 activity is sufficient to inhibit viral lytic reactivation in 
Burkitt’s lymphoma cells after TLR9 triggering 
As shown in the manuscript, the inactivation of TLR9, MyD88 or IRAK4 in 
CRIPSR/Cas9 single cell clones rescued the EBV lytic reactivation upon treatment of BL 
cells with ODN CpG 2006 prior to BCR cross-linking. To know if residual TLR9 activity 
impacts on EBV lytic reactivation, we stably transfected cells with shRNA against IRAK4 
(shIRAK4). The percentage of Akata cells containing the plasmid was determined for each 
cell line produced, by flow cytometry for GFP-expressing cells. IRAK4 silencing was verified 
at the mRNA and protein levels by RT-qPCR and Western Blot, respectively. As further 
controls, and to verify that the expression of shRNA for IRAK4 does not change the 
expression level of the receptors to be stimulated, the IgG protein expression on the cells 
surface and the TLR9 mRNA level were measured by flow cytometry and RT-qPCR, 
respectively. Finally, the IL-10 mRNA level was used as readout for the TLR9 pathway 
activity. The degradation of IRAK1 upon recruitment to the TLR9-MyD88-IRAK4 complex 
and phosphorylation by IRAK4 (169, 170) was used as a secondary readout for TLR9 
pathway activity.  
More than 98% of the independently produced AkatashIRAK4_1, AkatashIRAK4_2, 
AkatashIRAK4_3, AkatashIRAK4_4 and AkatashIRAK4_1 cell pools, transfected with shIRAK4 or 
shControl plasmids, expressed GFP as determined by flow cytometry (data not shown) and 
therefore contained the transfected plasmid. We measured a reduction of IRAK4 mRNA of 
20% in AkatashIRAK4_1, of 55% in AkatashIRAK4_2, of 52% in AkatashIRAK4_4, and of 40% in 
AkatashIRAK4_3 (Fig. 2a). This reduction was also detectable at the protein level, and ranged 
from a 50% IRAK4 expression reduction in AkatashIRAK4_1 to 80% in AkatashIRAK4_2 and 
AkatashIRAK4_3 and was below detection in AkatashIRAK4_4 (Fig. 2b). An Akata cell line 
expressing a dominant negative form of MyD88 (48) (AkataMyD88-DN) was used as a positive 
control for inactivation of the TLR9 pathway in the different experiments. The level of 
IRAK4 mRNA remained stable but a 70% protein expression reduction was measured in the 
AkataMyD88 DN cells when compared to the Akatashcontrol cells. The reduced IRAK4 expression 
in AkataMyD88 DN cells could be explained by decreased IRAK4 protein stability caused by the 
lack of myddosome complex formation. Indeed, upon ODN CpG 2006 stimulation of TLR9, 
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MyD88 binds to TLR9 dimers and initiates the formation of a protein complex with IRAK4, 
IRAK1 and other proteins called myddosome (171).  
Surface IgG protein (Fig. 2c) and TLR9 mRNA (Fig. 2d) expression levels were not 
affected by the IRAK4 down regulation in the 4 independent shIRAK4 clones tested, when 
compared to the cells transfected with a control plasmid (Akatashcontrol). 
Finally, IL-10 mRNA expression after ODN CpG 2006 treatment, measured as a 
readout for TLR9 pathway activity, was reduced about 2-fold in AkatashIRAK4_1, and about 3-
fold in AkatashIRAK4_2, AkatashIRAK4_3, and AkatashIRAK4_4 when compared to IL-10 mRNA 
expression in Akatashcontrol cells (Fig. 2e). IRAK1 protein expression, measured as a second 
readout for TLR9 pathway activity, was decreased to about 70% after 8h stimulation of 
Akatashcontrol cells with ODN CpG 2006, and, importantly, was decreased to about 20% after 
ODN CpG 2006 stimulation of AkataMyD88-DN control cells. This is consistent with a reduced 
signaling activity of the TLR9 pathway (Fig. 2f). AkatashIRAK4_1 and AkatashIRAK4_3 showed a 
50% decrease of IRAK1 protein after ODN CpG 2006 treatment, whereas the AkatashIRAK4_2 
and AkatashIRAK4_4 showed no significant changes. Taken together, these results show that the 
IRAK4 mRNA and protein levels could be decreased by the stable transfection of shRNA-
IRAK4 and result in a reduced, but not completely abrogated, TLR9 pathway activity.  
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Figure 2: Silencing of IRAK4 by shRNA does not completely abrogate TLR9 signaling activity. Independently 
produced Akata cell pools, stably transfected with shIRAK4 or shControl, were named AkatashIRAK4_ 1, 2, 3 and 4 and 
Akatashcontrol. Akata cell line expressing a dominant negative form of MyD88 (AkataMyD88 DN) was used as further 
control. (a) IRAK4 relative mRNA expression level over HMBS over Akatashcontrol was measured by RT-qPCR 
(b) IRAK4 protein level was measured by Western Blot before and after ODN CpG 2006 treatment for 8h. 
IRAK4 values were calculated relatively to β-actin and normalized to the untreated sample of Akatashcontrol. (c) 
Percentage of IgG positive cells tested by flow cytometry. (d) TLR9 relative mRNA expression level over to 
HMBS normalized to Akata WT cells measured by RT-qPCR. (e) IL-10 mRNA expression level relative to 
HMBS measured by RT-qPCR after 8h ODN CpG 2006 treatment. n= 3. (f) IRAK1 protein depletion measured 
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by Western Blot 8h after ODN CpG 2006 treatment. IRAK1 values were calculated relatively to the β-actin level 
of the same sample. Untreated samples were set to one and ODN CpG 2006 treated samples calculated relatively 
to it. 	
To know if the residual TLR9 activity is sufficient to inhibit EBV lytic reactivation or 
if the BZLF1 expression can be rescued by the IRAK4 protein reduction, Akata WT cells 
stably transfected with shRNA against IRAK4 were treated for 2h with ODN CpG 2006 
followed by treatment with anti-IgG for additional 6h. Interestingly, independently of the 
IRAK4 protein level and TLR9 pathway activity, the activation of the TLR9 pathway by 
ODN CpG 2006 inhibited the relative BZLF1 transcripts over HMBS over unstimulated cells 
induced by anti-IgG treatment by about 72.1 % (p=0.0182) in AkatashIRAK4_1 cells, 83.2 % 
(p=0.004) in AkatashIRAK4_2 cells, 82.3 % (p=0.0112) in AkatashIRAK4_3 cells and 77.2 % (p= 
0.0007) in AkatashIRAK4_4 cells (Fig. 3). For comparison, the activation of TLR9 in 
Akatashcontrol cells reduced about 86.1 % (p=0.0228) the relative BZLF1 transcripts expression 
induced by anti-IgG treatment. The AkataMyD88 dn control cells, on the other hand, showed a 
rescue of the BZLF1 expression after ODN CpG 2006 and anti-IgG treatment (Fig. 3).  
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Figure 3: TLR9 signaling activity of 30% or less is sufficient to inhibit BZLF1 expression after activation 
through ODN CpG 2006. BZLF1 mRNA expression level relative to HMBS was measured by RT-qPCR after 
ODN CpG 2006 pre-treatment for 2h followed by 6h incubation of stably transfected AkatashIRAK4 cells with anti-
IgG. Untreated BZLF1 values were set to one and treated samples calculated relatively to it. One representative 
experiment out of three is shown. 
Taken together, these results indicated that reduction of the TLR9 signaling activity, 
measured by the IL-10 mRNA increase and IRAK1 protein depletion after ODN CpG 2006 
treatment, does not affect the TLR9-induced inhibition of BZLF1 expression upon BCR cross-
linking. Moreover, these results suggested that residual IRAK4 kinase activity is sufficient to 
amplify the TLR9 signal leading to a complete inhibition of EBV lytic reactivation.  
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Manuscript II: TLR9 induction suppresses Epstein-Barr virus lytic 
reactivation in Burkitt’s lymphoma cells by modifying histones structure on 
the genomic Zp promoter but not on reporter systems 
Marc Jordi, Ludwig Zauner, Marta Wehrmüller, Natascha Andrea Wuillemin, Jürg A. Sigrist, 
Christoph Berger, Michele Bernasconi, David Nadal 
Manuscript under preparation 
Abstract 
Background: The triggering of Toll-like receptor 9 (TLR9) results in the suppression of 
EBV’s master regulatory lytic gene BZLF1. The reduction of EBV lytic gene expression 
promotes viral latency in the cells and latent EBV, in turn, might enhance the possibility for 
cell transformation. Lytic reactivation of EBV is associated with modification of chromatin 
structure on the BZLF1 promoter Zp.  
Results: To characterize the effect of TLR9 on the BZLF1 promoter Zp in more detail, we 
evaluated the TLR9-induced suppression of lytic EBV for different Zp regions coupled to a 
luciferase gene in a reporter system. Unexpectedly, TLR9 triggering inhibited BZLF1 
expression in BCR-induced Akata Burkitt’s lymphoma cells latently infected with EBV, but 
did not affect the activation of Zp reporter constructs. TLR9-induced histone modifications 
observed in genomic EBV upon lytic reactivation were not found in episomal reporter 
constructs. 
Conclusions: The underlying mechanism of the differential effect of TLR9 signaling might 
mirror the distinct chromatin structure of the transfected Zp reporter construct compared to 
EBV’s viral genome. This reporter system based research does not reflect the viral reality and 
other strategies should be considered to study EBV’s lytic reactivation in order to use it for 
cancer cell-tailored therapeutic approach. 
 
For detailed information see attached manuscript 2.  
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Manuscript III: TLR9 agonists induced cell death in Burkitt’s lymphoma 
cells is variable and influenced by TLR9 polymorphism 
Julia Noack, Marc Jordi, Ludwig Zauner, Davide Alessi, Andrea Burch, Michel Tinguely, M. 
Hersberger, Michele Bernasconi and Davide Nadal 
Cell Death and Disease (2012) 3, e323; doi:10.1038/cddis.2012.60; published online 21 June 
2012 
Abstract 
Toll-like receptor 9 (TLR9) triggering is a promising novel strategy to combat cancer as it 
induces innate and adaptive immunity responses. B-cell lymphoma is unique in this context as 
tumor cells express TLR9 and may harbor latent Epstein-Barr virus (EBV), a gamma-
herpesvirus with remarkable oncogenic potential when latent. Latent EBV may be promoted 
by TLR9 triggering via suppression of lytic EBV. Here, we elaborated an initial assessment of 
the impact of TLR9 triggering on EBV-positive and EBV-negative B-cell lymphoma using 
Burkitt’s lymphoma (BL) cell lines as an in vitro model. We show that, independent of the 
presence of EBV, the TLR9 ligand oligodeoxynucleotide (ODN) CpG-2006 may or may not 
induce caspase-dependent cell death in BL cells. Moreover, ODN CpG-2006-induced cell 
death responses of BL cells were associated with TLR9 single-nucleotide polymorphisms 
(SNPs) rs5743836 or rs352140, which we detected in primary BL tumors and in peripheral 
blood from healthy individuals at similar frequencies. Thus, our findings suggest that the 
effect of TLR9 agonists on BL cells should be tested in vitro before installment of therapy and 
TLR9 SNPs in BL patients should be determined as potential biological markers for the 
therapeutic response to treatment targeting innate immunity.  
 
For detailed information see attached manuscript 3.  
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GENERAL DISCUSSION AND OUTLOOK 
Our group used eBL cell lines as instrument to investigate the molecular mechanisms 
regulating the inhibition of lytic EBV. eBL is strongly associated to the co-infection with P. 
falciparum and EBV but develops also in HIV patients (30% of which are EBV positive).  
Interestingly, the infections by P. falciparum, HIV or primary EBV infection induce a great 
GC expansion. According to genetic, phenotypic and transcriptional analysis the origin of BL 
are GC B-cells. Although the mutation point is different, the eBL as well as the AIDS-
associated BL and the sBL are characterized by a chromosomal translocation between the c-
myc oncogene and one of the immunoglobulin loci, which leads to a constitutive expression 
of c-myc and to the uncontrolled growth of the cell. The c-myc translocation might thus by 
mediated through the expression of AID, which is highly expressed in the GC as it is 
responsible for the somatic hypermutation and class switch recombination of immunoglobulin 
genes as they undergo affinity maturation in the GC (31–33). Thus, factors like Malaria, EBV 
or HIV infection, inducing a GC expansion, increase the probability of c-myc translocation. 
Normally, the uncontrolled expression of c-myc as observed in eBL cell should lead to the 
apoptosis of the cell, but there are studies suggesting that the EBV infection of the cells 
provides a resistance to this apoptosis (36). The understanding of c-myc and EBV influence in 
eBL development has progressed in the last years, while the role of P. falciparum remains 
poorly understood. 
Our group could previously show that hemozoin, a disposal product formed from the 
digestion of blood by P. falciparum, suppresses through the activation of TLR9, the lytic 
reactivation of EBV in BL cells by affecting BZLF1 promoter histone sites (48). Here we 
aimed to characterize more in detail the TLR9-induced inhibiting mechanisms. In this work, 
we used ODN CpG 2006 as a TLR9 rather than hemozoin, as a TLR9 agonist. First, to direct 
our investigation, we tackled the question whether protein synthesis is decisive in EBV’s 
reactivation process upon TLR9 activation of host cells. Using translation inhibitors, we could 
provide evidence that TLR9-mediated inhibition of anti-IgG triggered BZLF1 expression does 
not require de novo protein synthesis. Protein translation inhibitors, as expected, abrogated 
the positive feedback loop that ZEBRA exerts on its own Zp promoter to amplify the lytic 
reactivation signal upon BCR cross-linking. But interestingly, TLR9 stimulation inhibited 
BZLF1 mRNA expression to a similar degree, whether protein synthesis was inhibited or not. 
This strongly suggests that the regulation of EBV’s lytic reactivation upon TLR9 stimulation 
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with ODN CpG 2006 is, to a large extend, protein synthesis independent and suggests post-
translational modifications to be responsible for EBV lytic gene repression. Moreover, TLR9-
induced cytokines like IL-10, IL-12 or IFNγ can be excluded to play a rule in the lytic 
inhibition in our system (139). The question weather TLR9 activation also affects ZEBRA’s 
activity via sumoylation (172) or other post-translation modifications remains open. Finally, 
even if, due to incomplete translation inhibition, we cannot completely exclude the existence 
of a newly synthesized unknown repressor factor(s), our results strongly indicate that EBV 
reinforces its latency by hijacking the TLR9-induced post-translational modifications to 
repress its lytic genes expression (Manuscript 1). Then, based on previous observations which 
stipulates that the suppression of lytic EBV treatment with ODN CpG 2006 is mediated 
through TLR9 but is independent of TLR9-elicited NF-kB activity as well as PI3K, ERK, 
JNK or p38, other known TLR9 signaling components (48) we inactivated TLR9, MyD88, or 
IRAK4 genes in single cell clones using the CRISPR/Cas9 methodology. We unequivocally 
and unprecedentedly show that MyD88 and IRAK4 are essential for the TLR9-dependent 
inhibition of EBV lytic reactivation upon BCR cross-linking (Manuscript 1). By contrast, 
silencing of IRAK4 with shRNA showed that a 70% decrease of IRAK4 mRNA and protein, 
which is sufficient to reduce the TLR9 pathway activity, was not sufficient to abolish the 
TLR9-blockade of EBV lytic reactivation. This suggests that a residual IRAK4 and thereby a 
low TLR9 signaling pathway activity, after stimulation with ODN CpG 2006, are sufficient to 
maintain EBV in a latent state upon BCR cross-linking with anti-IgG. It is commonly 
accepted that protein kinase activity is particularly difficult to block by silencing, considering 
that the residual kinase activity might be amplified. In fact, IRAK4 recruits and activates 
IRAK1 (169, 170), which, upon activation by IRAK4, is proposed to act in a positive 
feedback loop to activate other IRAK1 molecules and members of the IRAK family (170). 
This suggests a role for IRAK1 as an amplifier of the TLR9 signaling pathway, which would 
override the silencing of IRAK4 in TLR9 pathway activity. This would imply that IRAK4 is 
not an ideal target for intervention to support EBV lytic reactivation upon BCR cross-linking 
in TLR9 stimulated BL cells. Indeed, only a 100% inactivation of the IRAK4 protein, 
obtained by mutation of the gene using the CRISPR/Cas9 method, was able to rescue the 
TLR9-induced EBV lytic inhibition. Intriguingly, using the CRISPR/Cas9 method, we failed 
to establish IRAK1 mutated BL cell clones retaining EBV genomes. This preliminary finding 
suggests that IRAK1 could play a central role in steering EBV persistence. EBV nuclear 
protein EBNA1 binds to the origin of viral replication and is essential to mediate replication 
and partitioning of its episome during the division of the host cell. EBNA1 function is 
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regulated by the phosphorylation of ten specific sites (173). The kinases responsible for 
EBNA1 phosphorylation have not been identified, but IRAK1 could be a potential candidate. 
Thus, one hypothesis for the loss of EBV in the IRAK1-mutated clones is that EBNA1’s 
function is altered by the inactivation of IRAK1, which affects the replication and partitioning 
of EBV’s genomic DNA in dividing cells leading to the dilution of the virus in the daughter 
cells and finally to its loss. However, it is important to consider that this result has only been 
observed only in a limited number of clones, mostly transfected with the IRAK1-b 
CRISPR/Cas9 plasmid, the most efficient one, in three independent single cell cloning round. 
The potential importance of IRAK1 activity for EBNA1 function requires the analysis of 
more clones transfected with different IRAK1- CRISPR/Cas 9 plasmids as well as further 
investigations (Manuscript 1). 
The BZLF1 minimal promoter region Zp-221 is known to harbor the elements for 
maintaining low basal activity and for the transcriptional activation by agents inducing lytic 
EBV infection (174, 175). Notably, upstream of -221 bp several negative elements have been 
identified (155, 176). Nevertheless, the Zp promoter regions affected upon TLR9 triggering 
remain unknown. Using different Zp regions coupled to a luciferase gene in a reporter system, 
we could show that, unexpectedly, TLR9 triggering inhibited BZLF1 expression in BCR-
induced Akata Burkitt’s lymphoma cells latently infected with EBV, but did not affect the 
activation of Zp reporter constructs. Lytic reactivation of EBV is associated with modification 
of chromatin structure of the BZLF1 promoter Zp. Using ChIP assays, we observed that 
TLR9-induced inhibition of histone H3K9 acetylation at the full length genomic Zp region did 
not take place on the different Zp reporter constructs. This indicated that TLR9 triggering has 
a different effect on chromatin structure associated with genomic EBV than that associated 
with reporter plasmids. This, in turn, strongly suggests that the suppressive effect of TLR9 
signaling on Zp promoter activation is linked to a specific chromatin conformation associated 
with genomic EBV. Our findings further support the importance of chromatin reorganization 
in the regulation of transcription of BZLF1 and therefore in the balance between EBV latency 
and lytic reactivation in cancer cells. We showed that a reporter system based research does 
not reflect the full-length genomic viral context. Thus, one must consider other strategies for 
the further elucidation of chromatin reorganization in the regulation of transcription of BZLF1 
and the study Zp regulatory elements. Moreover, precaution should be taken when 
interpreting reporter system based results (Manuscript 2).  
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Synthetic TLR9 agonists are potential anti-cancer agents. B-cell activation can 
eventually lead to activation-induced cell death of cancer cells and therefore support anti-
cancer treatment. Therefore, we used BL-cell lines as an in vitro model for B-cell tumor to 
measure the direct effects of TLR9 agonists on malignant cells, investigate the influence of 
EBV, and assess the impact of TLR9 SNPs, which we found in primary BL samples or in 
healthy primary cells. We found that treatment with TLR9 ligands induces distinct cytokine 
expression and cell death responses in distinct BL cells. TLR9-induced apoptosis could be 
suppressed by pan caspase inhibitors, was not dependent on the presence or absence of EBV 
in the tumor cells and was associated with SNPs in the TLR9 gene. Thus, therapeutic TLR9 
triggering appears to be a double-edge sword that may induce apoptosis, or enhance 
lymphoproliferation. Our findings suggest that the effect of TLR9 agonists on BL cells should 
be tested in vitro before installment of therapy and that TLR9 SNPs in BL patients should be 
evaluated as potential biological markers for the response to treatment targeting innate 
immunity (manuscript 3). 
Finally, the presence of latent EBV in cancer cells and its capacity to kill its host cell 
upon lytic reactivation makes EBV an interesting target for the development of oncolytic 
therapies with the aim to kill specifically the EBV infected cancer cells and to spare the 
healthy bystander cells. In vitro, this can be initiated easily by a variety of agents and by 
cross-linking the immunoglobulin of the B-cell receptor on EBV-harboring cells but in vivo 
the EBV-lytic reactivation is more challenging. In transformed endemic BL cells, after c-myc 
translocation, the death of the tumor cells by a switch to lytic EBV might be blocked because 
of P. falciparum induced TLR9 activation, leading to an increased survival of the EBV-
infected malignant cells. Thus, an enhanced understanding of the regulation of EBV lytic 
reactivation by cellular signaling pathways, including TLR9 signaling, will allow optimizing 
therapeutic strategies based on manipulation of chromatin remodeling. 	 	
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Abstract		Latent	Epstein-Barr	virus	(EBV)	infection	is	associated	with	endemic	Burkitt’s	lymphoma	(eBL)	that	is	epidemiologically	linked	to	chronic	infection	with	the	malaria	agent	Plasmodium	falciparum.	Lytic	reactivation	of	EBV	eventually	leads	to	the	death	of	the	host	cell.	Previously,	we	showed	that	activation	of	the	innate	immunity	signaling	via	Toll-like	receptor	(TLR)	9	by	hemozoin,	a	pigment	of	P.	falciparum,	is	critical	in	inhibiting	EBV	lytic	reactivation	and	thereby	causing	reinforcement	of	its	latency	in	eBL	cells.	Here,	we	show	that	EBV	lytic	repression	is	reinforced	by	TLR9	engagement	via	a	mechanism	that	is	largely	protein	synthesis	independent	and	that	two	TLR9	downstream	signaling	molecules,	MyD88	and	IRAK4,	exhibit	central	roles.	Counteracting	signaling	of	these	molecules	could	allow	lytic	reactivation	and	thus	provide	novel	treatment	targets	to	combat	eBL.			
Keywords:	TLR9;	Burkitt’s	lymphoma;	Epstein–Barr	virus;	Plasmodium	falciparum;												
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Importance	Latent	Epstein-Barr	virus	(EBV)	infection	is	associated	with	endemic	Burkitt’s	lymphoma	(eBL)	that	is	epidemiologically	linked	to	chronic	infection	with	the	malaria	agent	Plasmodium	falciparum.	Lytic	reactivation	of	EBV	eventually	leads	to	the	death	of	the	host	cell.	Previously,	we	showed	that	activation	of	the	innate	immunity	signaling	via	Toll-like	receptor	(TLR)	9	by	hemozoin,	a	pigment	of	P.	falciparum,	is	critical	in	inhibiting	EBV	lytic	reactivation	and	thereby	causing	reinforcement	of	its	latency	in	eBL	cells.	Here,	we	show	that	EBV	lytic	repression	is	reinforced	by	TLR9	engagement	via	a	mechanism	that	is	largely	protein	synthesis	independent	and	that	two	TLR9	downstream	signaling	molecules,	MyD88	and	IRAK4,	exhibit	central	roles.	Counteracting	signaling	of	these	molecules	could	allow	lytic	reactivation	and	thus	provide	novel	treatment	targets	to	combat	eBL.	
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Introduction		Primary	infection	with	the	Epstein-Barr	virus	(EBV)	is	mostly	asymptomatic,	and	more	than	90%	of	the	adult	population	worldwide	are	EBV	carriers	after	the	virus	has	established	reversible	latent	infection	1,2.	This	life-long,	virtually	harmless,	host–virus	coexistence	must	be	regarded	as	the	result	of	a	long	co-evolution	based	on	modulation	of	EBV	gene	expression	in	different	subsets	of	infected	cells	and	the	finely	tuned	adaptation	to	the	immune	response	of	the	human	host	3.	Yet,	EBV	is	associated	with	endemic	Burkitt’s	lymphoma	(eBL),	one	of	the	most	common	cancers	in	children	in	equatorial	Africa,	i.e.,	in	areas	where	chronic	co-infection	with	EBV	and	the	malaria	parasite	Plasmodium	falciparum	prevails	4.	As	a	member	of	the	gammaherpesvirus	family,	EBV	establishes	latency	in	B	cells	5.	In	eBL	cells,	EBV	persists	in	a	highly	restricted	form	of	latency	6,	termed	latency	program	I.	In	this	program,	EBV’s	lytic	and	latent	genes	are	repressed	except	EBV	nuclear	antigen	(EBNA)1,	which	is	essential	for	episomal	retention	of	EBV	in	dividing	cells.	Thereby,	the	propagation	of	the	virus	to	daughter	cells	is	guaranteed	and	the	repression	of	EBV’s	gene	expression	contributes	to	the	evasion	from	the	host’s	immune	system	7.	Latency	of	EBV	is	reversible,	to	ensure	viral	transmission	to	uninfected	cells	and	to	new	hosts	2.	Thus,	EBV	periodically	lytically	reactivates,	which	leads	to	the	production	of	infectious	viral	particles	and	death	of	the	infected	B-cell.	The	lytic	reactivation	is	set	off	by	the	expression	of	the	immediate-early	protein	ZEBRA	encoded	by	EBV’s	master	lytic	gene	BZLF1.	ZEBRA	is	a	transcription	factor	that	induces	a	lytic	cascade	leading	to	early	and	late	lytic	EBV	gene	expression	8.	In	BL	cell	lines,	latently	infected	with	EBV	(e.g.	Akata	cells),	the	lytic	reactivation	can	be	induced	using	diverse	agents	including	phorbol	esters	(TPA),	sodium	butyrate	(SB),	transforming	growth	factor-β	(TGF-β),	and	B-cell	
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receptor	(BCR)	cross-linking	anti-immunoglobulin	G	(anti-IgG)	9–13.	EBV	particles	and	lytic	proteins	provoke	a	wide	range	of	immune	responses	through	innate	immune	mechanisms	14	and	adaptive	humoral	15	and	T-cell	responses	16.	Thus,	the	restriction	to	essential	proteins	required	for	the	latent	viral	persistence	and	replication	is	beneficial	for	both	EBV	and	the	host	cell.	To	prevent	aberrant	spontaneous	lytic	reactivation,	cell	death	and	subsequent	activation	of	the	immune	system,	EBV	latency	is	tightly	controlled	by	histone	modifications	17,18	and	by	DNA	methylation	19.	In	addition	to	these	intrinsic	regulating	factors,	EBV	can	hijack	the	innate	immune	system,	and,	in	particular,	the	signaling	via	Toll-like	receptors	(TLRs)	to	regulate	the	balance	between	latency	and	lytic	reactivation	20.	Our	group	showed	that	hemozoin,	a	disposal	product	formed	from	the	digestion	of	blood	by	P.	falciparum,	activates	TLR9	signaling	and	suppresses	the	lytic	reactivation	of	EBV	in	BL	B-cells	in	vitro	by	affecting	the	histones	state	at	the	promoter	of	BZLF1	21.	Nevertheless,	it	remains	unclear	whether	this	effect	is	protein	synthesis	independent,	thus	a	direct	consequence	of	the	activation	of	TLR9	signaling,	or	whether	it	requires	the	expression	of	a	specific	unknown	protein.		TLRs	are	essential	elements	of	the	innate	immune	system.	They	are	transmembrane	receptors	involved	in	the	recognition	of	pathogen	associated	molecular	patterns	(PAMPs)	or	danger	associated	molecular	patterns	(DAMPs),	which	initiate	the	inflammatory	response	by	the	production	of	cytokines	22,23.	Endosomal	TLR9	is	expressed	in	B	cells	and	acts	as	a	sensor	for	unmethylated	CpG	oligonucleotides	(ODN)	found	on	a	large	scale	in	bacterial	DNA	24.	Upon	stimulation,	the	TLR9	cytoplasmic	Toll/interleukin-1	receptor	(TIR)	domain	associates	with	the	TIR	domain-containing	adaptor	myeloid	differentiation	primary	response	gene	88	(MyD88).	The	latter	recruits	the	interleukin-1	receptor-associated	kinase	(IRAK)	4	to	TLR9	through	interaction	of	the	death	domains	of	both	molecules.	IRAK-1	is	activated	by	phosphorylation	and	associates	
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with	the	TNF	receptor	associated	factor	(TRAF)	6,	thereby	activating	the	IκB	kinase	(IKK)	complex,	leading	to	activation	of	mitogen-activated	protein	(MAP)	kinases	(JNK,	p38,	MAPK)	and	of	nuclear	factor	kappa	B	(NF-κB).	NF-κB	promotes	the	transcription	of	genes	involved	in	the	cellular	activation,	proliferation	and	in	the	production	of	pro-inflammatory	cytokines	25.	Recently,	we	showed	that	several	elements	of	the	TLR9	signaling	pathway,	including	NF-κB,	PI3K,	ERK,	JNK	and	p38,	are	not	necessary	for	the	inhibitory	effect	of	TLR9	signaling	on	BZLF1	mRNA	expression	21.	Thus,	additional	investigation	is	required	to	precisely	delineate	how	TLR9	signaling	impacts	on	EBV	lytic	reactivation.	Understanding	the	mechanisms	favoring	maintenance	of	lytic	EBV	infection	could	provide	potential	targets	for	treatments	aiming	at	activating	lytic	EBV	replication	and	inducing	lysis	of	EBV-harboring	cancer	B	cells.	Here,	we	aimed	at	advancing	the	detailed	understanding	of	TLR9	stimulation	suppressing	EBV	lytic	reactivation.	Using	protein	synthesis	inhibitors,	we	investigated	whether	inhibition	of	EBV	lytic	reactivation	requires	de	novo	protein	expression,	or	if	it	runs	through	already	existing	elements.	Moreover,	we	tested	the	importance	of	key	components	of	the	signaling	pathway,	which	are	directly	downstream	of	TLR9	by	generating	Akata	BL	cells	with	either	silenced	or	inactivated	TLR9,	MyD88,	IRAK4,	or	
IRAK1	genes.		
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Material	and	Methods		
Cells	and	cell	culture	The	BL	cell	line	Akata	12	was	obtained	from	Dr.	Andrew	Bell	(Birmingham,	UK).	Cells	were	grown	in	RPMI	1640	supplemented	with	10%	heat-inactivated	fetal	calf	serum,	streptomycin	(100	mg/ml),	penicillin	(100	U/ml)	and	L-glutamine	(2	mM).	Akata	cells	transfected	with	the	shLucGL3	(control)	or	shIRAK4	expressing	plasmids	were	grown	in	complete	medium	supplemented	with	200	μg/ml	Zeocin	(InvivoGen,	Nunningen,	Switzerland).	Akata	cells	expressing	a	dominant-negative	MyD88	(DN-MyD88	Akata)	21	were	grown	in	the	same	medium	supplemented	with	0.4	mg/ml	G418	(Promega,	Dübendorf,	Switzerland).		
Reagents	and	antibodies	ODN	2006	type	B	CpG	oligonucleotide	(#	11B15-MM)	was	bought	from	InvivoGen.	The	polyclonal	rabbit	α-human-IgG	antibody	(#A0423)	was	obtained	from	Dako	(DakoCytomation,	Zug,	Switzerland).	Cycloheximide	(VWR	international,	Dietikon,	Switzerland)	was	dissolved	in	H2O	to	a	concentration	of	10	mg/ml,	whereas	4E1RCat	(Sigma-Aldrich,	Buchs,	Switzerland)	was	adjusted	to	a	concentration	of	500	μg/ml	in	DMSO.	Digitonin	was	dissolved	in	DMSO	to	a	concentration	of	20	mg/ml.			
EBV	lytic	reactivation	and	ODN	CpG	2006	stimulation		Akata	cells	were	resuspended	at	1	x	106	cells/ml	in	supplemented	RPMI	1640	and	stimulated	with	0.5	mM	end	concentration	ODN	CpG	2006	(InvivoGen)	2	h	prior	to	stimulation	with	100	μg/ml	anti-IgG	(Dako).	At	6	h	after	treatment	with	anti-IgG,	cell	pellets	were	harvested	for	RNA	and	protein	extraction.	
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Protein	synthesis	inhibition	For	protein	synthesis	inhibition,	Akata	cells	were	treated	with	4E1RCat	(10	μM	or	25	μM)	or	cycloheximide	(33	μg/ml)	for	30	min	before	ODN	CpG	2006	treatment.	Cells	were	then	treated	as	described	in	the	section	above.	The	cells	viability	was	assed	by	Trypan	Blue	exclusion	assay.		
hIL-10	ELISA	hIL-10	protein	concentrations	were	determined	in	supernatants	from	stimulated	cultures	by	standard	capture	ELISA	(Ready-	SET-Go,	eBioscience,	Vienna,	Austria)	according	to	the	manufacturer’s	instructions.	Plates	were	read	using	a	Synergy	HT	Multi-Detection	Microplate	Reader	(BioTek,	Luzern,	Switzerland)	at	450	nm	and	570	nm.	The	values	measured	at	570	nm	were	subtracted	from	those	of	450	nm	and	the	cytokine	concentration	was	determined	by	extrapolation	from	the	standard	curve.		
RNA	preparation,	reverse	transcription	and	RT-qPCR	(TaqMan)		RNA	isolation,	DNAse	treatment,	reverse	transcription	and	quantitative	PCR	(RT-qPCR)	was	performed	as	described	before	20,26.	BZLF1,	hIL-10,	C-myc	(Hs00153408_m1;	Life	Technologies,	Zug,	Switzerland),	IRAK4	(Hs00211616_m1;	Life	Technologies)	or	TLR9	(Hs00152973_m1;	Life	Technologies)	mRNA	expression	was	normalized	to	the	mRNA	of	the	housekeeping	gene	HMBS	(same	as	above)	resulting	in	Δ	cycle	threshold	(ΔCT)	values.			
Cell	lysis	and	Western	blot	
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Total	protein	lysates	were	obtained	after	lysing	106	cells	in	RIPA	complete	buffer	(50mM	Tris-HCl	pH	7.5,	150mM	NaCl,	2mM	EDTA,	1%	NP40	complemented	with	0.1%	SDS,	1	x	EDTA-free	protease	inhibitor	cocktail	(Roche,	Rotkreuz,	Switzerland)).	Cell	extracts	were	passed	10	times	through	a	25-G	syringe.	Protein	content	was	determined	using	the	Pierce	BCA	Protein	Assay	Kit	(ThermoScientific,	Zug,	Switzerland),	according	to	the	manufacturer’s	instructions.	To	analyze	protein	expression	by	western	blot,	protein	(20	mg/well)	was	loaded	into	a	NuPAGE	4–12%	Bis-Tris	Gel	(Life	Technologies),	subjected	to	SDS-PAGE	and	transferred	to	a	nitrocellulose	membrane	(GE	Healthcare,	Glattbrugg,	Switzerland).	The	membrane	was	incubated	with	rabbit	anti-IRAK1	(sc-7883,	Santa	Cruz	Biotech,	Santa	Cruz,	CA),	rabbit	anti-Akt	(#9272),	rabbit	anti-pAkt	(#4058),	rabbit	anti-Mek1/2	(#9122),	rabbit	anti-pMek1/2	(#2338),	rabbit	anti-Syk	(#12358),	rabbit	anti-pSyk	(#2710)		or	rabbit	anti-β-actin	(#	4967,	all	from	Cell	Signaling	Technology,	Allschwil,	Switzerland)	primary	antibodies;	subsequently	with	anti-rabbit	(#	7074)	or	anti-mouse	(#	7076)	IgG	HRP-linked	secondary	antibodies	(Cell	Signaling	Technology).	The	signal	was	detected	with	the	ECL	Western	Blotting	Detection	Reagents	(GE	Healthcare)	and	imaged	using	the	LAS-3000	image	reader	(Fujifilm,	Dielsdorf,	Switzerland).	
	
EBV	genome	measurement	Genomic	DNA	was	extracted	from	2	x	106	Akata	cells	using	the	QIAamp	DNA	Mini	Kit	(Qiagen,	Hombrechtikon,	Switzerland).	Primers	were	diluted	to	a	concentration	of	300	nM	with	150	ng	DNA,	1x	SYBR	green	MasterMix	(#4309155,	Life	Technologies)	and	filled	with	water	to	a	volume	of	10	μl.	Samples	were	measured	in	triplicates.	Measurements	were	carried	out	on	an	ABI	7900HT	Fast	real-time	PCR	system	(Applied	
ATTACHMENTS 	
	 65 
Biosystems,	Rotkreuz,	Switzerland)	and	analyzed	with	SDS	2.2	software.	SYBR	green	primers	were	as	following:	
genomic	BamH1	W:	forward:	GCCAGACAGCAGCCAATTGT;	reverse:	GACTCCTGGCGCTCTGATG;	genomic	HMBS:	forward:	ACCAGCTCCCTGCGAAGAG;	reverse:	GAACTCCAGATGCGGGAACTT		
CRISPR/Cas9	genome	editing	Single	guide	RNA	sequences	targeting	IRAK4,	IRAK1,	MyD88	and	TLR9	were	designed	using	the	CRIPR	Design	webtool	(http://crispr.mit.edu/).	The	three	sequences	having	the	lowest	number	of	off-target	sites	were	selected	for	each	gene	(Table	1,	Figure	1).			Complementary	oligonucleotides	containing	the	guide	RNA	(without	PAM	sequence)	and	BpiI	ligation	adapter	were	synthesized	by	Microsynth	(Balgach,	Switzerland).	The	annealed	oligos	were	ligated	into	BpiI	digested	pSpCas9(BB)-2A-GFP	(px458)	vector,	a	gift	from	Feng	Zhang	(Addgene	plasmid	#	48138).	The	sequence	of	the	constructs	was	verified	by	DNA	sequencing.	CRISPR	single	cell	clones	were	obtained	by	electroporation	(Neon®	Transfection	system,	ThermoFisher	Scientific,	Zug,	Switzerland)	of	Akata	cells	with	the	px458	plasmids.	Transfected	single	cells,	positive	for	green	fluorescent	protein	(GFP),	were	sorted	48h	after	transfection	using	a	FACS	ARIA	II	cell	sorter	(BD	Biosciences,	Allschwil,	Switzerland).	Single	cell	clones	were	genotyped	and	characterized	after	expansion	(Table	2,	Figure	1).		
Statistics	Level	of	significance	was	evaluated	by	an	unpaired	Student’s	t	test	or	Tukey’s	multiple	comparison	test	(ANOVA)	using	Prism	6	(GraphPad	Software,	Inc.).	P	levels	<	0.05	were	regarded	as	statistically	significant.	
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Results		
TLR9-induced	inhibition	of	lytic	BZLF1	expression	is	largely	protein	synthesis	independent			Hemozoin,	a	pigment	expressed	by	the	malaria	agent	Plasmodium	falciparum,	activates	the	TLR9	pathway	21,27.	We	have	previously	shown	that	TLR9-triggering	by	ODN	CpG	2006	or	Hemozoin	inhibits	EBV	lytic	reactivation,	i.e.	expression	of	BZLF1,	induced	by	BCR	cross-linking	in	BL	cells	in	vitro	21.	Here,	we	aimed	to	elucidate	the	mechanism	by	which	TLR9	inhibits	BZLF1	expression.	In	particular,	we	wanted	to	understand	if	BZLF1	expression	is	inhibited	directly	e.g.	through	post-translational	modification	of	existing	proteins	induced	by	the	TLR9	signaling,	or	indirectly,	through	de	novo	expression	of	proteins,	e.g.	of	a	transcription	or	repressor	factor	expressed	upon	TLR9	stimulation.	We	treated	Akata	BL	cells	with	a	protein	synthesis	inhibitor,	either	cycloheximide	or	4E1RCat.	We	chose	these	inhibitors	because	they	act	at	the	translational	level	and	should	not	influence	BZLF1	mRNA	levels.	First,	in	order	to	determine	the	cytotoxicity	of	the	protein	synthesis	inhibitors,	we	assessed	the	cell	viability	8.5h	after	treatment	of	Akata	BL	cells	with	33	μg/ml	of	cycloheximide,	or	10	μM	and	25	μM	of	4E1RCat,	respectively	(Fig.	2a).	Treatment	with	33	μg/ml	cycloheximide,	or	10	μM	4E1RCat	did	not	affect	cell	viability,	whereas	25	μM	4E1RCat	or	vehicle	treatment,	with	the	same	volume	DMSO	as	for	25	μM	4E1RCat,	decreased	cell	viability	compared	to	untreated	cells	to	60%	(p=0.554),	and	to	73%	(p=0.23),	respectively.	The	treatment	of	the	cells	with	digitonin,	used	as	positive	control,	significantly	reduced	the	cell	viability	to	30%	(p=0.0034)	(Fig.	2a)..	Akata	BL	cells	first	treated	with	protein	synthesis	inhibitors,	cycloheximide	or	4E1RCat	for	30	min,	were	tested	for	EBV	lytic	reactivation	after	additional	treatment	
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with	ODN	CpG	2006	or/and	anti-IgG.	After	6h	treatment	with	anti-IgG,	EBV	lytic	reactivation	was	assessed	by	the	measurement	of	the	increase	of	the	mRNA	expression	of	the	immediate	early	lytic	transcription	factor	BZLF1	(Fig.	2b	and	c).	Treatment	with	ODN	CpG	2006,	cycloheximide	or	4E1RCat	had	per	se	no	effect	on	BZLF1	mRNA	expression	levels	(Fig.	2b).	In	cells	with	no	protein	synthesis	inhibition,	activation	of	TLR9	with	ODN	CpG	2006	inhibited	the	BZLF1	mRNA	increase	after	BCR	cross-linking	with	anti-IgG,	and	thus	lytic	reactivation,	by	83.7%	(p=0.0317)	(Fig.	2c).	Treatment	with	cycloheximide	or	4E1RCat	led	to	respectively	a	14-times	and	to	an	11-times	lower	
BZLF1	mRNA	expression	after	BCR	triggering	via	anti-IgG	compared	to	cells	with	no	protein	synthesis	inhibition.	This	was	expected,	since	expression	of	BZLF1	upon	BCR	crosslinking	is	reinforced	by	a	positive	feedback	loop	exerted	by	ZEBRA,	the	protein	expressed	by	the	BZLF1	gene,	on	its	own	promoter	28–30	(Fig.	2c).	Importantly,	upon	protein	synthesis	inhibition	with	cycloheximide	or	10	μM	4E1RCat,	TLR9	triggering	via	ODN	CpG	2006	inhibited	BZLF1	mRNA	increase	by	77.7%	(p=0.0418)	and	by	78.7	%	(p=0.011),	respectively.	Therefore,	TLR9	stimulation	can	inhibit	BZLF1	expression	directly	through	a	largely	protein	synthesis	independent	mechanism.			
TLR9-induced	inhibition	of	EBV	lytic	reactivation	is	MyD88,	IRAK4	and	IRAK1	dependent	in	
Burkitt’s	lymphoma	cells		As	shown	above,	TLR9	activation	triggered	inhibition	of	EBV	lytic	reactivation	is	largely	
de	novo	protein	synthesis	independent	and	is	strictly	MyD88-dependent	21.	However,	the	downstream	TLR9	signaling	elements,	NF-κB,	phosphatidylinositol-3	kinase	(PI3K),	extra-cellular	signal	regulated	kinase	(ERK),	c-jun	N	terminal	kinase	(JNK)	and	p38,	are	not	fully	responsible	for	TLR9-dependent	BZLF1	inhibition	21.	IRAK4	and	IRAK1	
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molecules,	which	act	immediately	downstream	of	MyD88,	were	not	tested.	Thus,	to	know	the	importance	of	IRAK4	and	IRAK1	proteins	in	TLR9-induced	inhibition	of	BZLF1	expression,	we	used	the	CRISPR/Cas9	genome	editing	method	31	to	inactivate	IRAK4	and	IRAK1,	respectively.	In	separate	experiments,	TLR9	and	MyD88	were	also	inactivated	to	further	confirm	our	previous	results,	and	to	use	the	TLR9	or	MyD88	inactivated	cells	as	positive	controls.	After	transfection	of	Akata	cells	with	modified	Cas9-gRNA-GFP	(px458)	expression	plasmids	(Fig.	1),	GFP-positive	single	cells	were	sorted	and	amplified.	The	clones	were	sequenced	and	2-3	clones	containing	an	early	stop	codon	in	the	TLR9,	MyD88,	IRAK4,	or	IRAK1	coding	sequences	were	selected	for	further	characterization	(Table	2).	To	verify	that	every	cell	clone	had	the	same	receptors	expression	level,	IgG	protein	expression	on	the	cells’	surface	was	characterized	by	flow	cytometry	(Fig.	3a),	and	for	TLR9	mRNA	levels	by	were	measured	by	RT-qPCR	(Fig.	3b).	We	then	measured	IL-10	protein	levels	in	the	supernatants	(Fig.	3c)	and	the	NF-κB	nuclear	translocation	(Fig.	4),	after	8h	treatment	with	ODN	CpG	2006,	as	readouts	for	the	integrity	of	the	TLR9	pathway	activity.	Finally,	we	amplified	the	conserved	EBV	BamHI	W	sequence,	present	in	multiple	copies	on	the	viral	genome,	by	RT-qPCR	to	determine	the	EBV	presence	in	the	cell	clones.		None	of	the	inactivating	mutations	did	affect	the	BCR	surface	expression	levels	of	the	cloned	cells	as	determined	by	flow	cytometry.	81.1%	of	the	Akata	WT	cells	expressed	IgG	on	the	surface,	whereas	90.4	%	of	the	IRAK4-	a3,	94.3	%	of	the	IRAK4-	a4,	92.3	%	of	the	IRAK1-	b2,	93.1	%	of	the	IRAK1-	b8,	91.8	%	of	the	TLR9-	b3,	91.7	%	of	the	TLR9-	b5,	92.7	%	of	the	TLR9-	b6,	92.9	%	of	the	MyD88-	a3,	94.2	%	of	the	MyD88-	a5	and	95.3	%	of	the	MyD88-	b1	cell	clones	were	IgG	positive	(Fig.	3a).	The	TLR9	mRNA	levels	in	the	clones	ranged	between	0.5-fold	and	1.2-fold	of	the	mRNA	levels	measured	in	the	
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Akata	WT	cells	(Fig.	3b).	On	the	other	hand,	the	5.5-fold	IL-10	protein	level	increase	measured	after	8h	ODN	CpG	2006	treatment	of	WT	Akata	cells	was	not	observed	in	the	IRAK4-	a3,	IRAK4-	a4,	IRAK1-	b2,	IRAK1-	b8,	TLR9-	b3,	TLR9-	b5,	TLR9-	b6,	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	cell	clones,	(Fig.	3c)	indicating	that	the	inactivation	of	the	TLR9	pathway	was	not	a	consequence	of	the	variation	in	TLR9	mRNA	levels.	We	confirmed	the	inactivation	of	the	TLR9	pathway	by	measuring	the	NF-κB	nuclear	translocation	by	WB.	After	90	min	treatment	with	ODN	CpG	2006,	Akata	WT	cells	showed	a	strong	nuclear	NF-κB	protein	levels	increase	compared	to	untreated	cells,	on	the	other	hand	in	IRAK4-	a3,	IRAK4-	a4,	TLR9-	b3,	TLR9-	b5,	TLR9-	b6,	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	cell	clones	the	nuclear	NF-κB	was	not	increased	by	ODN	CpG	2006	treatment	(Fig.	4).	The	selected	cell	clones	IRAK4-a3,	IRAK4-a4,	TLR9-b3,	TLR9-b5,	TLR9-b6,	MyD88-a3,	MyD88-a5	and	MyD88-b1	contained	between	20	and	95	BamHI	W	copies	per	cell.	For	comparison	the	Akata	WT	cells	contained	about	85	BamHI	W	copies	(Fig.	3d).		Despite	variable	EBV	DNA	copy	numbers	per	cell,	the	detection	of	BamHI	W	copies	allowed	us	to	use	the	cell	clones	IRAK4-	a3,	IRAK4-	a4,	TLR9-	b3,	TLR9-	b5,	TLR9-	b6,	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	for	further	BZLF1	expression	assays.	By	contrast	and	surprisingly,	the	BamHI	W	sequence	was	not	detectable	in	IRAK1	cell	clones	IRAK1-	b2	and	IRAK1-	b8,	kept	about	1	month	in	culture	for	the	amplification	step	after	single	cell	cloning.	For	this	reason,	the	BZLF1	reactivation	upon	BCR	cross-linking	was	not	detectable	anymore	in	the	IRAK1-	clones.	The	transfection,	selection	and	amplification	steps	were	therefore	repeated	using	IRAK1-b	px458	plasmid.	In	order	to	control	that	the	loss	of	EBV	copies	in	IRAK1	inactive	clones	was	not	due	to	the	long	culture	time	required	for	the	amplification	step,	Akata	cells	transfected	with	a	control	px458	plasmid	lacking	a	sgRNA	target	sequence,	as	well	as	untransfected	Akata	WT	cells	
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were	isolated	and	amplified	in	parallel.	The	cells	were	directly	tested	for	the	TLR9	pathway	activity	by	the	measurement	of	IL-10	mRNA	and	proteins	in	the	supernatant,	as	well	as	for	the	presence	of	EBV	by	the	measurement	of	BamHI	W	copies	(Table	3).	To	sum	up	the	CRISPR/Cas9	plasmid	transfection	experiments,	Akata	cells	transfected	with	control	px458	plasmid	as	well	as	untransfected	Akata	single	cell	clones	all	had	a	active	TLR9	pathway	and	about	83.3%	of	the	clones	where	EBV	positive.	This	shows	that	the	control	px458	plasmid	and	the	transfection,	selection	and	amplification	steps	necessary	to	obtain	single	cell	clones	had	no	influence	on	the	TLR9	pathway	activity	and	the	EBV	presence	in	the	cells.	On	the	other	hand,	respectively	56.5%,	40%,	50%	and	60%	of	the	IRAK1-,	IRAK4-,	TLR9-	and	MyD88-	px458	transfected	clones	had	an	inactive	TLR9	pathway.	Interestingly,	respectively	75%,	60%	and	83.3%	of	the	IRAK4-,	TLR9-	and	MyD88-	px458	transfected	clones	that	had	an	inactive	TLR9	pathway	and	were	EBV	positive	(Table	3).	In	IRAK1-b	px458	transfected	cell	clones,	about	56.5	%	of	the	clones	had	an	inactive	TLR9	pathway,	and	all	had	completely	lost	EBV	genome	(Table	3),	which	could	suggests	a	role	for	IRAK1	in	EBV	viral	persistence	and	transmission	to	dividing	daughter	cells.	For	this	reason,	the	BZLF1	reactivation	upon	BCR	cross-linking	was	not	detectable	anymore	in	the	IRAK1-	clones.	Next,	in	order	to	determine	the	importance	of	IRAK4	in	the	TLR9-induced	inhibition	of	BZLF1	expression	the	CRISPR/Cas9	mutated	clones	were	treated	with	ODN	CpG	2006	for	2h,	followed	by	treatment	with	anti-IgG	for	6h.	TLR9	and	MyD88	knockouts	were	used	as	controls.	EBV	lytic	reactivation	was	determined	by	the	measurement	of	BZLF1	mRNA	levels	by	RT-qPCR.	For	the	IRAK4	inactive	clones	IRAK4-	a3	and	IRAK4-	a4,	we	measured	194	and	463	BZLF1	relative	transcripts	over	HMBS	over	untreated	sample	after	BCR	cross-linking,	respectively	(Fig.	5a);	and	for	the	TLR9	inactive	clones	TLR9-	b3,	TLR9-	b5	and	TLR9-	b6,	we	measured	789,	627	and	940	BZLF1	
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relative	transcripts	over	HMBS	over	untreated	sample	after	BCR	cross-linking,	respectively	(Fig.	5b).	For	comparison,	for	WT	Akata	cells	we	measured	1583	BZLF1	relative	transcripts	over	HMBS	over	untreated	sample	after	BCR	cross-linking.	In	the	MyD88	inactive	clones	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	we	measured	1623.8,	1632	and	1837	BZLF1	relative	transcripts	over	HMBS	over	untreated	sample	after	BCR	cross-linking,	respectively	(Fig.	5c).		The	basal	BZLF1	mRNA	levels	measurement	in	untreated	and	ODN	CpG	2006	treated	cells	shows	that	the	differences	of	spontaneous	lytic	reactivation	between	the	TLR9-,	MyD88-	and	IRAK4-	CRISPR/Cas9	clones	compared	to	WT	Akata	cells,	are	minor,	although	statistically	significant	for	TLR9-b5,	MyD88-a3	and	MyD88-b1	clones	(Supplementary	Fig.	S1).	Moreover,	the	differences	in	basal	BZLF1	mRNA	levels	do	not	correlate	with	the	EBV	DNA	copies	measured	in	each	clones	(Fig.	3d)	and	neither	with	the	EBV	lytic	reactivation	upon	BCR	cross-linking	(Fig.	5).	Spontaneous	lytic	reactivation	is	therefore,	not	the	reason	explaining	neither	the	differences	in	EBV	DNA	loads	nor	the	differences	in	BZLF1	mRNA	expression	upon	BCR	cross-linking.	In	order	to	investigate	if	the	BCR	signaling	is	affected	by	the	mutation	we	stimulated	the	IRAK4-	a3,	IRAK4-	a4,	TLR9-	b3,	TLR9-	b5	and	TLR9-	b6	clones	with	anti-IgG	for	15,	30,	60	and	120	minutes.	The	phosphorylation	levels	of	Akt,	Mek	and	Syk	were	measured	in	stimulated	CRISPR/Cas9	clones	by	western	blot	and	compared	with	the	levels	in	Akata	WT	cells.	The	results	show	an	increased	Akt,	Mek	and	Syk	phosphorylation	upon	treatment	with	anti-IgG	with	only	minor	differences	between	the	IRAK4-	and	TLR9-	clones	and	the	Akata	WT	cells	(Supplementary	Fig.	S2,	S3	and	S4).	From	these	results	we	exclude	an	influence	of	IRAK4	or	TLR9	abrogation	on	the	BCR	pathway	to	be	the	reason	for	the	differences	in	BZLF1	mRNA	expression	upon	lytic	reactivation.			
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The	activation	of	TLR9	by	ODN	CpG	2006	in	WT	Akata	cells	reduced	the	expression	of	BZLF1	mRNA	about	4.5	times	to	379.7	(p=0.0005)	relative	transcripts	after	BCR	cross-linking.	Interestingly,	we	showed	that,	despite	differences	in	the	BZLF1	mRNA	level	after	BCR	cross-linking	between	the	clones	and	WT	Akata	cells,	the	TLR9-induced	reduction	of	BZLF1	mRNA	expression	was	completely	rescued	in	the	IRAK4-a3	and	IRAK4-a4	clones	with	264.6	(p=0.0363)	respectively	527.3	(p=0.1855)	BZLF1	relative	transcripts	(Fig.	5a);	and	in	the	TLR9-b3,	TLR9-b5	and	TLR9-b6	control	clones,	with	respectively	855.5	(p=0.0112),	527.2	(p=0.078)	and	998.1	(p=0.2435)	BZLF1	relative	transcripts	(Fig.	5b);	and	in	the	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	control	clones	with	respectively	1408.6	(p=0.2998),	1861.2	(p=0.3735)	and	1682.9	(p=0.064)	
BZLF1	relative	transcripts	(Fig.	5c).	To	sum	up,	by	transfecting	Akata	cells	with	CRISPR/Cas9	plasmids	containing	sgRNA	targeting	IRAK4,	TLR9	or	MyD88	genes,	insertions	or	deletions	could	be	induced	leading	to	an	early	stop	codon	in	the	target	genes.	The	characterization	of	the	single	cell	clones	showed	that	the	surface	IgG	protein	level	remained	stable	and	comparable	to	the	levels	measured	in	WT	Akata	cells;	that	the	TLR9	pathway	activity	was	completely	abrogated	by	the	early	stop	codon	in	the	target	genes;	and	not	as	a	consequence	of	the	variation	in	TLR9	mRNA	level;	finally,	despite	variable	EBV	DNA	copy	numbers	per	cell,	the	IRAK4-	a3,	IRAK4-	a4,	TLR9-	b3,	TLR9-	b5,	TLR9-	b6,	MyD88-	a3,	MyD88-	a5	and	MyD88-	b1	clones	could	be	used	for	lytic	reactivation	assays.	In	conclusion,	these	results	show	that	in	BL	cells	the	TLR9-induced	inhibition	of	lytic	reactivation	requires	functional	IRAK4,	TLR9	and	MyD88	proteins.				
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Discussion		EBV	lytic	reactivation	upon	BCR	cross-linking	is	inhibited	by	TLR9	stimulation	with	ODN	CpG	2006	in	B	cells	21.	Here,	we	studied	the	importance	of	protein	synthesis,	and	the	involvement	of	the	signaling	proteins	MyD88,	IRAK4	and	IRAK1,	in	this	process.	We	found	that	(i)	TLR9-induced	inhibition	of	EBV	lytic	reactivation	in	B-cells	upon	BCR	cross-linking,	is	largely	independent	from	de	novo	protein	synthesis;	(ii)	the	inactivation	of	either	TLR9,	MyD88,	or	IRAK4	completely	abrogates	the	effect	of	ODN	CpG	2006	on	TLR9	signaling	resulting	in	unhindered	EBV	lytic	reactivation	upon	BCR	cross-linking	in	the	presence	of	ODN	CpG	2006.	Our	results	unprecedentedly	show	that	TLR9	triggering	activates	a	signaling	pathway	that	does	not	only	depend	on	protein	synthesis	to	favor	EBV	latency	in	B	cells	upon	stimulation	of	the	BCR;	and	demonstrate	the	central	roles	of	MyD88	and	IRAK4	in	this	mechanism	contributing	to	EBV’s	persistence	in	the	host’s	B-cell	pool.	Remarkably,	activation	of	TLR9	by	ODN	CpG	2006	inhibited	the	transcription	of	EBV’s	master	lytic	gene	BZLF1	in	BL	cells	to	a	similar	degree,	even	when	mRNA	translation	was	strongly	inhibited.	To	direct	our	investigation,	we	tackled	the	question	whether	protein	synthesis	is	decisive	in	EBV’s	reactivation	process	upon	challenges	imposed	to	the	host	cells.	In	Akata	BL	cells	the	strong	increase	of	ZEBRA	expression	upon	BCR	cross-linking,	the	protein	coded	by	BZLF1,	goes	through	a	bi-phasic	process	that	requires	protein	synthesis	to	be	amplified	28.	Protein	synthesis	inhibitors	are	therefore	expected	to	abrogate	the	positive	feedback	loop.	In	fact,	upon	BCR	cross-linking,	we	observed	lower	BZLF1	mRNA	expression	levels	in	cells	treated	with	cycloheximide	or	4E1RCat.	Interestingly,	TLR9	stimulation	with	ODN	CpG	2006	inhibited	BZLF1	mRNA	expression	at	the	same	ratio,	whether	protein	synthesis	was	
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inhibited	or	not.	This	strongly	suggests	that	the	regulation	of	EBV’s	lytic	reactivation	upon	TLR9	stimulation	with	ODN	CpG	2006	is,	to	a	large	extend,	protein	synthesis	independent	and	suggests	post-translational	modifications	to	be	responsible	for	EBV	lytic	gene	repression.	The	question	weather	TLR9	activation	also	affects	ZEBRA’s	activity	and	the	positive	amplification	ZEBRA	exerts	on	its	own	promoter	remains	open.	Our	group	revealed	that	TLR9	triggering	affects	histone	modifications,	which	is,	at	least	partly,	responsible	for	EBV	lytic	gene	repression	21.	In	addition,	several	studies	showed	that	epigenetic	mechanisms	including	histone	modifications	or	DNA	methylation	are	responsible	for	the	regulation	of	EBV	lytic	gene	expression	upon	BCR	cross-linking	32,33.	Consequently,	even	if	we	cannot	completely	exclude	the	existence	of	a	newly	synthesized	unknown	repressor	factor(s),	our	results	strongly	indicate	that	EBV	reinforces	its	latency	by	hijacking	the	TLR9-induced	post-translational	modifications	to	repress	its	lytic	genes	expression.		We	unequivocally	and	unprecedentedly	show	that	MyD88	and	IRAK4	are	essential	for	the	TLR9-dependent	inhibition	of	EBV	lytic	reactivation	upon	BCR	cross-linking.	This	was	possible	after	we	inactivated	TLR9,	MyD88,	or	IRAK4	genes	in	single	cell	clones	by	CRISPR/Cas9	methodology.	Importantly,	we	proved	that	the	canonical	TLR9	signaling	pathway	was	completely	abrogated	by	the	inactivating	mutations	as	revealed	by	the	lower	IL-10	concentrations	in	the	supernatant	and	the	missing	NF-κB	nuclear	translocation	after	stimulation	with	ODN	CpG	2006.	Of	note,	we	excluded	that	
TLR9,	MyD88,	or	IRAK4	inactivation	affects	the	degree	of	BCR	expression	on	the	cell	surface.	Thus,	the	TLR9-induced	abrogation	of	the	effects	subsequent	to	BCR-cross-linking	is	not	due	to	changes	in	BCR	expression	degree.		Our	findings	contribute	to	an	increased	understanding	of	the	mechanisms	involved	in	the	TLR9-induced	inhibition	of	EBV	lytic	reactivation	and	confirm	our	
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previously	reported	observations	21.	Moreover,	as	reported	earlier,	TLR9-mediated	suppression	of	EBV	lytic	gene	expression	is	not	restricted	to	latently	infected	BL	cells	but	can	also	be	observed	ex	vivo	in	primary	cells	upon	EBV	infection	20.	It	seems	likely	that	this	feature	is	shared	by	other	gammaherpesviruses,	as	we	found	that	stimulation	of	TLR9,	as	well	as	of	TLR7,	similarly	suppresses	spontaneous	and	induced	MHV-68	reactivation	in	mice	34.	In	addition,	NF-κB	nuclear	translocation	was	shown	to	suppress	the	lytic	genes	of	the	Kaposi's	sarcoma-associated	herpesvirus	35.	Thus,	gammaherpesviruses	seem	to	have	evolved	to	exploit	cellular	signaling	mechanisms	in	order	to	keep	their	latent	state	and	avoid	unnecessary	aberrant	lytic	reactivation.	The	infectious	viral	particles	produced	upon	EBV	lytic	reactivation	are	recognized	by	the	host’s	immune	system	and	lead	to	an	inflammatory	response	that	could	be	harmful	for	both	the	virus	and	the	host	36.	Our	findings	indicate	that	EBV	developed	a	very	strong	and	efficient	strategy,	by	taking	advantage	of	the	host	cells	innate	immune	TLR9	signaling	machinery	through	MyD88	and	IRAK4,	to	ensure	and	maintain	its	reversible	latency.	Most	intriguingly,	we	failed	to	establish	IRAK1	mutated	BL	cell	clones	retaining	EBV	genomes.	Since	the	3	CRISPR	plasmids	we	developed	were	efficient	in	mutating	
IRAK1	gene	in	at	least	one	single	cell	clone,	this	preliminary	finding	suggests	that	IRAK1	could	play	a	central	role	in	steering	EBV	persistence.	EBV	nuclear	protein	EBNA1	binds	to	the	origin	of	viral	replication	and	is	essential	to	mediate	replication	and	partitioning	of	its	episome	during	the	division	of	the	host	cell.	EBNA1	function	is	regulated	by	the	phosphorylation	of	ten	specific	sites	37.	The	kinases	responsible	for	EBNA1	phosphorylation	have	not	been	identified,	but	IRAK1	could	be	a	potential	candidate.	Thus,	one	hypothesis	for	the	loss	of	EBV	in	the	IRAK1-mutated	clones	is	that	EBNA1’s	function	is	altered	by	the	inactivation	of	IRAK1,	which	affects	the	replication	and	
ATTACHMENTS 	
	 76 
partitioning	of	EBV’s	genomic	DNA	in	dividing	cells	leading	to	the	dilution	of	the	virus	in	the	daughter	cells	and	finally	to	its	loss.	However,	it	is	important	to	consider	that	these	result	has	only	been	observed	in	a	limited	number	of	clones,	mostly	transfected	with	the	IRAK1-b	CRISPR/Cas9	plasmid,	the	most	efficient	one,	in	three	independent	single	cell	cloning	round.	The	potential	importance	of	IRAK1	activity	for	EBNA1	function	requires	the	analysis	of	more	clones	transfected	with	different	IRAK1-	CRISPR/Cas	9	plasmids	as	well	as	further	investigations.	In	summary,	our	results	demonstrate	that	IRAK4	is	essential	and	very	efficient	to	inhibit	EBV	lytic	reactivation	upon	TLR9-induction.	The	TLR9-MyD88-IRAK4	pathway	activation	favors	EBV	latency	by	post-translational	modifications	and	is	largely	protein	synthesis	independent.	Therefore,	the	TLR9-MyD88-IRAK4	pathway	is	a	potential	therapeutic	target	to	support	disruption	of	EBV	latency	in	EBV-associated	lymphoproliferative	disorders.		
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Figure	Legends	
Figure	1:	Experimental	design	for	the	establishment	of	CRISPR/Cas9	single	cell	clones.	Steps	for	reagent	design,	construction,	cell	line	expansion	and	characterization	are	depicted.	Three	different	custom	sgRNAs	(light	blue	bars)	were	designed	in	silico	via	the	CRISPR	Design	Tool	(http://crispr.mit.edu/).	sgRNA	guide	sequences	were	cloned	into	the	expression	plasmid	pSpCas9(BB)-2A-GFP	(PX458)	bearing	sgRNA	scaffold	backbone	(BB),	Cas9,	and	GFP.	Cloned	and	sequence-verified	pSpCas9(BB)-2A-GFP	(PX458)	plasmids	were	then	electroporated	into	Akata	cells,	after	48h,	GFP-positive	cells	were	single	cell	sorted	by	FACS.	Finally,	the	GFP	positive	single	cell	clones	were	expanded,	genotyped	and	characterized.	(Adapted	from	31)		
Figure	2:	TLR9	triggering	via	ODN	CpG	2006	inhibits	EBV	master	lytic	gene	BZLF1	mRNA	expression	in	BL	cells	despite	protein	synthesis	inhibition	with	cycloheximide	and	4E1RCat.	(a)	Akata	cells	were	treated	with	the	protein	synthesis	inhibitors	cycloheximide	(33	μg/ml)	or	4E1RCat	(10	μM	and	25	μM),	for	8.5h.	Cell	viability	was	determined	by	Trypan	blue	exclusion	assay.	Untreated	and	vehicle-treated	cells	(H2O	for	cycloheximide	and	DMSO	for	4E1RCat)	were	used	as	negative	controls;	digitonin	(30	μg/ml)	treated	cells	as	a	positive	control	for	cell	toxicity	after	8.5h	incubation.	Results	are	shown	as	percentage	of	viable	cells	(n=3).	(b)	and	(c)	Protein	synthesis	inhibitors	cycloheximide	(33	μg/ml)	and	4E1RCat	(10	μM),	were	added	first	to	the	Akata	cells.	After	30	min	incubation,	cells	were	treated	for	2h	with	ODN	CpG	2006,	and	finally	for	6h	with	anti-IgG.	After	a	total	incubation	time	of	8.5h	the	cells	were	lysed	and	the	mRNA	extracted.	The	BZLF1	mRNA	level	relative	to	HMBS	was	measured	by	RT-qPCR.	(n=3).	(b)	Represents	an	enlargement	of	the	BZLF1	mRNA	levels	measured	upon	incubation	with	ODN	CpG	2006,	
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cycloheximide	or	4E1RCat	only,	which	is	presented	in	(c).	Data	are	represented	as	mean	±	SD.	Statistics	were	calculated	using	the	unpaired	t	test.	(*,	P<0.05)		
Figure	3:	CRISPR/Cas9	mutation	of	TLR9,	MyD88,	IRAK4	and	IRAK1	result	in	a	complete	TLR9	signaling	abrogation,	and	affect	EBV	viral	copy	numbers	per	cells.	Akata	Burkitt’s	lymphoma	B	cells	transfected	with	px458	plasmids	coding	for	Cas9	and	containing	a	sgRNA	targeting	TLR9	(TLR9-b3,	TLR9-b5	and	TLR9-b6),	MyD88	(MyD88-a3,	MyD88-a5	and	MyD88-b1),	IRAK4	(IRAK4-a3	and	IRAK4-a4)	and	IRAK1	(IRAK1-b2	and	IRAK1-b8),	respectively,	were	diluted	for	single	cell	cloning,	sequenced	and	clones	containing	an	early	stop	codon	were	selected	for	further	characterization.	(a)	%	of	IgG	positive	cells	was	measured	by	flow	cytometry.	(b)	TLR9	mRNA	level	was	measured	by	RT-qPCR	and	normalized	over	HMBS	and	over	WT	Akata	cells.	(c)	IL-10	cytokine	expression	level	measured	by	ELISA	in	the	supernatant	of	untreated	cells,	and	cells	treated	for	8h	ODN	CpG	2006.	(d)	Viral	BamH1	W	copy	numbers	over	cellular	HMBS	determined	by	qPCR.	(a)	Has	been	performed	only	once	(b,	c,	d)	Shows	one	representative	experiment	out	of	three.	Data	are	represented	as	mean	±	SD		
Figure	4:		TLR9,	MyD88	or	IRAK4	inactivation	inhibits	NF-κB	nuclear	translocation	upon	TLR9	activation	with	ODN	CpG	2006.	Results	show	NF-κB	p65	protein	expression	in	the	cytoplasmic	and	nuclear	fraction	of	Akata	WT	cells	and	TLR9	(TLR9-b3,	TLR9-b5	and	TLR9-b6),	MyD88	(MyD88-a3,	MyD88-a5	and	MyD88-b1)	and	IRAK4	(IRAK4-a3	and	IRAK4-a4)	CRISPR	single	cell	clones.	Cells	were	treated	with	ODN	CpG	2006	for	90’.	Lamin	A/C	and	tubulin	protein	expressions	were	measured	as	loading	control	for	the	cytoplasmic	respectively	nuclear	fractions.		One	representative	experiment	is	shown	out	of	three	independent	experiments.	
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Figure	5:	TLR9-induced	inhibition	of	BZLF1	expression	is	strictly	TLR9,	MyD88	and	IRAK4	dependent.	CRISPR/Cas9	mutated	TLR9,	MyD88	and	IRAK4	clones	were	treated	for	2h	with	ODN	CpG	2006	prior	to	lytic	reactivation	by	Ig-crosslinking	with	anti-IgG	for	6h.	BZLF1	mRNA	expression	level	normalized	to	HMBS	was	measured	by	RT-qPCR	and	relative	over	untreated	cells	in	TLR9	clones,	MyD88	clones	and	IRAK4	clones.	Shown	is	one	representative	experiment	out	of	three.	Data	are	represented	as	mean	±	SD	(n=3).	Statistics	were	calculated	using	the	unpaired	t	test.	(***,	P<0.001;	*,	P<0.05;	n.s.,	not	significant).	
	
Table	1:	CRISPR	single	guide	RNA	target	sequences.		
Target name Genomic locus Target Sequence (5’-3’) 
IRAK4- a IRAK4 exon 2 AGGCAGCGCACATATGTTGATGG 
IRAK4- b IRAK4 exon 2 TATGTGCGCTGCCTCAATGTTGG 
IRAK4- c IRAK4 exon 2 GCCTCAATGTTGGACTAATTAGG 
IRAK1- a IRAK1 exon 2 CGGTCTGGTCGCGCACGATCAGG 
IRAK1- b IRAK1 exon 2 GATCAACCGCAACGCCCGTGTGG 
IRAK1- c IRAK1 exon 2 GGTCTGGTCGCGCACGATCAGGG 
MyD88- a MyD88 exon 1 GTTCTTGAACGTGCGGACACAGG 
MyD88- b MyD88 exon 1 GCTCCAGCAGCACGTCGTCGCGG 
MyD88- c MyD88 exon 3 ATGAAGGCATCGAAACGCTCAGG 
TLR9- a TLR9 exon 2 CGCTGATGCGGTTGTCCGACAGG 
TLR9- b TLR9 exon 2 ACTGGGTGTACAACGAGCTTCGG 
TLR9- c TLR9 exon 2 GCTCACGGCTATTCGGCCGTGGG 
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Table	2:	Sequencing	summary	of	CRISPR/Cas9	IRAK4-,	TLR9-	and	MyD88-	clones.		
Clones DNA sequence changes Amino acid change 
IRAK4- a3 c.25inA p.Thr9AspfsX19 
IRAK4- a4 c.24delA p.Thr9HisX17 
TLR9- b3 c.2615_2690delCCTTCGTGGTCTTCGACAAAACGCAGAGC
GCAGTGGCAGACTGGGTGTACAACGAGCTTCGGGGGCA
GCTGGAGGA + c.2692T>C 
p.Ala872GlyX945 
TLR9- b5 c.2672inC p.Leu891ProfsX921 
TLR9- b6 1* c.2672inC p.Leu891ProfsX921 
TLR9- b6 2* c.2655_2682delCTGGGTGTACAACGAGCTTCGGGGGCAG p.Val887ArgfsX960 
MyD88- a3 c.153_165delGTGCGGACACAG  p.Arg53AlafsX122 
MyD88- a5 c.161delC p.Thr54AspfsX99 
MyD88- b1 c.336delC p.Asp112GlufsX273 DNA	sequence	changes	nomenclature	is	based	on	the	coding	DNA	sequence.	*	TLR9-	b6	derives	from	two	different	clones	whose	sequence	was	determined	by	TA	cloning	and	sequencing.		
Table	3:	Summary	of	the	CRISPR	Cas9	transfection	and	characterization	experiments.		
	
	
	
	
	
a	=	number	of	single	cell	clones	with	an	inactive	TLR9	pathway	over	the	total	number	of	single	cell	clones	analyzed;	b	=	number	of	EBV	positive	single	cell	clones	over	the	total	number	of	single	cell	clones	analyzed;	c	=	number	of	EBV	positive	single	cell	clones	over	the	number	of	single	cell	clones	with	an	inactive	TLR9	pathway.		
  IRAK1- IRAK4- TLR9- MyD88- Akata px458-ctl 
Inactive TLR9 pathway (ko) 13/23a 4/10a 5/10a 6/10a 0/12a 
EBV positive 7/23b 6/10b 6/10b 9/10b 10/12b 
EBV positive / TLR9 ko 0/13c 3/4c 3/5c 5/6c 0/0c 
ATTACHMENTS 	
	 85 
Figure	1:	
												
ATTACHMENTS 	
	 86 
Figure	2:		
	
																										
Un
tre
ate
d
OD
N 
Cp
G 
20
06
0.00
0.05
0.10
0.15
0.20
Treatments
B
ZL
F1
 m
R
N
A
 e
xp
re
ss
io
n 
ov
er
 H
M
B
S 
Untreated
cycloheximide
10µM 4E1RCat
n.s.
n.s.
n.s.
n.s.
Un
tre
ate
d
OD
N 
Cp
G 
20
06
α-
IgG
OD
N 
Cp
G 
20
06
 + 
α-
IgG
0
2
4
6
8
35
40
45
50
Treatments
B
ZL
F1
 m
R
N
A
 e
xp
re
ss
io
n 
ov
er
 H
M
B
S 
Untreated
cycloheximide
10µM 4E1RCat
*
*
*
b
c
a
un
tre
ate
d c
ell
s
H 2
O
DM
SO
33
 µg
/m
l c
yc
loh
ex
im
ide
10
µM
 4E
1R
Ca
t
25
µM
 4E
1R
Ca
t
Di
git
on
in
0
25
50
75
100
125
Treatments
Pe
rc
en
ta
ge
 o
f v
ia
bl
e 
ce
lls
**
ATTACHMENTS 	
	 87 
Figure	3:		
																				
ATTACHMENTS 	
	 88 
Figure	4:			
																												
ATTACHMENTS 	
	 89 
Figure	5:		
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Supplementary	Figure	S1:			CRISPR/Cas9	mutated	TLR9,	MyD88	and	IRAK4	clones	were	treated	for	2h	with	ODN	CpG	2006.	BZLF1	mRNA	expression	level	normalized	to	HMBS	was	measured	by	RT-qPCR	in	TLR9-	clones,	MyD88-	clones	and	IRAK4-	clones.	Shown	is	one	representative	experiment	out	of	three.	Data	are	represented	as	mean	±	SD	(n=3).	Statistics	were	calculated	using	the	unpaired	t	test.	(***,	P<0.001;	*,	P<0.05;	n.s.,	not	significant).	
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Supplementary	Figure	S2:			Akata	WT	cells	and	TLR9	(TLR9-b3,	TLR9-b5	and	TLR9-b6)	and	IRAK4	(IRAK4-a3	and	IRAK4-a4)	CRISPR/Cas9	single	cell	clones	were	treated	with	ODN	CpG	2006	for	15’,	30’,	60’	and	120’.	(a)	Results	show	pAkt	and	Akt	protein	expression.	GAPDH	or	Tubulin	protein	expressions	were	measured	as	loading	control.	(b)	Graphical	representation	of	the	densitometric	measurement	of	(a).	pAkt	values	were	calculated	relatively	to	the	Akt	level.	One	representative	experiment	is	shown.	
a	
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Supplementary	Figure	S3:			Akata	WT	cells	and	TLR9	(TLR9-b3,	TLR9-b5	and	TLR9-b6)	and	IRAK4	(IRAK4-a3	and	IRAK4-a4)	CRISPR/Cas9	single	cell	clones	were	treated	with	ODN	CpG	2006	for	15’,	30’,	60’	and	120’.	(a)	Results	show	pMek1/2	and	Mek1/2	protein	expression.	GAPDH	or	Tubulin	protein	expressions	were	measured	as	loading	control.	(b)	Graphical	representation	of	the	densitometric	measurement	of	(a).	pMek1/2	values	were	calculated	relatively	to	the	Mek1/2	level.	One	representative	experiment	is	shown.	
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Supplementary	Figure	S4:			Akata	WT	cells	and	TLR9	(TLR9-b3,	TLR9-b5	and	TLR9-b6)	and	IRAK4	(IRAK4-a3	and	IRAK4-a4)	CRISPR/Cas9	single	cell	clones	were	treated	with	ODN	CpG	2006	for	15’,	30’,	60’	and	120’.	(a)	Results	show	pSyk	and	Syk	protein	expression.	GAPDH	or	Tubulin	protein	expressions	were	measured	as	loading	control.	(b)	Graphical	representation	of	the	densitometric	measurement	of	(a).	pSyk	values	were	calculated	relatively	to	the	Syk	level.	One	representative	experiment	is	shown.	
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Abstract  
Background: The triggering of Toll-like receptor 9 (TLR9) results in the suppression of 
EBV’s master regulatory lytic gene BZLF1. The reduction of EBV lytic gene expression 
promotes viral latency in the cells and latent EBV, in turn, might enhance the possibility for 
cell transformation. Lytic reactivation of EBV is associated with modification of chromatin 
structure on the BZLF1 promoter Zp.  
Results: To characterize the effect of TLR9 on the BZLF1 promoter Zp in more detail, we 
evaluated the TLR9-induced suppression of lytic EBV for different Zp regions coupled to a 
luciferase gene in a reporter system. Unexpectedly, TLR9 triggering inhibited BZLF1 
expression in BCR-induced Akata Burkitt’s lymphoma cells latently infected with EBV, but 
did not affect the activation of Zp reporter constructs. TLR9-induced histone modifications 
observed in genomic EBV upon lytic reactivation were not found in episomal reporter 
constructs. 
Conclusions: The underlying mechanism of the differential effect of TLR9 signaling might 
mirror the distinct chromatin structure of the transfected Zp reporter construct compared to 
EBV’s viral genome. This reporter system based research does not reflect the viral reality and 
other strategies should be considered to study EBV’s lytic reactivation in order to use it for 
cancer cell-tailored therapeutic approach. 
 
 
Keywords: Innate immunity, CpG, TLR9, Epstein-Barr virus, EBV, Burkitt’s lymphoma
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Background 
Epstein-Barr virus (EBV) is a B-lymphotropic DNA gamma-herpesvirus that persists 
benignly in a latent state in over 90 % of the world’s adult population. EBV’s genome is 
maintained as an episome in latently infected cells [1]. Intermittently, an appropriate stimulus 
leads to the induction of EBV lytic replication, resulting in the production of new EBV 
particles and death of the host cell [2].  
Latent state EBV is associated with B-cell malignancies including Burkitt’s lymphoma 
(BL) [3], the endemic form of which is epidemiologically linked to Plasmodium falciparum 
malaria [4]. Based on the lethal effect of lytic EBV for the host cell, induction of lytic EBV is 
being explored as a specific cancer cell-targeted therapy for EBV-associated malignancies [5].  
The physiological stimuli that control the switch from latency to lytic EBV in vivo are 
not known [6]. The study of EBV reactivation in vivo or ex vivo is hampered by the low 
abundance of B-cells carrying latent EBV. Thus, BL-derived cell lines are used as model to 
study the switch from EBV latency to lytic reactivation [7, 8]. Various agents including 12-O-
tetradecanoylphorbol-13-acetate [9], the cytokine transforming growth factor-β [10], and B-
cell receptor (BCR) cross-linking antibodies [11] induce EBV lytic reactivation by triggering 
cellular signaling pathways resulting in the induction of EBV’s immediate-early lytic gene 
BZLF1, which is essential for reactivation of EBV [12]. 
We have shown that induction of EBV lytic reactivation in BL cells can be suppressed by 
triggering B-cell Toll-like receptor (TLR)9 in vitro [13] and that TLR9-mediated suppression 
of BZLF1 involves chromatin remodeling impeding activation of the immediate-early lytic 
gene [14]. TLRs are transmembrane receptors that sense microbes, and the interaction of a 
TLR with its pathogen-associated molecular pattern mediates an intracellular signal that 
results in the production of chemical mediators and cell surface molecules directing innate 
and acquired immune responses [15]. Endosome-located TLR9, highly expressed by all 
developmental stages of mature B-cells [16], recognizes pathogen DNA, which contains 
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unmethylated cytosine-phosphatidyl-guanosine (CpG) motifs [17] and P. falciparum pigment 
hemozoin [18], and can also be triggered by synthetic oligodeoxynucleotides (ODN) 
containing unmethylated CpG [19]. TLR9 signaling favors EBV latency and likely promotes 
EBV-associated B-cell lymphoma by counteracting induction of EBV lytic gene expression. 
The control of the Zp promoter is a key step in the switching from latency to lytic 
infection [7, 20]. BZLF1 encodes the transcription factor Zta, and Zta binds specific target 
sequences in the promoters of EBV’s early lytic genes, but also to its own promoter Zp. This 
auto activation of BZLF1 expression appears to be the basis for EBV’s efficient switch to lytic 
infection [21]. The Zta minimal promoter region Zp-221 is known to harbor the elements for 
maintaining low basal activity and for the transcriptional activation by agents inducing lytic 
EBV infection [9, 21]. Notably, upstream of -221 bp several negative elements have been 
identified [22, 23]. Nevertheless, the Zp promoter regions affected upon TLR9 triggering 
remain unknown. A detailed understanding of the regulation of the Zp promoter could offer 
new insights in mechanisms contributing to securing EBV’s latency, potentially promoting 
EBV-associated B-cell lymphomas, and also to devise anti-cancer treatments aiming at the 
induction of lytic EBV.  
Here, we aimed to further elucidate the mechanism leading to TLR9 triggering-induced 
suppression of EBV lytic reactivation. Thus, we transfected Akata BL cells with various 
episomal Zp reporter constructs and measured the activation of the Zp promoter in response to 
TLR9 triggering and subsequent BCR cross-linking. Our study demonstrates that TLR9 
triggering-induced suppression of EBV lytic reactivation is dependent on inhibition/reversal 
of H3K9 acetylation on EBV genomic BZLF1 promoter induced by BCR-signaling. This has 
implications on treatment modalities of EBV-associated cancers based on lytic reactivation of 
EBV. 
 
 
ATTACHMENTS 	
	 101 
Results and discussion 
The Zp-221 region of the reporter construct is alone sufficient for the induction of EBV 
lytic gene expression mediated by BCR cross-linking 
Triggering of TLR9 results in the suppression of EBV BZLF1 lytic gene expression [13, 14]. 
The region of the BZLF1 promoter Zp that is affected by TLR9 signaling leading to 
suppression of BZLF1 expression is unknown. We aimed at elucidating the affected region by 
using Zp reporter constructs. To this end, we first validated the function of the BZLF1 reporter 
constructs by co-transfection of HeLa cells with the pHEBo-221 Zp luciferase plasmid and the 
BZLF1 pLenti4 plasmid, which constitutively expresses the transcription factor Zta. 
Constitutively expressed Zta binds to the BZLF1 promoter region in the reporter constructs 
and therefore induces expression of luciferase [24]. By increasing the amount of transfected 
pHEBo-221 Zp luciferase plasmid, we detected a striking augmentation of luciferase 
expression (Supplementary Figure 1). Thus, we confirmed functionality of BZLF1 reporter 
constructs.  
To identify the promoter region responsible for the TLR9 triggering-mediated inhibition 
of lytic EBV, we stably transfected Akata BL cells with various reporter constructs including 
sequences of varying length of the BZLF1 promoter: pHEBo-221 Zp luciferase, pHEBo-554 
Zp luciferase pHEBo-900 Zp luciferase. Experiments with pHEBo-2.3Kb Zp luciferase were 
performed as transient transfections, since, despite our efforts, it was not possible to select for 
Akata cells stably transfected with the pHEBo-2.3Kb Zp luciferase construct. We confirmed 
successful transfection of Akata BL cells using a sequence specific PCR targeting the 
pHEBO-221 Zp luciferase region (data not shown). Additionally, we used the pHEBo 
luciferase plasmid without a BZLF1 promoter as a negative control. BCR cross-linking on 
transfected Akata BL cells led to a significant increase in luciferase expression in pHEBo-221 
Zp luciferase, pHEBo-554 Zp luciferase pHEBo-900 Zp luciferase and pHEBo-2.3Kb Zp 
luciferase but not in pHEBo luciferase transfected Akata cells (Figure 1). Akata BL cells 
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transiently transfected with the different BZLF1 reporter constructs showed similar results 
(data not shown). Our data confirmed that the short Zp-221 region is alone sufficient for 
activation by BCR cross-linking [25].  
 
TLR9 triggering mediates inhibition of BZLF1 expression in full-length EBV, but does 
not affect activity of Zp reporter constructs 
We investigated whether TLR9 triggering affects BCR cross-linking-induced luciferase 
expression in Akata BL cells transfected with the plasmids pHEBo-221 Zp luciferase, 
pHEBo-554 Zp luciferase, pHEBo-900 Zp luciferase or pHEBo-2.3Kb Zp luciferase. 
Therefore, we triggered TLR9 using CpG2006, and 2 hours later the BCR was cross-linked 
with anti-IgG to induce lytic EBV reactivation. Most remarkably, TLR9 triggering in Akata 
BL cells did not lead to a significant suppression of the luciferase expression from the reporter 
plasmids after 6 hours (Figure 2) or 16 hours (data not shown). We obtained similar results in 
transient transfection experiments (data not shown). Thus, TLR9 triggering was not able to 
suppress BCR-induced expression of Zp-controlled luciferase expression in reporter plasmids 
in Akata BL cells.  
The results above stand in contrast to the TLR9 triggering-induced suppression of 
BZLF1 expression from genomic EBV. Cross-linking of the BCR in transfected Akata BL 
cells with anti-IgG for 6 hours resulted in an up-regulation of BZLF1 mRNA expression and 
thus in lytic reactivation of the full-length EBV genome. The prior treatment with CpG2006 
significantly suppressed BCR-induced BZLF1 expression levels in transfected and non-
transfected Akata BL cells (Figure 3). Thus, TLR9 triggering modulates full-length EBV 
genome Zp-controlled BZLF1 expression, but does not affect the stably transfected Zp-
controlled luciferase gene expression. 
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Chromatin structure and modification differs between full-length EBV genome and 
transfected reporter plasmids 
To investigate further the differential regulation of Zp activation in the full-length genomic 
EBV versus the transfected reporter constructs, we looked at the possible involvement of 
histone modifications. The histones bound to the promoter region of BZLF1 were reported to 
be acetylated and phosphorylated upon BCR cross-linking; an important step in the induction 
of the lytic cycle of EBV [7, 26-28]. To test whether the discrepant regulation of the full-
length EBV genome and the stably transfected reporter constructs might be due to a distinct 
chromatin structure, we performed ChIP assay on Zp reporter constructs.  
 
As others, we observed histone modifications on the BZLF1 promoter of the EBV viral 
episome upon BCR cross-linking [7, 26-28]. Similarly to the genomic full length Zp 
promoter, an increased acetylation of histones H3 on the lysine 9 (H3K9ac) could be 
measured on the pHEBo-221 Zp luciferase reporter constructs upon BCR cross-linking 
(Figure 4). H3K9ac on the genomic Zp promoter is inhibited by the TLR9 signaling. On the 
contrary the activation of TLR9 did not affect the acetylation state of the luciferase reporter 
constructs. These results show that full-length EBV genome and Zp reporter constructs have 
distinct histones modification and chromatin structures. TLR9 signaling does modify histones 
on the episomal Zp promoter leading to a suppression of BZLF1 expression, but TLR9 
signaling does not affect Zp-luciferase expression due to the inability of TLR9 signaling to 
induce histone modifications on transfected reporter constructs. We conclude that the activity 
of Zp is differentially controlled in the full-length EBV genome versus transfected reporter 
constructs.  
 In this study, we aimed to further elucidate the mechanism leading to TLR9 
triggering-induced suppression of EBV lytic reactivation in BL cells and examined the effect 
of TLR9 triggering on the regulation BZLF1 promoter using reporter constructs of increasing 
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length, starting with the minimal Zp-221. First, we established Akata cells stably transfected 
with different episomal Zp reporter constructs and confirmed activation of the minimal 
BZLF1 promoter Zp-221 by BCR cross-linking. Next, we showed that TLR9 triggering in 
Akata BL cells exhibits no effect on the activity of the Zp-221-Luc promoter upon BCR cross-
linking, nor on larger Zp fragments up to 2.3 Kbp, whereas it suppresses expression of Zp-
controlled BZLF1 lytic gene in the full-length genomic EBV context. Finally, we showed that 
TLR9 triggering does not lead to modification of acetylation on histone H3K9 on the Zp-221-
Luc promoter in contrast to what was observed for Zp on genomic EBV. Our results have 
implications on treatment modalities for EBV-associated cancers based on lytic reactivation 
of EBV. 
The extent of activation of the different Zp reporter constructs measured here upon 
BCR cross-linking was rather similar. Our results are in line with those of Amon et al. [29] 
who originally engineered the Zp-luciferase reporter constructs. One important feature of 
these reporter constructs is that they are maintained in the nucleus as episomes, since they 
carry EBV OriP and EBNA1 expression cassette, and allow the generation of cell lines stably 
carrying the reporter plasmids as episomes. The robustness of these systems was confirmed 
by the fact that we consistently observed activation of the promoter elements upon BCR 
cross-linking and that the minimal Zp-221 promoter was sufficient to drive expression of the 
reporter gene. Therefore, these systems should allow mirroring faithfully the regulation of 
genomic EBV Zp. 
To our surprise, TLR9 triggering did not suppress luciferase gene expression driven by 
the Zp promoters of different length in reporter plasmids upon BCR cross-linking of Akata 
BL cells. In contrast, in the very same cells, transcription of BZLF1 upon BCR cross-linking 
was suppressed by TLR9 activation. Thus, there must be a fundamental difference in the 
regulation of Zp activity in the genomic context vs. reporter constructs, specifically in the 
impact that TLR9 signaling has on transcription driven by Zp promoter. We have previously 
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shown that modification of histones on Zp promoter is directly correlated with TLR9 induced 
suppression of BZLF1 transcription [14]. Others have shown that a plasmid similar to the 
longest Zp-reporter construct (2.3 kbp) used here is embedded into nucleosomal structure [7], 
supporting the hypothesis that these reporter constructs may faithfully reproduce the wild type 
nucleosomal structure and regulation. Nevertheless, our functional studies suggest that a 
difference in the regulation of chromatin reorganization might subsist between Zp in full 
lenght EBV and in recombinant reporter constructs. 
As shown here, and earlier by us [14], acetylation of histones H3 and H4, as well as 
phosphorylation of H3, are induced by BCR cross-linking on EBV genomic Zp in Akata BL 
cells, and these modifications are suppressed by TLR9 signaling. Thus, we analyzed the 
acetylation status of histone H3K9 in Zp reporter constructs. This histone modification was 
also induced by BCR cross-linking in the Zp reporter constructs analyzed. On the other hand, 
TLR9-induced inhibition of acetylation on histone H3K9 observed for the genomic Zp did not 
take place on the Zp reporter constructs, indicating that TLR9 triggering has a different effect 
on chromatin structure associated with genomic EBV than that associated with reporter 
plasmids. This, in turn, strongly suggests that the suppressive effect of TLR9 signaling on Zp 
promoter activation is linked to a specific chromatin conformation associated with genomic 
EBV. 
 
Conclusion 
Our findings further support the importance of chromatin reorganization in the regulation of 
transcription of BZLF1 (Figure 5) and therefore in the balance between EBV latency and lytic 
reactivation in cancer cells, as observed by the efficient induction of lytic EBV by a specific 
set of histone deacetylase (HDAC) inhibitors [30]. Notably, histone methylation has been 
shown to be associated with latent EBV BZLF1 promoter region and to be at least partly 
involved in the maintenance of EBV latency in Raji BL cells [31]. Further elucidation of 
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chromatin reorganization in the regulation of transcription of BZLF1 is important in view of 
the fact that lytic EBV reactivation is being explored as a specific cancer cell-targeted therapy 
for EBV-associated malignancies [5] and improved HDAC inhibitors are being developed for 
the treatment of diverse malignancies. An enhanced understanding of the regulation of EBV 
lytic reactivation by cellular signaling pathways, including TLR9 signaling, will allow 
optimizing therapeutic strategies based on manipulation of chromatin remodeling. 
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Methods	
Cell culture 
EBV-positive Akata BL cells were cultured in RPMI 1640 medium (BioConcept, Allschwil, 
Switzerland) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), L-
glutamine (2 mM), and 10 % heat-inactivated fetal calf serum. Transfected cells were selected 
with 0.3 mg/ml hygromycin B (Invitrogen, California, USA). The human epithelial cell line 
HeLa was cultured in DMEM medium (BioConcept) supplemented with penicillin (100 
U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM), and 10 % heat-inactivated fetal calf 
serum. Both cell lines were maintained in a humidified atmosphere containing 5% CO2 at 
37°C. 
Plasmids 
Akata BL cells were transfected with a pHEBo vector containing different Zta promoter (Zp) 
regions followed by a gene encoding the firefly luciferase. The pHEBo luciferase, the 
pHEBo-221 Zp luciferase, and the pHEBo-554 Zp luciferase plasmids were kindly provided 
by P.J. Farrell [32]. The pHEBo-900 Zp luciferase and pHEBo-2.3 Kb Zp luciferase plasmids 
were cloned in our laboratory (see below).	
Cloning of pHEBo-900 Zp luciferase and pHEBo-2.3 Kb Zp luciferase 
Total DNA from Akata BL cells was isolated using the DNeasy Blood & Tissue Kit (Qiagen, 
Venlo, Netherlands) according to the manufacturer’s protocol. The -900 bp and -2.3 Kb Zp 
regions were amplified from Akata BL cells by PCR using the following primers:  
- 900 bp Zp: 
Forward: 5’-GCT AGC GCC CAA CCG TGG TCA AAC TC-3’ 
Reverse: 5’-CTC GAG GTG CAA TGT TTA GTG AGT TAC-3’. 
- 2.3 Kb Zp:  
Forward: 5’-GTC GAC TCC TTG GGG GAG TAG TAG CTT-3’ 
Reverse: 5’-GCT AGC GTG CAA TGT TTA GTG AGT TAC -3’. 
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 The PCR amplifications were cloned into the pCR 2.1-TOPO vector and amplified using 
TOP10 competent cells according to supplier’s protocol (TOPO TA Cloning Kit, Invitrogen). 
The TOPO vector containing the -900 Zp was digested with Bcu1 and Xho1 (New England 
Biolabs, Ipswich, MA, USA) and the -2.3 Kb Zp with Nhe1 and Sal1 (New England Biolabs). 
The minimal promoter Zp-221 from the pHEBo-221 Zp luciferase was cut out using Nhe1 and 
Xho1. To avoid self-ligation, the vector was incubated for 1 hour with calf intestine alkaline 
phosphatase (CIP). Purification was performed with the QIAquick PCR Purification Kit 
(Qiagen) according to the manufacturer’s protocol.  
 Ligation was realized in two ratios. 1:3 (insert: vector) with 150 ng vector and 1:5 with 
100 ng vector. Vector and insert were mixed with 2.5 µl 10x Buffer for T4 DNA Ligase (New 
England Biolabs), 1 µl T4 DNA Ligase (New England Biolabs) and water to a total of 25 µl. 
Samples were incubated overnight at 16°C. 
 Amplification of ligated plasmids was performed in One Shot Stbl3 chemically 
competent Escherichia coli according to manufacturer’s protocol (Invitrogen, Basel, 
Switzerland), followed by plasmid isolation using the GeneElute HP Plasmid Midiprep Kit 
(Sigma-Aldrich, St. Louis, MO, USA). Plasmids were sequenced through the Zp region to 
confirm their identity. Sequencing was performed at Microsynth (Balgach, St. Gallen, 
Switzerland). The following primers were used: 5’-CTT TAT GTT TTT GGC GTC TTC CA-
3’ (GLprimer2; for the -221 Zp, -554 Zp,  -900 Zp and the 2.3 Kb Zp); 5’-CGG CTT TGG 
CAG GAA CAT AC-3’ (only for the -900 bp Zp); and 5’-AGA GCC CTG ACA TCC TTA 
AC-3’ (only for the 2.3 Kb Zp). 
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Transfection 
Nucleoporation of Burkitt’s lymphoma cells 
Harvested cells were pelleted and resuspended in Cell Line Nucleofecter Solution T (Lonza 
Group Ltd, Basel, Switzerland) to a final concentration of 3.5 x 106 cells / 1000 µl, followed 
by addition of 7 µg of the appropriate plasmid. The mixture was transferred to an Amaxa 
cuvette. Program A-23 was run by an amaxa Nucleofecter II (Amaxa, since 2008 Lonza 
Group Ltd, Basel, Switzerland). Pre-warmed culture medium (500 µl) was added to the 
cuvette and cells were transferred immediately to 6.5 ml pre-warmed RPMI 1640 in a culture 
flask. The cuvette was washed several times with culture medium to make sure that the 
remaining cells were also transferred to the flask. Transfection efficiency was determined 24 
to 72 h after transfection by a sample nucleoporated with 4 µg of pmaxGFP (Lonza), using a 
Leica DMIL microscope (Leica Microsystems, Heerbrugg, Switzerland). 
 
CaCl2 transfection of HeLa cells 
HeLa cells (1.5 x 105 cells / ml in complete DMEM) were seeded on a 6-well tissue culture 
plate (250,000 cells per well). The next day, transfection was performed by diluting the 
according amounts of plasmids with HEPES-buffered water (2.5 mM HEPES in water) to a 
total volume of 35 µl. Pre warmed (37 °C) 0.5 M CaCl2 (35 µl) was added. While vortexing, 
the mixture was pipetted to 70 µl HEBS 2x (37°C) and then incubated at RT for 20 to 30 
minutes. Cells were added and incubated for one day at 37°C. 	
Cell treatment 
Cells were treated with the histone deacetylase inhibitor Trichostatin A (TSA; Sigma) (50 
ng/ml final concentration). At 12 h to 14 h later, ODN CpG-2006 (Eurogentec, Seraing, 
Belgium) with a final concentration of 0.5 µM was added. Two hours polyclonal rabbit anti-
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human IgG (100 µg / ml) (Dako Denmark, Glostrup, Denmark) was added to induce lytic 
EBV infection. Cells were harvested 4, 6 and 16 h after inducing lytic EBV infection. 
Luciferase Assay 
The harvested cells were resuspended in 150 µl Reporter Lysis Buffer 5x (Promega, Madison, 
WI, USA) and incubated for 15 minutes at 37°C gentle rocking. To guarantee perfect lysis, 
cells were frozen on dry ice and then unfrozen at 37°C. Tubes were vortexed for 15 seconds 
and centrifuged for 2 minutes at 16,000 g and 4°C. The supernatant was transferred to a new 
tube. Triplicates of 20 µl cell extract per well were pipetted on a flat-bottom 96-well plate. 
100 µl Assay Substrate (Promega) per well were added. Luminescence was measured with a 
sensitivity of 250 nm by the Synergy HT reader (Bio-Tek, Winoosiki, VT, USA). 
RNA isolation and quantitative Real time PCR (TaqMan) 
Cells were harvested 4, 6 and 16 h after the induction of lytic EBV infection by anti-IgG. 
RNA was isolated using the Qiagen RNEasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. DNAse treatment (DNAfree; Ambion Europe, Huntington, 
Cambridgeshire, UK) was performed, and RNA concentration was measured using NanoDrop 
(ND-1000 spectrophotometer). An amount of 1 µg of RNA was reverse transcribed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington, United 
Kingdom) as recommended by the supplier. Primer (300nM), probe (200nM), TaqMan master 
mix, cDNA and DEPEC-treated water were pipetted into a 376-well plate. Quantitative real 
time PCR (qRT-PCR) was performed with validated TaqMan systems for the housekeeping 
gene hydroxymethylbilane synthase (HMBS) and the EBV immediate-early lytic gene BZLF1 
[13, 33]. Primer and probes sequences: HMBS-forward 5`-GCTCGCATACAGACGGACAG-
3`, HMBS-reverse 5`-AGGCCAGGGTACGAGGCTT-3`, HMBS-probe 5`-
TGGTGGCAACATTG-3`; BZLF1-forward 5`-CACGACGRACAAGGAAAC-3`, BZLF1-
reverse 5`-CGCTTTATTTCTAGTTCAGAATCGC-3`, BZLF1-probe 5`-
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CAGCCAGAATCGCTGGAGGAA-3`. 18S rRNA primer and probes used were from 
Applied Biosystems. 
 The 7900 HT Fast Real Time PCR System (Applied Biosystems) with the appropriate 
temperature profile was used as follows. Initial denaturation for 10 min at 95°C, 40 cycles 
with denaturation for 15 seconds at 95°C and elongation for 1 minute at 60°C. Threshold 
cycle (Ct) numbers were determined using the SDS 2.2 software (Applied Biosystems). Gene 
transcription was normalized to mRNA expression of HMBS or 18S rRNA by calculating 
Ct(housekeeping gene)-Ct(BZLF1) resulting in threshold cycle (∆Ct) values. Results were 
analyzed calculating 2∆Ct.  
 
Chromatin immunoprecipitation (ChIP) analysis 
ChIP was preformed according to the manufacturer’s instructions (ChIP-IT Express, Active 
Motif, La Hulpe, Belgium). Briefly, 1.5 x 107 transfected cells were fixed by formaldehyde. 
Cells were lysed and homogenized using a 25G syringe. Chromatin shearing was performed 
by 15 x 20 seconds sonication at 25% with a 30 seconds break between each pulse using the 
Epishear™ Probe Sonicator (Active Motif, La Hulpe, Belgium). 7-25 µg (40 µl) sheared 
chromatin was incubated over night on a rotating wheel with 3 µg H3K9Ac antibody 
(AbCam, Cambridge, UK) and protein G magnetic beads. Washing steps and elution of 
chromatin was followed by proteinase treatment. The DNA purification was performed 
according to the QIAquick® PCR Purification Kit (Qiagen, Hombrechtikon, Switzerland). 
Quantitative real time PCR (qRT-PCR) was performed for the antibody selected sample as 
well as their corresponding 25% input samples with the following primers: Genomic Zp: ZP4 
F 5’-GAGCCACAGGCATTGCTAA-3’, Rev BZ1 967 5’AAGATAGCAAAGGTGGCCGG-
3’, Reporter Zp: ZP4 F 5’-GAGCCACAGGCATTGCTAA-3’, Rev LUC-5178 5’-	
CAGTACCGGAATGCCAAGCT-3’, both pairs with the probe: 5’-
AAGCCAAGGCACCAGCCTCC-3’. 
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 The 7900 HT Fast Real Time PCR System (Applied Biosystems) with the appropriate 
temperature profile was used as follows. Initial denaturation for 10 min at 95°C, 40 cycles 
with denaturation for 15 seconds at 95°C and elongation for 1 minute at 60°C. Threshold 
cycle (Ct) numbers were determined using the SDS 2.2 software (Applied Biosystems). The 
IP efficiency was calculated using the equation: 25% x 2(Ct 25% input sample – Ct IP sample). 
Statistical Analysis 
Values are reported as means (± standard error of the mean) from at least 3 independent 
biological replicates. Statistical analysis to determine the corresponding P value was 
performed using ANOVA (Bonferroni post-test) or unpaired t-tests. We computed all 
statistics with Prism 4 (Graph Pad, San Diego, CA, USA). P values < 0.05 were regarded as 
statistically significant. 
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Figure legends 
Figure 1: BCR cross-linking induces expression of luciferase in Akata cells stably 
transfected with different BZLF1 reporter constructs. Akata cells stably transfected with 
the plasmids pHEBo luciferase, pHEBo-221 Zp luciferase, pHEBo-554 Zp luciferase, pHEBo-
900 Zp luciferase, and transiently transfected with pHEBo-2.3 Kb Zp luciferase were treated 
with anti-IgG for 6 hours. The activation of the BZLF1 promoter regions was measured by 
luciferase assay. Experiments were performed three times, with cells originating from one 
transfection for pHEBo luciferase, pHEBo-221 Zp luciferase and pHEBo-554 Zp luciferase 
and originating from three different transfections for pHEBo-2.3Kb Zp luciferase. Relative 
luciferase units (RLUs) were calculated by dividing the absolute luciferase values of anti-IgG 
treated cells by the absolute luciferase values of mock treated cells. Values are reported as 
means +/- standard error of the mean. Abbreviations are as follows: *: P< 0.05, **: P<0.01.  
 
Figure 2: TLR9 triggering by CpG does not significantly affect BCR-induced up-
regulation of luciferase expression in Akata cells transfected with pHEBo-221 Zp 
luciferase, pHEBo-554 Zp luciferase, pHEBo-900 Zp luciferase or pHEBo-2.3Kb Zp 
luciferase. Activity of the enzyme luciferase after treatment with CpG and anti-IgG is shown 
for the cells transfected with different Zp promoter constructs. Cells were harvested 6 hours 
after adding anti-IgG. All experiments were performed three times. Relative luciferase units 
(RLUs) were calculated by dividing the absolute luciferase values of anti-IgG treated cells by 
the absolute luciferase values of mock treated cells. Values are reported as means +/- standard 
error of the mean. Abbreviations are as follows: *: P< 0.05, **: P<0.01.  
 
Figure 3: TLR9 triggering suppresses BCR-induced BZLF1 mRNA expression. 
Untransfected and transfected Akata cells were treated with anti-IgG and CpG. Reactivation 
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of EBV in Akata cells was quantified by measuring BZLF1 mRNA expression over the 
housekeeping gene HMBS. Cells were harvested 6 hours after adding anti-IgG.  
 
Figure 4: TLR9 signaling influences histone H3 acetylation on lysine 9 on the genomic 
Zp promoter of BZLF1 but not on stably transfected pHEBo-221 Zp luciferase reporter 
plasmid.  
Akata cells stably transfected with pHEBo Zp-221 luciferase plasmids were treated with 
CpG2006, anti-IgG or both. Cells were harvested and ChIP assay was performed with 
antibodies against H3K9ac. One ChIP using untreated lysed cells was performed with a 
normal rabbit IgG antibody as negative control and one ChIP was performed with a anti-H3 
antibody as positive control. ChIP reactions were followed by a q-rtPCR for the genomic Zp 
promoter region and for the pHEBo Zp-221 luciferase region based on the reporter plasmid. 
Shown in ng is the quantity of isolated chromatin from each ChIP reaction. One representative 
experiment is shown out of at least three independent experiments. 
 
Figure 5: Regulation of BZLF1 promoter Zp activity on genomic EBV by TLR9 
signalling.  
Viral lytic reactivation is characterized by histone acetylation on the promoter region of the 
immediate early lytic gene BZLF1 contributing to its expression. It has been observed that 
BCR cross-linking on Burkitt‘s lymphoma cells, results in the acetylation of histones on the 
Zp promoter and to the expression of Zta. It is still unclear if BCR cross-linking leads to 
histone acetylation through direct (or indirect) activation of histone acetyltransferases (HAT) 
and / or through inhibition of histone deacetylases (HDAC). We showed that TLR9 activation 
hinders BCR cross-linking’s effect on Zp histones and thus to abolish BZLF1 expression. We 
hypothesise that this repression affects the balance between HAT and HDAC activity either 
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by activating HDACs or by inhibiting HATs. As result, the histones on the Zp promoter are 
deacetylated when TLR9 is triggered prior to viral lytic reactivation.
ATTACHMENTS 	
	 121 
Figure 1 
pH
EB
o l
uc
ife
ras
e
pH
EB
o-2
21
 Zp
 lu
cif
era
se
pH
EB
o-5
54
 Zp
 lu
cif
era
se
pH
EB
o-9
00
 Zp
 lu
cif
era
se
pH
EB
o-2
.3 
Kb
 Zp
 lu
cif
era
se
0
1
2
3
4
5
6
*  
*  
*  
*  
*  
R
LU
 (o
ve
r m
oc
k 
tr
ea
te
d)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATTACHMENTS 	
	 122 
Figure 2:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pHEBo 2.3 Kb Zp luciferase
mo
ck Cp
G
aIg
G
Cp
G +
 aI
gG
0
1
2
3
4
5
6
7
8
RL
U 
(o
ve
r m
oc
k 
tre
at
ed
)
*	
ATTACHMENTS 	
	 123 
Figure 3:  
Untransfected
mo
ck
Cp
G
aIg
G
Cp
G 
+ a
IgG
0
10
20
B
ZL
F1
m
R
N
A
 e
xp
re
ss
io
n 
ov
er
H
M
B
S
(o
ve
r 
m
oc
k 
tr
ea
te
d)
pHEBo-221 Zp luciferase
mo
ck
Cp
G
aIg
G
Cp
G 
+ a
IgG
0
10
20
B
ZL
F1
m
R
N
A
 e
xp
re
ss
io
n 
ov
er
H
M
B
S
(o
ve
r 
m
oc
k 
tr
ea
te
d)
pHEBo-900 Zp luciferase
mo
ck
Cp
G
aIg
G
Cp
G 
+ a
IgG
0
10
20
B
ZL
F1
m
R
N
A
 e
xp
re
ss
io
n 
ov
er
H
M
B
S
(o
ve
r 
m
oc
k 
tr
ea
te
d)
pHEBo-554 Zp luciferase
mo
ck
Cp
G
aIg
G
Cp
G 
+ a
IgG
0
10
20
B
ZL
F1
m
R
N
A
 e
xp
re
ss
io
n 
ov
er
H
M
B
S
(o
ve
r 
m
oc
k 
tr
ea
te
d)
pHEBo-2.3 Kb Zp luciferase
mo
ck
Cp
G
aIg
G
Cp
G 
+ a
IgG
0
5
10
15
20
25
B
ZL
F1
m
R
N
A
 e
xp
re
ss
io
n 
ov
er
H
M
B
S
(o
ve
r 
m
oc
k 
tr
ea
te
d)
 
 
 
ATTACHMENTS 	
	 124 
 
Figure 4 
 
Genomic Zp
C
hr
om
at
in
 q
ua
nt
ifi
ca
tio
n 
(n
g)
un
tre
ate
d
un
tre
ate
d
un
tre
ate
d
Cp
G 
20
06
an
ti-
IgG
Cp
G 
+ a
nti
-Ig
G
0.0
0.1
0.2
0.3
Treatment
phEBo-221 Zp Luciferase
C
hr
om
at
in
 q
ua
nt
ifi
ca
tio
n 
(n
g)
un
tre
ate
d
un
tre
ate
d
un
tre
ate
d
Cp
G 
20
06
an
ti-
IgG
Cp
G 
+ a
nti
-Ig
G
0.0
0.1
0.2
0.3
Treatment
ATTACHMENTS 	
	 125 
Figure 5:  
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Supplementary Figure 1: Functionality of BZLF1 reporter constructs. Seven different 
concentrations of pHEBo-221 Zp luciferase plasmid were co-transfected by CaCl2 transfection 
with a constant amount of pLenti4-BZLF1 plasmids. Co-transfection with pHEBo luciferase 
and BZLF1 pLenti4 served as a control. Relative luciferase units (RLUs) were calculated by 
dividing the absolute luciferase values by the appropriate beta-galactosidase values, and 
setting of the highest value to 100 %. 
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Abstract  
Toll-like receptor 9 (TLR9) triggering is a promising novel strategy to combat cancer as it 
induces innate and adaptive immunity responses. B-cell lymphoma is unique in this context as 
tumor cells express TLR9 and may harbor latent Epstein-Barr virus (EBV), a 
gammaherpesvirus with remarkable oncogenic potential when latent. Latent EBV may be 
promoted by TLR9 triggering via suppression of lytic EBV. Here, we elaborated an initial 
assessment of the impact of TLR9 triggering on EBV-positive and EBV-negative B-cell 
lymphoma using Burkitt’s lymphoma (BL) cell lines as an in vitro model. We show that, 
independent of the presence of EBV, the TLR9 ligand ODN CpG-2006 may or may not 
induce caspase-dependent cell death in BL cells. Moreover, ODN CpG-2006-induced cell 
death responses of BL cells were associated with TLR9 single nucleotide polymorphisms 
(SNPs) rs5743836 or rs352140, which we detected in primary BL tumors and in peripheral 
blood from healthy individuals at similar frequencies. Thus, our findings suggest that the 
effect of TLR9 agonists on BL cells should be tested in vitro prior to installment of therapy 
and TLR9 SNPs in BL patients should be determined as potential biological markers for the 
therapeutic response to treatment targeting innate immunity. 
 
Keywords: Burkitt’s lymphoma, Epstein-Barr virus, Toll-like receptor TLR 9 agonists, 
polymorphism, CpG 
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Abbreviations 
 
BL  Burkitt’s lymphoma 
Ct  Cycle threshold 
EBV  Epstein-Barr virus 
hIL-10  human interleukin 10 
MFI  mean fluorescence intensity 
MyD88 myeloid differentiation factor D 88 
NF-kB  nuclear factor kappa-light-chain-enhancer of activated B cells 
ODN  oligodeoxynucleotide 
PBS  phosphate-buffered saline 
qRT-PCR  quantitative real-time polymerase chain reaction 
rhIL-10 recombinant human interleukin 10 
TLR   Toll-like receptor 
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Introduction 
Toll-like receptors (TLRs) are important players of the innate immune system 1, and 
expression of the ten TLRs known in humans 2, 3 depends on the cell subset and 
differentiation status 4-6. TLR9 is preferentially expressed by B-cells and plasmacytoid 
dendritic cells (reviewed in ref. 1). Synthetic TLR9 ligands, short oligodeoxynucleotides 
(ODN) with unmethylated CpG motifs 7, activate TLR9 that recruits the adaptor protein 
myeloid differentiation factor 88 (MyD88) and induces a cascade leading to the nuclear 
translocation of the transcription factor nuclear factor κB (NF-κB) 2. 
The immune response following TLR9 engagement is highly desirable for cancer 
treatment 8. Synthetic TLR9 agonists are regarded as potential anti-cancer agents. Clinical 
trials have shown promising results for the treatment of various cancer types with CpG ODNs 
9. Their effects can be indirect by enhancing the anti-tumor immune response or direct by 
inducing apoptosis in the malignant cells. Direct effects would be expected for B-cell 
malignancies as they express TLR9. B-cell activation can eventually lead to activation-
induced cell death of cancer cells and therefore support anti-cancer treatment 10. Nevertheless, 
the TLR9 agonist effects vary strongly between B-cell cancer types, and the responses of B-
cell lymphomas to ODN CpG-2006 show high variability 11. Thus, the effects of CpG ODNs 
on B-cell malignancies are not predictable. Moreover, CpG ODN treatment has tumor-
promoting effects on benign B-cells and strongly enhances their proliferation and 
differentiation 12-14. 
Stimulation of TLR9 with ODN CpG-2006 suppresses lytic reactivation of Epstein-
Barr virus (EBV), a B-cell tropic gamma-herpesvirus, and can thereby promote latent EBV 15, 
16. The latter is associated with several types of B-cell lymphomas including Burkitt’s 
lymphoma (BL) 17. EBV is present in nearly all cases of the high-incidence form of BL 
(‘endemic BL’), in up to 85% of the intermediate-incidence cases, and in 15% of the low-
incidence cases (‘sporadic’ BL). Up to 40% of BL in human immunodeficiency virus carriers 
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harbor EBV 17. Since latent EBV exhibits unique growth transformation potential on B-cells 
in vitro 18 and TLR9 triggering enhances EBV-induced B-cell transformation 19 and promotes 
latent EBV in vitro 15, 16, TLR9 stimulation in the treatment of EBV-positive BL could 
provoke detrimental rather than beneficial outcomes. 
Single nucleotide polymorphisms (SNPs) of TLR9 are associated with increased risk 
for certain B-cell lymphomas 20 and have the potential to exhibit deregulation of signaling 
thereby promoting tumorigenesis. The responses of TLR9 SNPs in B-cell tumors to CpG 
ODN treatment are not reported. 
 Here, we used BL cell lines to model direct effects of TLR9 stimulation on malignant 
cells, investigate the influence of EBV, and assess the impact of TLR9 SNPs, which we found 
in primary BL samples or in healthy primary cells. 
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Results 
 
TLR9 triggering alters gene expression and activates Akata cells in a MyD88-dependent 
manner. CpG ODNs activate B-cells by impacting on gene expression 21. We asked how the 
gene expression pattern of BL cells is affected by TLR9 triggering using CpG ODN. We 
performed a microarray analysis comparing ODN CpG-2006-treated versus untreated Akata 
cells. Most of the ≥ 2-fold changes in gene expression were up-regulation and only few down-
regulation. Among up-regulated genes, we were mainly interested in those involved in 
cytokine (hIL-10) and chemokine expression (CXCL10), B-cell activation (CD40), 
transcription (NF-κB) and apoptosis (FAS) as these genes are those that preferentially 
determine cell proliferation and survival (Suppl. Table 1). Thirteen genes including two 
regulating cell cycle, one transcription factor, one involved in B-cell differentiation and 
apoptosis, four of diverse functions, and four of unknown function showed down-regulation 
following ODN CpG-2006 treatment (Suppl. Table 2). 
We earlier confirmed that TLR9 triggering of Akata cells with ODN CpG-2006 
increases hIL-10 expression and leads to the translocation of NF-κB to the nucleus 16. To 
validate a marker for B-cell activation, in this context, we measured CD40 expression by flow 
cytometry. CD40 expression was increased upon ODN CpG-2006 treatment (Figure 1a). After 
48 hours, CD40 expression on ODN CpG-2006-treated cells was increased 2.7-fold compared 
to untreated cells (Figure 1a and 1b). Surprisingly, the control ODN GpC-2006, which is 
similar to ODN CpG-2006 but lacks the CpG motifs, also led to a 2.4-fold increase in CD40 
expression (Figures 1a and 1b). This might reflect a TLR9-independent mechanism or the 
ability of the control ODN to stimulate TLR9 in BL cells.  
To clarify this point, we used Akata cells overexpressing a dominant negative mutant 
of the adaptor protein MyD88 (DN-MyD88) 16. Treatment with ODN CpG-2006 or ODN 
GpC-2006 induced increased CD40 expression, corroborating our first observation (Figure 
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1c). By contrast, neither ODN CpG-2006 nor ODN GpC-2006 significantly induced an 
increase in CD40 expression in DN-MyD88 Akata cells (Figure 1c). Finally, we validated the 
ODN CpG-2006 treatment-induced up-regulation of STAT3 (Suppl. Table 1) by quantitative 
real-time polymerase chain reaction (qRT-PCR) and confirmed activation of STAT3 by 
Western blot (data not shown). 
Collectively, we validated our microarray data showing that triggering with ODN 
CpG-2006 activates Akata cells to induce CD40 and STAT3 expression. Moreover, our 
results indicated that both ODNs used here act in a MyD88-dependent manner and that the 
ODN lacking CpG motifs activates Akata cells to a similar extent as the ODN containing CpG 
motifs.  
 
TLR9 triggering by CpG ODN does not impact on the cell cycle of Akata cells. TLR9 
triggering leads to cell cycle entry and proliferation of B chronic lymphatic leukemia cells11, 
12, 22. We analyzed the cell cycle of mock-treated or ODN CpG-2006-treated Akata cells after 
initiation of treatment by propidium iodide staining and flow cytometry. Most cells were in 
the S phase during the time frame of 48 hours (Suppl. Figure 1). Treatment with ODN CpG-
2006 did not alter the cell cycle compared to mock treatment. Similar results were obtained 
with Akata31 cells (data not shown), an EBV-negative subclone of Akata cells 23. Thus, 
although TLR9 triggering by ODN CpG-2006 resulted in BL cell activation based on 
increased expression of certain genes, it did not seem to influence the cell cycle. 
 
ODN-induced cell death of BL Akata cells is MyD88-dependent. Treatment with ODN 
GpC-2006 unexpectedly induced CD40 up-regulation in Akata cells in a MyD88-dependent 
manner similar to treatment with ODN CpG-2006. We determined whether treatment with 
distinct TLR9 ligands would similarly result in a MyD88-dependent effect on cell survival. 
Also, we explored whether a class A ODN, that displays low specificity for B-cells, exerts 
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similar effects on BL cells as class B ODNs that possess a high specificity for B-cells. 
Therefore, we treated Akata cells or DN-MyD88 Akata cells with ODN CpG-2216 (type A), 
ODN CpG-2006 (type B) and ODN GpC-2006 (type B control), respectively, and analyzed 
the viability of the cells by Trypan Blue exclusion assay and PE-Annexin V/7-AAD staining. 
The Trypan Blue exclusion assay showed that treatment of Akata cells with ODN CpG-2006 
or ODN GpC-2006 reduced the survival of cells within 48 hours to below 50% of not treated 
cells and treatment with ODN CpG-2216 to almost 50% of not treated cells after 72 hours 
(Figure 2a). By contrast, the survival of DN-MyD88 Akata cells was not, if at all, reduced by 
treatment with any of the three ODNs for 72 hours (Figure 2a). These findings were 
corroborated by the Annexin V/7-AAD assay revealing that the viability of Akata cells was 
drastically affected by treatment with class B ODNs and to a lesser extent with class A ODN, 
contrasting DN-MyD88 Akata cells that were not affected by treatment with ODNs for 72 
hours (Figure 2b and quantification in Figure 2c). Thus, treatment of Akata cells with ODNs 
CpG-2006 and GpC-2006 triggers TLR9 signaling via MyD88 and results in cell death.  
 
ODN-induced cell death of BL Akata cells is caspase-dependent. To explore the 
mechanism of ODN-induced cell death of Akata cells we set out to investigate whether 
caspases were involved. Thus, the activity of caspase-3 and -7 in ODN-treated Akata cells 
was detected using a luminogenic substrate which gives rise to a luminescent signal 
proportional to caspase-3/7 activity. Triggering with TLR9 ligands for 48 hours increased the 
luminescent signal about 2-fold as compared to no triggering. This increase was abolished by 
treatment with the caspase inhibitor z-VAD-FMK (Figure 3a), indicating that TLR9 triggering 
resulted in increased caspase activity in Akata cells and that this activity was not increased if 
cells were concomitantly treated with a caspase inhibitor. These findings were corroborated 
using PI staining, which indicate that Akata cell death induced by treatment with ODNs can 
be abrogated by the caspase inhibitor z-VAD-FMK (Figure 3b); and by Western blotting 
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showing that PARP cleavage is increased by ODN treatment and can be reduced by the 
inhibitor (Figure 3c). Thus, ODN-induced cell death of Akata cells was found to be caspase-
3/7 dependent and therefore due to apoptosis. 
 
Survival of distinct BL cells following treatment with CpG ODNs differs considerably, 
independently of the presence of EBV. ODN CpG-2006 suppresses EBV lytic gene 
expression in Akata cells and primary B-cells promoting latent EBV that may provide cell 
survival signals15, 16. Since we observed Akata cell death upon TLR9 triggering, we asked 
whether the absence of EBV would result in even more pronounced cell death following 
TLR9 triggering. Hence, we tested whether TLR9 agonists affect the survival of EBV-
positive Akata cells and of EBV-negative Akata31 cells in a similar fashion. Treatment with 
ODN CpG-2006 or ODN GpC-2006 strongly decreased the percentages of surviving Akata 
cells or Akata31 cells between 24 hours and 72 hours compared to untreated cells. 
Nevertheless, the effect on Akata31 cells was less marked (Figure 4a). The percentages of 
apoptotic Akata31 cells assessed by Annexin V/7-AAD staining after 72 hours of treatment, 
however, were comparable to those of Akata cells (Figure 4b). Treatment with ODN CpG-
2216, ODN CpG-2006, or ODN GpC-2006 resulted in similar respective decreases in 
viability of Akata cells vs. Akata31 cells due to apoptosis. Treatment with class A ODN CpG-
2216 exhibited almost no negative impact on cell survival compared to treatment with the 
class B ODNs CpG-2006 and GpC-2006 (Figure 4b). These results showed that EBV-
negative Akata31 cells exhibited a higher level of spontaneous cell death by apoptosis 
compared to EBV-positive Akata cells and corroborated the lower effect of TLR9 triggering 
by class A ODN compared to triggering by class B ODNs. Moreover, the results suggested 
that the presence of EBV does not prevent EBV-positive Akata cells from TLR9 triggering-
induced cell death compared to EBV-negative Akata31 cells. 
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 Next, we investigated whether our observations in EBV-positive versus EBV-negative 
BL cells hold true in BL cells other than Akata. To this end, we used EBV-positive BL cells 
Mutu-I and EBV-negative BL cells BJAB and Ramos. Treatment with ODN CpG-2006 or 
with ODN GpC-2006 did not affect Mutu-I cell or BJAB cell survival (Figure 4c) but it 
decreased Ramos cell survival between 48 hours and 72 hours (Figure 4c). Thus, the survival 
of BL cells following TLR9 triggering considerably differs between distinct BL cells and does 
not seem to depend on the presence or absence of EBV. 
 
Exogenous hIL-10 does not prevent ODN CpG-2006-induced cell death. hIL-10 plays an 
important role in B-cell lymphoma biology as it seems to act as autocrine growth factor 22, 24-
26. We previously reported 16 and corroborate here, a strong hIL-10 induction in Akata cells 
following TLR9 triggering with ODN CpG-2006 (Suppl. Table 1). Nevertheless, the very 
same treatment resulted in drastic Akata cell death (Figure 2), suggesting that the latter could 
not be prevented by the induction of hIL-10 expression. Otherwise, a recent report suggested 
that treatment with ODN CpG-2006 induced hIL-10 in chronic lymphocytic leukemia B-cells 
mediating their cell death 10. Therefore, we treated Akata cells and DN-MyD88 Akata cells 
with ODN CpG-2006, recombinant hIL-10 (rhIL-10), or a combination thereof. The 
concentration of rhIL-10 was based on the peak hIL-10 protein concentration induced by 
ODN CpG-2006 treatment in Akata cells 16. Additionally, ODN CpG-2006 treatment was 
reiterated at 48h in a fraction of BL cells. 
As expected, treatment with ODN CpG-2006 for 72 hours reduced the viability of 
Akata cells to < 20% but did not reduce viability of DN-MyD88 Akata cells compared to no 
treatment (Figure 5a-c). Reiterated treatment with ODN CpG-2006 after 48 hours did not 
further reduce viability of Akata cells compared to one-time treatment and did not reduce 
viability of DN-MyD88 Akata cells (Figure 5a-c). Treatment with rhIL-10 for 72 hours also 
did not reduce viability of Akata cells or DN-MyD88 Akata cells compared to no treatment. 
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Treatment with rhIL-10 did not counteract ODN CpG-2006 treatment-induced reduction of 
BL cell viability or further decreased their viability. DN-MyD88 Akata cells were not affected 
by any of the treatments (Figure 5a-c). Thus, maximal negative impact of ODN CpG-2006 on 
cell survival in Akata cells occurred after one treatment. Moreover, rhIL-10 did not change 
the number of viable Akata cells, or rescue Akata cells from ODN CpG-2006 treatment-
induced cell death. This suggested that hIL-10 cannot counteract TLR9 triggering-induced 
cell activation resulting in death of Akata cells and is not responsible for their cell death.  
 
BL cells express distinct hIL-10 mRNA and hIL-10 levels following TLR9 triggering. 
The distinct survival of BL cells following TLR9 triggering with ODN CpG could be due to 
distinct magnitudes of ensuing cellular responses. The induction of hIL-10 following ODN 
CpG treatment can be regarded as a surrogate marker for the magnitude of cell activation 
mediated by TLR9 triggering. Thus, we assessed hIL-10 mRNA expression in BL cells treated 
with ODN CpG-2006 or ODN GpC-2006. All 5 BL cell lines tested expressed hIL-10 mRNA 
following treatment with ODN CpG-2006, the values peaking preferentially at 6h post 
treatment (Figure 6a). Peak hIL-10 mRNA expression levels varied from 1.3 transcripts over 
HMBS in Ramos BL cells to 48 transcripts in Mutu-I BL cells. Treatment with ODN GpC-
2006 also resulted in induction of hIL-10 mRNA expression but in lower levels, except in 
Akata cells. Similar variation of results was observed when analyzing hIL-10 protein levels 
(Figure 6b). Thus, TLR9 triggering of distinct BL cells resulted in a broad range of hIL-10 
mRNA and hIL-10 protein expression levels, and the magnitude of the level seemed 
independent of EBV status.  
Next, we determined TLR9 mRNA expression levels in BL cells by qRT-PCR. 
Although distinct BL cells showed up to 6-fold different relative TLR9 mRNA expression 
levels (Figure 6c), ODN CpG-2006 treatment-induced hIL-10 mRNA peak expression levels 
did not correlate with the relative TLR9 mRNA expression levels (Figure 6d). Collectively, 
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TLR9 triggering in distinct BL cells resulted in distinct hIL-10 mRNA expression, not linked 
to presence or absence of EBV, and not correlated to TLR9 mRNA expression levels. 
 
TLR9 polymorphisms of BL cells might correlate with distinct responses to TLR9 
triggering. TLR9 polymorphisms in patients are linked to different outcomes of inflammatory 
diseases and the development of cancer 27, 28. We hypothesized that TLR9 polymorphisms 
could be a possible explanation for our observations. Thus, we isolated the genomic DNA 
from BL cell lines and analyzed it for the presence of TLR9 polymorphisms. We found 
specific SNPs for each cell line, allowing segregation of the BL cell lines into three groups 
(Table 1): -1237 TT/1635 GA (Akata and Akata31), -1237 TT/1635 GG (Ramos) and -1237 
TC/1635 GG (Mutu-I and BJAB). This sub-grouping correlated with the degree of BL cell 
survival in response to ODN treatment (Figure 4c), suggesting that the distinct BL cell 
responses to TLR 9 triggering may depend on the SNPs present. 
Next, we analyzed TLR9 SNPs in genomic DNA from primary BLs or blood from 
healthy individuals. Indeed, we found the TLR9 SNPs detected in our BL cell lines in primary 
BL samples and blood of healthy individuals (Table 4). Importantly, the TLR9 SNP 
frequencies were statistically not significantly different between BL cell lines, primary BLs 
and blood from healthy individuals, respectively. This suggested that if the direct response to 
TLR9 agonists depends on the TLR9 SNP, this could be an important factor regarding the 
treatment of BL patients by TLR9 triggering. 
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Discussion 
We analyzed the effects of TLR9 agonists on BL cell lines as an in vitro model for B-cell 
tumor. We found that treatment with TLR9 ligands induces distinct cytokine expression and 
cell death responses in distinct BL cells. Cell-death was (i) dependent on TLR9-MyD88 
signaling; (ii) occurred concomitantly with activation and could be suppressed by pan caspase 
inhibitors; (iii) was not dependent on the presence or absence of EBV in the tumor cells; and 
(iv) was associated with SNPs in the TLR9 gene. Our results suggest that individualized in 
vitro pretesting of BL responses to CpG ODNs could help to predict the outcome of 
therapeutic TLR9 triggering and tailor adjuvant molecular treatment of BL. 
Our observation that BL cells of different origin show distinct cell survival following 
TLR9 triggering is novel. We previously demonstrated that TLR9 triggering counteracts lytic 
EBV reactivation in BL cells and promotes latent EBV that is associated with B-cell 
lymphoproliferation 16. Here, we observed CpG type B ODN-induced cell death by apoptosis 
in EBV-positive Akata and EBV-negative Akata31 cells, but not or to a much lower extent in 
the other EBV-positive or EBV-negative BL cell lines tested. Thus, the EBV status of the 
tumor cells does not rule the responses of BL cells to TLR9 triggering. 
TLR9-triggered BL cells consistently upregulated hIL-10 expression. hIL-10 
influences the development and growth of B-cells 29 and acts as an autocrine growth factor for 
different B-cell lymphomas 25, 26, 30. Importantly, here, rhIL-10 did neither prevent nor 
enhance cell death induced by TLR9 triggering. hIL-10, as an anti-inflammatory cytokine, 
inhibits the Th1 immune response 31 and this effect would be detrimental in cancer therapy 
that is based on intact or enhanced immune responses 9, since an unintended proliferation of 
the malignant cells could be provoked. Thus, the function of CpG type B ODN-induced hIL-
10 expression in BL cells seems to considerably differ from that in chronic lymphocytic 
leukemia B-cells that were reported to undergo hIL-10-mediated apoptosis 10. 
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Surprisingly, ODN GpC-2006 induced cell death to the same extent as ODN CpG-
2006. ODN GpC-2006 binds to TLR9, but in contrast to CpG-2006 it does not lead to TLR9 
signaling in HEK293 cells or to changes in the secondary structure of the ectodomain 32. 
Therefore, we examined whether downstream signaling of TLR9 via MyD88 is involved in 
the induction of cell death. Indeed, experiments using Akata cells overexpressing a MyD88 
dominant negative mutant indicated that both ODNs induce cell death of BL cells in a 
MyD88-dependent manner. Others demonstrated that ODNs induce cell death independently 
of the CpG motif, of TLR9 33 or even of the whole ODN sequence 34. Another pathway that is 
triggered by CpG ODNs, but is TLR9-independent, was described in monocytes and involves 
the activation of the Src family kinases Lyn and Hck 35. In our experiments, BL cell death 
induced by TLR9 triggering correlated with increased caspase activity and was caspase-
dependent, thus most likely due to apoptosis. 
The BL cell lines tested differed in their TLR9 mRNA expression level and TLR9 
SNPs. mRNA expression did not correlate with cell death responses to TLR9 triggering, but 
the distinct TLR9 SNPs did. The role of TLR9 SNPs in BL is unknown. To start to investigate 
this we analyzed the frequencies of given SNPs in BL patients and healthy individuals and 
found them to be similar. A recent report suggests that the rs5743836 polymorphism, which 
was also detected here, confers an increased risk for non-Hodgkin lymphoma in people from 
Portugal and Italy but not from the US 20. The association of the C allele rs5743836 with lack 
of cell death upon TLR9 triggering observed here in the Mutu-I and BJAB BL cell lines is 
striking. It does not allow establishing a causal link, but justifies the hypothesis that the 
distinct cell death responses upon CpG ODN treatment in BL cells may be linked to TLR9 
SNPs. Notably, the C allele of rs5743836 exhibits greater NF-κB binding affinity because of 
an additional NF-κB transcriptional binding site that may lead to increased production of 
proinflammatory cytokines 36. Hence, the presence of the C allele seems to result in enhanced 
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NF-κB activation following TLR9 triggering. This may lead to protection of ODN CpG 
treatment-induced apoptosis that can be observed in BL cells without the C allele. 
 In conclusion, therapeutic TLR9 triggering appears to be a double-edge sword that 
may induce apoptosis, or enhance lymphoproliferation. Our findings suggest that the effect of 
TLR9 agonists on BL cells should be tested in vitro prior to installment of therapy and that 
TLR9 SNPs in BL patients should be evaluated as potential biological markers for the 
response to treatment targeting innate immunity. 
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Material and Methods 
 
Cell lines. The EBV-positive BL cell lines Akata and Mutu-I, and the EBV-negative BL cell 
lines Akata 31, BJAB and Ramos were grown in RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum, streptomycin (100 mg/ml), penicillin (100 U/ml) and L-glutamine 
(2mM). EBV-positive BL Akata cells expressing a dominant negative MyD88 (DN-MyD88 
Akata) 16 were grown in the same medium supplemented with 0.4 mg/ml G418 (Promega, 
Mannheim, Germany). 
 
Primary BL tissue samples and peripheral blood from healthy individuals. Burkitt’s 
lymphomas were retrieved from the database of the Institute of Surgical Pathology, 
University Hospital of Zurich (PathoPro Software, Institute of Medical Software, 
Saarbrücken, Germany). The BL diagnosis was performed according to the WHO 
classification of tumors of hematopoietic and lymphoid tissues 37. DNA was extracted from 
paraffin-embedded whole tissue sections, according to standard procedures. This study was in 
accordance with Swiss laws and approved by the official authorities of the ethical committee 
of the Canton of Zurich (StV2-2007).  Peripheral blood was collected from 402 healthy blood 
donors (aged 19-70 years) who were randomly selected according to the criteria of the Swiss 
Red Cross 38.  
 
 
Single-nucleotide-polymorphism analysis. Whole genomic DNA was extracted with the 
DNeasy® Blood & Tissue Kit (Qiagen, Hombrechtikon, Switzerland) according to the 
manufacturer’s instructions. Genotyping of the TLR9 polymorphisms –1237 T/C (rs5743836) 
and 2848 G/A (rs352140) was done by tetra-primer assays as previously described 39. 
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Treatment with TLR9 agonists. Cells were split to a density of 0.5x106 cells/ml. The TLR9 
ligands ODN CpG-2216 (type A), ODN CpG-2006 (type B) and ODN GpC-2006 (type B 
control) were applied at concentrations of 0.5 µM. Oligodeoxynucleotide (LabForce-
InvivoGen, Nunningen, Switzerland) sequences: ODN CpG-2216: 5’-
ggGGGACGATCGTCgggggg-3’, bases are phosphodiester (capital letters) or 
phosphorothioate (lower case); ODN CpG-2006: 5’-tcgtcgttttgtcgttttgtcgtt-3’, full 
phosphorothioate backbone; ODN GpC-2006: 5’- tgctgcttttgtgcttttgtgctt -3’, full 
phosphorothioate backbone.  
 
 
Microarray analysis. Akata cells were mock treated or treated with CpG-2006, and 
harvested 6 hours later. Total RNA was isolated with RNeasy mini kit (Qiagen) according to 
the manufacturer’s instructions. Microarray analysis was performed at the Functional 
Genomic Centre Zurich (University of Zurich, Zurich, Switzerland). Human Exon 1.0 ST 
Array chips (Affymetrix, Santa Clara, CA, USA) and Genespring GX software (Agilent 
Technologies, Basel, Switzerland) were used for the analysis. An at least 2-fold change in 
gene expression (up-regulation or down-regulation) in the treated versus the mock-treated 
sample was regarded as significant. 
 
 
qRT-PCR (Taqman). Total RNA was extracted from 106 cells with the RNeasy Kit (Qiagen) 
and DNA was removed with DNA-free (Ambion). 1 µg of the purified RNA was used to 
generate cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Rotkreuz, Switzerland). Quantitative real-time PCR was performed with specific 
Taqman primers and probes on ABI 7200 (Applied Biosystems). Data were analyzed with the 
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software SDS2.2 (Applied Biosystems). Delta cycle threshold (Ct) values for the respective 
genes were normalized to HMBS.  
 
 
Staining for surface antigens. 105 cells were stained with FITC mouse anti-human IgM 
(Clone G20-127), PE-CyTM5 mouse anti-human IgG (Clone G18-145), PE mouse anti-human 
IgD (Clone IA6-2) or the respective isotype controls, FITC IgG1κ isotype control (Clone 
MOPC-21), PE-CyTM5 mouse IgG1κ isotype control (Clone MOPC-21), PE mouse IgG2aκ 
isotype control (Clone G155-178) or PE-Cy5 anti-human CD40 (Cat. 555590) (all from BD 
Biosciences, Allschwil, Switzerland) for 30 min at 4 °C in the dark. Cells were counted with a 
flow cytometer (FACSCanto II, BD Biosciences).  
 
Annexin V/7-AAD staining. To assess apoptotic, necrotic or dead and viable cells, 105 cells 
were harvested, washed with PBS and resuspended in 100 µl Annexin V binding buffer (140 
mM NaCl, 2.5 mM CaCl2, 10 mM HEPES, pH 7.4) and incubated with 5 µl Annexin V and 5 
µl 7-Amino-Actinomycin (7-AAD) (BD Biosciences) for 15 min at room temperature in the 
dark. After addition of 200 µl Annexin V binding buffer, cells were analyzed with the 
FACSCanto II flow cytometer (BD Biosciences).  
 
Propidium Iodide staining. To discern between dead and viable cells, treated cells were 
stained with 50 µg/ml PI (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) for 15 min at 
room temperature and then analyzed with the FACSCanto II flow cytometer (BD Biosciences, 
Allschwil, Switzerland).  
 
Protein isolation, quantification, and Western blot. Total protein lysates were obtained 
after lysing the cells in RIPA complete buffer [50 mM Tris–HCl pH7.5, 150 mM NaCl, 2 mM 
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EDTA, 1% NP40 complemented with 0.1% SDS, 1x EDTA-free protease inhibitor cocktail 
(Roche, Rotkreuz, Switzerland)]. Cell extracts were passed 10 times through a 25G syringe. 
Protein content was determines using the Pierce® BCA Protein Assay Kit (ThermoScientific, 
Erembodegem, Belgium), according to the manufacturer’s instructions. To analyze protein 
expression by Western blot, protein (20µg/ per well) was loaded into a NuPAGE® 4-12% Bis-
Tris Gel (life technologies, Zug, Switzerland) and subjected to SDS–PAGE electrophoresis, 
transferred electrophoretically to a nitrocellulose membrane (GE Healthcare, Glattbrugg, 
Switzerland), incubated with rabbit anti-PARP antibody or rabbit anti-β-Actin antibody, and 
subsequently with anti-rabbit IgG, HRP-linked antibody (all diluted 1:1000 and from, Cell 
Signaling Technology (Allschwil, Switzerland). The signal was detected with the ECL 
Western Blotting Detection Reagents (GE Healthcare) and imaged using the LAS-3000 
(Fujifilm, Dielsdorf, Switzerland) and image reader LA-3000 (Fujifilm). 		
hIL-10 ELISA. hIL-10 protein concentrations were determined in supernatants from TLR9-
stimulated cultures by standard capture ELISA (Ready-SET-Go, eBioscience,	 Vienna, 
Austria) according to the manufacturer’s instructions Plates were read at 450 nm once the 
substrate had developed, and cytokine concentration was determined by extrapolation from 
the standard curve. 
 
Caspase-3/7 activity. Activity of caspase-3/7 was assessed with the Caspase-Glo® 3/7 Assay 
according to the manufacturer’s protocol (Promega, Wallisellen, Switzerland). Cells, 
dispensed at 0.5 x 106 cells/mL/well in a 24-well plate were treated with TLR9 ligands and 
incubated at 37°C for 48 hours. At the end of the incubation period, 100 µL of Caspase-Glo® 
3/7 reagent was added to 100 µL cell suspension in a white-walled 96-well plate and 
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incubated at room temperature for 1 hour. Luminescence intensity was determined using a 
Synergy HT Multi-Detection Microplate Reader (BioTek, Luzern, Switzerland). 
 
Treatment of BL cells with rhIL-10. One day before the experiment, the cells were split to a 
density of 0.5x106cells/ml. The next day, 106 cells were incubated with 900 pg rhIL-10/ml 
(Immunotools, Friesoythe, Germany) for the indicated time points. This concentration 
corresponds to the hIL-10 protein concentration induced by ODN CpG-2006 in Akata cells 16. 
 
 
 
Acknowledgements 
This work was funded by the Swiss National Foundation (310040-114118), Oncosuisse, and 
the Cancer League of the Canton of Zurich. 
ATTACHMENTS 	
	 147	
References 
 
1. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. 
Nat Immunol 2004; 5: 987-95. 
 
2. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like 
receptors: lessons to learn from normal and malignant human B cells. Blood 2008; 
112: 2205-13. 
 
3. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like 
receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 
204: 27-42. 
 
4. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor 
repertoire of human B lymphocytes: inducible and selective expression of TLR9 and 
TLR10 in normal and transformed cells. Blood 2003; 102: 956-63. 
 
5. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L et al. Plasma cell 
toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR 
triggering enhances immunoglobulin production. Immunology 2009; 128: 573-9. 
 
6. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al. 
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human 
peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J 
Immunol 2002; 168: 4531-7. 
 
ATTACHMENTS 	
	 148	
7. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide 
TLR9 agonists. Adv Drug Deliv Rev 2009; 61: 195-204. 
 
8. Weiner GJ. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv 
Drug Deliv Rev 2009; 61: 263-7. 
 
9. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 
2008; 27: 161-7. 
 
10. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR et al. 
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic 
pathway in human chronic lymphocytic leukemia B cells. Blood 2010; 115: 5041-52. 
 
11. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E et al. 
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin 
Cancer Res 2005; 11: 1490-9. 
 
12. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. 
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, 
and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 
95: 999-1006. 
 
13. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. Toll-like receptors on tumor 
cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-14. 
 
ATTACHMENTS 	
	 149	
14. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in 
carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009; 14: 248-72. 
 
15. Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M et al. Immune 
activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 
2007; 9: 2055-69. 
 
16. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M et al. TLR9 
triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription 
via histone modification. Oncogene 2010; 29: 4588-4598. 
 
17. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 
757-68. 
 
18. Rickinson A, Kieff E. Epstein-Barr virus. In: Knipe DM (ed) Fields Virology, 4th edn. 
Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 2575–2627. 
 
19. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR et al. 
An efficient method to make human monoclonal antibodies from memory B cells: 
potent neutralization of SARS coronavirus. Nat Med 2004; 10: 871-5. 
 
20. Carvalho A, Cunha C, Almeida AJ, Osorio NS, Saraiva M, Teixeira-Coelho M et al. 
The rs5743836 polymorphism in TLR9 confers a population-based increased risk of 
non-Hodgkin lymphoma. Genes Immun 2012; 13:197-210. 
 
ATTACHMENTS 	
	 150	
21. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005; 17: 
230-6. 
 
22. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G et al. 
CpG DNA increases primary malignant B cell expression of costimulatory molecules 
and target antigens. J Leukoc Biol 2001; 69: 81-8. 
 
23. Jenkins PJ, Binne UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr 
virus from latency. J Virol 2000; 74: 710-20. 
 
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the 
interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765. 
 
25. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous 
growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045-51. 
 
26. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of 
interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma 
herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999; 94: 
2871-9. 
 
27. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J et al. Increase in 
NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C 
polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect 
Immun; 78: 1345-52. 
 
ATTACHMENTS 	
	 151	
28. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez Mdel M, Salinas A, 
Pulido I et al. Influence of the Toll-like receptor 9 1635A/G polymorphism on the 
CD4 count, HIV viral load, and clinical progression. JAIDS (1999) 2008; 49: 128-35. 
 
29. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH et al. Interleukin 10 
is a potent growth and differentiation factor for activated human B lymphocytes. Proc 
Natl Acad Sci U S A 1992; 89: 1890-3. 
 
30. Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE et al. Interleukin-
10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-
cell lymphoma. Blood 1995; 85: 3423-30. 
 
31. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev 
Immunol 2010; 10: 170-81. 
 
32. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC et al. Ligand-induced 
conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007; 
8: 772-9. 
 
33. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S et al. 
TLR ligands in the local treatment of established intracerebral murine gliomas. J 
Immunol 2008; 181: 6720-9. 
 
34. Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M et al. Thymidine-
phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells 
independently of CpG motifs or BCL-2 gene interference. Leukemia 2006; 20: 680-8. 
ATTACHMENTS 	
	 152	
 
35. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A et al. CpG-induced tyrosine 
phosphorylation occurs via a TLR9-independent mechanism and is required for 
cytokine secretion. J Cell Biol 2006; 172: 1057-68. 
 
36. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J et al. Increase in 
NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C 
polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect 
Immun 2010; 78: 1345-52. 
 
37. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO 
Classification of Tumours of Haematopoietic and Lymphoid Tissues,  IARC: Lyon, 
2008. 
 
38. Muntwyler J, Marti-Jaun J, Luscher TF, Hanseler E, Hersberger M. The Asp298 but 
not the C-786 genotype of the endothelial nitric oxide synthase is reduced with age in 
healthy Swiss men. Clinical chemistry and laboratory medicine : CCLM / FESCC 
2005; 43: 971-3. 
 
39. Krayenbuehl PA, Hersberger M, Truninger K, Mullhaupt B, Maly FE, Bargetzi M et 
al. Toll-like receptor 4 gene polymorphism modulates phenotypic expression in 
patients with hereditary hemochromatosis. Eur J Gastroenterol Hepato. 2010; 22: 
835-41. 
 
 
ATTACHMENTS 	
	 153	
 
Table 1. TLR9 single nucleotide polymorphisms in the five investigated BL cell lines 
 
 
 
 
  Single nucleotide polymorphism 
  rs5743836 rs352140 
BL cell line Epstein-Barr virus -1237 T/C 2848 G/A (P545P) 
 
Akata 
 
Positive 
 
T/T 
 
G/A 
Akata 31 Negative T/T	 G/A 
Ramos Negative T/T	 G/G 
Mutu-I Positive T/C	 G/G 
BJAB Negative T/C	 G/G 
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Table 2. Frequencies of TLR9 single nucleotide polymorphisms in five BL cell lines, 15 
primary BL tumors, and blood samples from 402 healthy individuals 
 
Single nucleotide    
polymorphism    
rs5743836 rs352140 BL cell lines BL tumors Healthy individuals 
-1237 T/C 2848 G/A 
(P545P) N  N (%) N (%) 
T/T G/G 1 4 (27) 178 (44) 
T/T  G/A 2 5 (33) 165 (41) 
T/T A/A - 2 (13) - 
T/C G/G - - 1 (0) 
T/C G/A 2 1 (7) 55 (14) 
T/C A/A - 3 (20) 5 (1) 
The frequencies of the polymorphisms were statistically not significantly different
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Titles and legends to figures 
 
Figure 1 TLR9 agonists induce CD40 expression in Akata cells in a MyD88-dependent 
manner. Akata cells or DN-MyD88 Akata cells were left untreated or treated with 0.5 µM 
ODN CpG-2006 or ODN GpC-2006 for 48 hours. After 6 hours, 24 hours and 48 hours, 105 
cells were harvested, washed with PBS and stained with PE-Cy5-conjugated mouse anti-
human CD40 antibody or a PE-Cy5 mouse IgG1κ isotype control and analyzed with a flow 
cytometer. (a) FACS plots of Akata cells. Isotype control: shaded grey line; anti-CD40 PE-
Cy5: black line. Numbers indicate the mean fluorescence intensity (MFI) (b) Quantification 
of (a). (c) Comparison of CD40 expression in Akata cells and DN-MyD88 Akata cells. 
 
Figure 2 The cell death induced by TLR9 agonists is MyD88 dependent. Akata cells and DN-
MyD88 Akata cells were incubated with medium only, ODN CpG-2216, ODN CpG-2006, or 
ODN GpC-2006. (a) The cell survival was assessed by Trypan Blue exclusion assay 0 hours, 
24 hours, 48 hours, and 72 hours after treatment. (b) Apoptosis assay after 72 hours of 
treatment. 105 cells were stained with PE-Annexin V/ 7-AAD and analyzed by flow 
cytometry. The double-negative population represents viable cells while PE-Annexin V 
positive or double-positive populations represent non-viable cells. (c) Quantification of the 
Annexin V/7-AAD assay in (b). Shown are the results of a representative experiment of two 
experiments (showing mean values). 
 
Figure 3 TLR9 ligands induce cell death of Akata cells via caspase activation. (a) Caspase 
activity in 0.5 x 106 Akata cells measured 48 hours after treatment with the TLR9 ligands 
ODN CpG-2006, ODN GpC-2006 and ODN CpG-2216 without or with z-VAD-FMK. Cells 
were incubated with the Caspase-Glo luminogenic substrate to detect activated caspases and 
analyzed with a luminometer. Results represent the relative light units generated by active 
caspases 3 and 7. Shown in the bar graph are the results of a representative experiment out of 
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three performed in duplicate. (b) Treatment of Akata cells with caspase inhibitor z-VAD-
FMK reduces TLR9 ligand-induced cell death. 106 Akata cells were treated with the TLR9 
ligands ODN CpG-2006, ODN GpC-2006 or ODN CpG-2216 with or without addition of z-
VAD-FMK. After 48 hours cells were stained with PI, and analyzed by flow cytometry. 
Shown are the results of a representative experiment out of two experiments performed in 
duplicate. (c) Treatment of Akata cells with TLR9 ligand induces PARP cleavage. Lysates 
from 106 Akata cells 48 hours after incubation with the TLR9 ligands ODN CpG-2216, ODN 
CpG-2006 and ODN GpC-2006 with or without z-VAD-FMK were analyzed by 
immunoblotting for PARP cleavage. The relative density of the cleaved PARP was calculated 
using densitometry and normalized to β-actin. 	
 
Figure 4 TLR9 agonists induce cell death of Akata cells and Akata 31 BL cells, but not of 
Mutu-I BL cells or BJAB BL cells, while Ramos BL cells are intermediately affected. 106 
cells were treated with the TLR9 ligands ODN CpG-2216, ODN CpG-2006 and ODN GpC-
2006. (a) Survival of untreated, ODN CpG-2006 treated or ODN GpC-2006 treated Akata 
cells and Akata 31 BL cells was assessed by Trypan Blue exclusion assay and counting of 
viable and dead cells and compared to the untreated control. (b) Apoptosis of Akata and 
Akata 31 BL cells after 72 hours of treatment. 105 cells were stained with PE-Annexin V/7-
AAD and analyzed by flow cytometry (left panel); percentages of PE-Annexin V/7-AAD 
negative cells (right panel). (c) The survival of untreated, ODN CpG-2006 or ODN GpC-2006 
treated Mutu-I, BJAB, and Ramos BL cells was evaluated by Trypan Blue exclusion. Shown 
are the results of a representative experiment out of at least two experiments performed in 
duplicate (showing mean values) or in triplicate (showing mean values + s.e.m., indicated by 
error bars). 
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Figure 5 hIL-10 does not influence ODN CpG-2006-induced cell death. Akata cells and DN-
MyD88 Akata cells were incubated with medium only, 0.5 µM ODN CpG-2006, 900 pg/ml 
rhIL-10, or combination of ODN CpG-2006 and rhIL-10. To one ODN CpG-2006-stimulated 
sample, 0.5 mM ODN CpG-2006 was added again after 48 hours (rep. CpG-2006). (A) The 
cell viability was monitored by the Trypan Blue exclusion test 0 hours, 48 hours, and 72 hours 
after treatment. (b) After 72 hours cells were harvested and 105 cells were stained with PE-
Annexin V/7-AAD and analyzed by flow cytometry. (c) Quantification of (b).  
 
Figure 6 Treatment of BL cell lines with TLR9 agonists induces distinct hIL-10 mRNA and 
hIL-10 expression levels. (a) TLR9 triggering results in a wide range of hIL-10 mRNA 
expression levels. BL cells were left untreated or treated with 0.5 µM ODN CpG-2006 or 
ODN GpC-2006 for the indicated time points. (b) hIL-10 protein expression levels in the 
culture supernatants of BL cell lines 6 hours after treatment or no treatment as in (a) measured 
by ELISA. (c) TLR9 mRNA expression levels differ between BL cell lines by up to 6-fold. 
EBV positive (black bars) and EBV negative (grey bars) BL cells. (d) The hIL10 mRNA peak 
expression responses to ODN CpG-2006 did not correlate with the corresponding relative 
TLR9 mRNA levels. Total RNA of 106 cells was isolated and transcribed into cDNA. HMBS, 
hIL-10 or TLR9 mRNA expression levels were determined by qRT-PCR. The Ct values for 
hIL-10 and TLR9 were normalized to the Ct values of the housekeeping gene HMBS. 
Maximal values of relative hIL-10 mRNA expression were correlated with the respective 
relative TLR9 mRNA expression using a two-tailed Pearson correlation. Shown are the results 
of a representative experiment out of at least two experiments performed in duplicate 
(showing mean values). 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
ATTACHMENTS 	
	 159	
Figure 2: 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
Cell cycle analysis 
DNA of treated or untreated cells was measured by staining with propidium iodide (PI) and 
subsequent flow cytometric analysis. 106 cells were harvested, washed with PBS and fixed 
and permeabilized with cold 70% ethanol. The fixed and permeabilized cells were stored at 4 
°C for 1h to one week. Before the staining, cells were washed with 1xPBS and resuspended in 
200 µl PI-staining solution: 0.1% Triton X-100 (Sigma-Aldrich, Buchs, Switzerland), 0.2 
mg/ml RNase A (Qiagen), 2 mg/ml PI (Sigma-Aldrich) in PBS. Cells were incubated at room 
temperature for 30 min and analyzed by flow cytometry (FACSCanto II, BD Biosciences).  
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Suppl Fig 1. TLR9 triggering with ODN CpG 2006 does not impact on the cell cycle of Akata 
BL cells. 106 cells were treated with or without 0.5 mM ODN CpG 2006 for the indicated 
time points, washed and fixed and permeabilized with cold 70 % Ethanol. The DNA content 
of the cells was measured by staining with propidium iodide and subsequent flow cytometric 
analysis. The frequencies of the cell cycles stages of the living cells were calculated using the 
Watson algorithm of the software FlowJo 7.6. Data represent the average of three independent 
experiments. 
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Suppl. Table 1. Selection of up-regulated genes in microarray analysis of ODN CpG 2006 
treated versus untreated Akata BL cells. 
	
GenBank gene 
symbol Name Fold change over untreated 
 
Cytokines 
 
  
hIL-10 human interleukin 10 3.901 
CXCL10 chemokine (C-X-C motif) ligand 10 3.543 
   
B cell activation 
CD40 cluster of differentiation 40 3.011 
CD69 cluster of differentiation 69 4.008 
CD80 cluster of differentiation 80/ B7.1 2.833 
CD83 cluster of differentiation 83 4.996 
CD86 cluster of differentiation 86/ B7.2 2.340 
    
Transcription factors  
CIITA class II, major histocompatibility complex, transactivator 2.354 
STAT3 signal transducer and activator of transcription 3 2.738 
STAT5A signal transducer and activator of transcription 5A 3.038 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 3.018 
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 3.091 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 2.740 
NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon 2.124 
NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 8.414 
   
Apoptosis   
FAS Fas Receptor/ TNF receptor superfamily, member 6/Apo-1/ CD95 3.837 
BCL2A1 Bcl-2-related protein A1 3.384 
   
Fold change over untreated ≥ 2.0, p ≤ 0.05. 	
Suppl. Table 2: Down-regulated genes in microarray analysis of ODN CpG 2006 treated 
versus untreated Akata BL cells. 	
GenBank gene 
symbol Name Fold change over untreated 
   
B cell differentiation 
AICDA activation-induced cytidine deaminase 2.413 
   
Transcription factor  
BTBD3 BTB (POZ) domain containing 3 2.362 
   
Cell cycle   
C13orf5 chromosome 13 open reading frame 15 2.214 
CAB39L calcium binding protein 39-like 2.714 
   
Apoptosis   
RNF144B ring finger 144B 2.116 
   
Other   
SH2D1A SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) 2.817 
 positive regulation of natural killer cell mediated cytotoxicity  
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4: response to unfolded protein 2.341 
SLAMF6 SLAM family member 6: receptor activity 2.207 
USP53 ubiquitin specific peptidase 53: ubiquitin-dependent protein catabolic process 2.518 
   
Unknown function  
IGLV6-57 immunoglobulin lambda variable 6-57 2.471 
LOC253012  2.320 
SUSD3 sushi domain containing 3 2.006 
CCDC144 coiled-coil domain containing 144 | TL132 protein 2.265 
   
Fold change over untreated ≤ 2.0, p ≤ 0.05. 	
 
ACKNOWLEDGMENTS 	
	 166	
ACKNOWLEDGMENTS 
A doctoral thesis is so much more than just the sum of all the experiments performed. 
It would not have been possible to reach this point without the great support of many people. 
Therefore I would like to thank all the people who guided and supported me during my time 
as Ph.D. student, in particular:  
Prof. Dr. David Nadal 
I am deeply indebted to you for your constant support and motivation, for your steady 
guidance and for providing me with the opportunity to participate in this challenging research 
project. I appreciate that your door was always open for discussion. 
PD Dr. Michele Bernasconi 
Thank you so much for your support and patience. I appreciated your technical and 
scientific guidance as much as I enjoyed any off-topic discussion we had and last but not least 
thank you for always having a kind word when I needed some encouragement. 
Prof. Dr. Cornel Fraefel, Prof. Dr. Stefan Kunz, Prof. Dr. Beat Schaefer and Prof. Dr. 
Roberto F. Speck 
Thank you for being members of my thesis committee, for taking your time to judge 
my yearly progress and your stimulating suggestions for my project. 
Former and present members of the Infectiology group: Tarik Azzi, Roberta 
Aslandogmus Andrea Burch, Simone Bürgler, Florian Haas, Patricia Krukowski, Anna 
Lünemann, Jeannine Marty, Vanessa Mordasini, Monika Murat, Julia Noack Corinne 
Peng, Jürgen Rac, Patrick Meyer Sauteur, Asim Siddique, Jürg Sigrist, Sabrina Traxel, 
Seigo Ueda and Ludwig Zauner 
It was a great pleasure for me to be part of this fantastic group. Thank you so much for 
your support and for sharing all these happy and sometimes as well frustrating moments I 
experienced during the last years. 
ACKNOWLEDGMENTS 	
	 167	
All the present and former members I got to know of the oncology and leukemia groups 
Special thanks to Nathalie, for her patience and presence.  
CURRICULUM VITAE 	
	 168	
CURRICULUM VITAE 
Name:      Marc JORDI 
Date of Birth:    06.12.1985 
Place of Origin and Canton:  Huttwil, BE 
Nationality:     Swiss 
 
Education: 
Since 03.2010 PhD thesis: Impact of TLR9 activation on Epstein-Barr 
Virus lytic reactivation in Burkitt’s Lymphoma B cells 
Experimental Infectious Disease and Cancer Research, 
Universtity Children’s Hospital, Zürich, Supervisor: Prof 
David Nadal 
  
02.2009 – 02.2010 Master Thesis: Functional characterization of Epstein-Barr 
Virus encoded latent membrane protein 1 variants isolated 
from lymphoproliferative disorders 
Institute of Microbiology, Centre Hospitalier Universitaire 
Vaudois (CHUV), Lausanne, Supervisor: Prof. Stefan Kunz 
 
09.2008 – 12.2008 Premaster project: Effect of dessication stress on soil 
bacteria Sphingomonas wittichii RW1 that degrade 
environmental pollutants 
Department of Fundamental Microbiology, University of 
Lausanne, Supervisor: Prof. Jan Roelof van der Meer 
 
07.2007 – 05.2008 Corporal of NBC defense, Army (long service)  
NBC (Nuclear Biologycal Chemical) Competecence Center, 
Spiez 
 
09.2004 – 06.2007 Bachelor of Science in Biology, University of Neuchâtel 
 
08.2001 – 06.2004 Maturity Degree, Gymnase Français de Bienne (option 
Biology-Chemistry) 
  
  
  
  
	 
 
